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1.1. The Nightmare of Cancer: when good cells go bad 
        
ancer continues to be a worldwide killer, despite the enormous amount of research 
investments and rapid developments seen during the past decade. According to 
recent statistics, cancer is the second most common cause of death after heart 
disease but, if the latter can benefit from increasingly effective pharmacological and surgical 
therapies, cancer continues to be a disease with few alternative therapies. Because every type 
of cancer is unique, a treatment that works wonders for a leukemia patient, for example, might 
do little or nothing for a woman with breast cancer. Even patients with the same kind of 
cancer will have different responses to the same therapy, because the way the cancer arises 
and plays out depends on unique cellular events and the patient’s individual genome. Cancer 
isn’t just a single condition; it’s actually a complex collection of diseases that can arise in 
almost any tissue in the body. The remarkable thing about cancer is that,  although in many 
ways the disease acts like a foreign invading body,  it is actually our own cells that have 
started to misbehave. When we look at how cancer cells operate they can seem crafty, clever 
and at times downright evil. Of course they’re not. They’re cells – unable to think or have any 
emotion-like behavior. Although cancer comprises at least 100 different diseases, all cancer 
cells share one important characteristic: they are abnormal cells in which the processes 
regulating normal cell division are disrupted. These changes are often the result of inherited 
mutations or are induced by environmental factors such as UV light, X-rays, chemicals, 
tobacco products, and viruses. All evidence suggests that most cancers are not the result of 
one single event or factor. A multicellular organism can thrive only when all its cells function 
in accordance with the rules that govern cell growth and reproduction. Why does a normal 
C 
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cell suddenly become a “rebel”, breaking the rules, dividing recklessly, invading other tissues 
and in some cases eventually killing the body in which it lives? Cancer cells differ from the 
normal cells of the body in their ability to divide indefinitely and evade programmed cell 
death. The cells are constantly in the process of making decisions about what they want to do 
next and the decision to grow is one such major choice. Most cells in our body behave the 
way they should. When they get signals from the tissue surrounding telling them to multiply 
they will divide into two new cells; when they get old or damaged they will kill themselves in 
a cell-suicide process called apoptosis. Cells are very altruistic in this way. Cancer cells are 
not altruistic. What characterizes cancer cells is that they’ve become decidedly anti-social, 
carrying on their activities without regard to the other cells and tissues around them. While 
normal cells function solely to benefit the organism as a whole, cancer cells have their own 
agenda and that is to stay alive and to keep dividing.!Cancer is frequently considered to be a 
disease of the cell cycle. As such, it is not surprising that the deregulation of the cell cycle is 
one of the most frequent alterations during tumor development. The abnormal behaviors 
demonstrated by cancer cells are the result of a series of mutations in key regulatory genes 
(tumor suppressors and proto-oncogenes). Normal cells grow and divide in an orderly fashion, 
in accordance with the cell cycle.!In cancer this regulatory process malfunctions, resulting in 
uncontrolled cell proliferation. The cells become progressively more abnormal as more genes 
become damaged.. The normal speed of a car can be maintained by controlled use of both the 
accelerator and the brake. Similarly, controlled cell growth is maintained by regulation of 
proto-oncogenes, which accelerate growth, and tumor suppressor genes, which slow cell 
growth. Potential cancer cells become really dangerous when they not only divide in an 
uncontrolled way but also fail to recognize when they need to commit suicide. Normally the 
cell will detect a mistake and either rectify it or if that’s not possible commit suicide. 
Therefore, the rates of new cell growth and old cell death are kept in balance. In cancer this 
balance is disrupted and, when these processes break down, cancer begins to form and a mass 
of abnormal cells that grows out of control. Abnormal cells can also grow out of control and 
invade other tissues something that normal cells cannot do. Even though every cancer is 
different, there’s a shared set of behaviors that characterizes all cancer cells (Figure 1).  
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Figure 1. Acquired functional capabilities of cancer cells. 
Researchers are working on identifying drugs that target, destroy or stop division of cancer 
cells. During the last 30 years, investigation of the transcriptional and translational 
mechanisms of gene expression has been a major focus of molecular cancer biology. More 
recently, it has become evident that cancer-related mutations can also affect post-translational 
processing of cellular proteins controlling vital processes. In this context, one of the post-
translational mechanisms that is receiving considerable attention, is the protein turnover 
regulated by the Ubiquitin-Proteasome pathway (UPS), whose diverse components represent 
potential anti-cancer targets.  
 
1.2 Ubiquitin-Proteasome pathway: destruction for the sake of construction 
“Every minute of every day a scene straight out of an Indiana Jones movie plays out in all our 
cells. One second a hapless protein is tooling along just trying to do its job. The next instant it 
is branded for destruction and gets sucked into a dark tunnel, where it is quickly cut to pieces. 
Unlike Indiana Jones, for the protein there is no escape. Inside the chamber of doom, the 
protein is stretched out like a medieval prisoner on the rack and fed through a series of 
enzymatic knives that deliver the Death of a Thousand Cuts. A few seconds later the remnants 
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emerge from the tunnel, only to be pounced on and chewed up further by simpler enzymes” 
(The cellular chamber of Doom by A.L. Goldberg, S.J.Elledge and J. Wade Harper-2001). 
 
Many diseases are manifestations of homeostatic imbalances like cancer. The number of cells 
in a healthy adult organism must be kept relatively constant. This is accomplished by 
balancing the processes of cell proliferation and programmed cell death (apoptosis). 
Therefore, one of the common strategies for cancer therapy is the targeting of cell 
homeostasis leading to dysfunction of cell processes necessary for survival. Cancer occurs 
when the balance between cell proliferation and apoptosis is altered and cells proliferate faster 
than they die.  
In eukaryotic cells, the ubiquitin-proteasome pathway (UPS) is the central non-lysosomal 
pathway for protein degradation. It is estimated that more than 80% of intracellular proteins 
can be degraded by this system. One major function of the UPS is to protect the cell against 
misfolded, oxidized or otherwise damaged-and potentially toxic-proteins. Therefore, the UPS 
constitutes a kind of the cell’s quality control system. Additionally, it also regulates the half-
life of many proteins involved in important biological processes such as transcription, cell 
cycle regulation, oncogenesis, differentiation and apoptosis. For this reason, the UPS system 
plays a critical role in preserving cellular homeostasis, particularly in cancerous cells. In order 
to sustain their higher levels of metabolic activity, cancer cells rely more heavily upon the 
proper function of the UPS as compared to their normal counterpart. Therefore, tumoral cells 
are more sensitive to the proapoptotic effects of proteasome inhibition than normal cells, 
making the proteasome a rational therapeutic target in oncology.! Its inhibition disturbs the 
critical intracellular balance between proapoptotic and antiapoptotic signals shifting it towards 
tumor growth inhibition, apoptosis, and decreased metastasis. 
 
1.2.1 Ubiquitin Is Linked to Substrates through an Enzymatic Cascade 
In the UPS pathway, which is present ubiquitously in both the nucleus and the cytosol, most 
substrates are first marked for degradation by covalent linkage to multiple ubiquitin 
molecules. In fact,!polyubiquitination,  an enzymatic, post-translational modification process, 
is the triggering signal that leads to degradation of the protein in the proteasome. It is 
polyubiquitination that constitutes the "kiss of death" for the protein.  
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Ubiquitin, an evolutionary highly conserved 76 amino acid protein that acts as a death 
warrant, is covalently linked to proteins in a multistep process involving E1 (ubiquitin-
activating enzyme), E2 (ubiquitin-conjugating enzyme) and E3 (ubiquitin ligase) enzymes 
(Figure 2).  Polyubiquitin chains are assembled via an isopeptide linkage between the 
carboxylic acid group of the last ubiquitin's glycine (glycine 76) and  the epsilon amino group 
of the substrate's lysine. The process of ubiquitination is balanced by the process of de-
ubiquitination, which is mediated by a number of enzymes.! The polyubiquitin chain is 
removed from the substrate prior to entering the proteolytic core of proteasome, and is 
recycled to free ubiquitin by the action of a deubiquitinating enzyme (DUB).  
 
Figure 2. The conjugation of ubiquitin (Ub) to substrates usually involves three steps: an 
initial activation step catalyzed by E1; an intermediate step in which the ubiquitin is 
covalently linked to a conjugating enzyme, E2; and a final step in which the ubiquitin reaches 
its ultimate destination of the substrate amino group. The last step is facilitated by the E3 
ligase enzyme family. 
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1.2.2 The Proteasome 
The rapid degradation of ubiquitinated proteins is catalyzed by the 26S proteasome which can 
be defined as the cell's garbage shredder. This complex is found in the nucleus and the cytosol 
of all cells and constitutes approximately 1 to 2% of cell mass [1]. It's absolutely essential for 
survival. The 26S particle is composed of approximately 60 subunits and therefore is 
approximately 50 to 100 times larger (1500–2000 kDa) than the typical proteases that 
function in the extracellular environment and differs in critical ways. The most fundamental 
difference is that it is a proteolytic machine in which protein degradation is linked to ATP 
hydrolysis. The 26S complex is composed of a central barrel-shaped 20S proteasome with a 
19S regulatory particle at either or both of its ends (Figure 3). The 20S proteasome is a 
hollow cylinder that contains the mechanisms for protein digestion. It is composed of four 
stacked, hollow rings, each containing seven distinct but related subunits [1]. The two outer α 
rings are identical, as are the two inner β rings. Three of the subunits in the β rings contain the 
proteolytic active sites that are positioned on the interior face of the cylinder: chymotrypsin-
like (CT-L), trypsin-like (T-L) and caspase-like (C-L) activities which are associated with β5, 
β2 and β1 subunits, respectively. All three of these proteolytic activities regulate one another 
to coordinate their actions on a substrate protein [2]. When the chymotrypsin-like activity is 
turned on, the caspase-like and trypsin-like activities are off. This system for concerted and 
cooperative interactions between the proteasome activities is termed the ‘‘bite/chew’’ model, 
because the chymotrypsin-like activity bites a chunk out of the substrate protein, and the other 
two activities chew it into smaller pieces. The active sites in the proteasome cleave peptide 
bonds by a unique mechanism: peptide bonds are cleaved by the hydroxyl group on a critical 
threonine residue [3]*!Therefore,! proteasomes are a novel type of threonine proteases. The 
outer α subunits of the 20S particle surround a narrow, central, and gated pore through which 
substrates enter and products exit [4]. Substrate entry is a complex process that is catalyzed by 
the 19S particle. This complex architecture evolved to isolate proteolysis within a nano-sized 
compartment and to prevent the nonspecific destruction of cell proteins. One can view protein 
ubiquitination and the functioning of the 19S particle as mechanisms that ensure proteolysis 
as an exquisitely selective process; only certain molecules get degraded within the 20S 
proteasome [5]. The 19S regulatory particles at  the ends of the 20S proteasome are composed 
of at least 18 subunits [6]. Its base contains six homologous ATPases in a ring and adjoins the 
outer ring of the 20S particle. These ATPases bind the proteins to be degraded and use ATP 
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hydrolysis to unfold and translocate the protein into the 20S particle [7]. The 19S’s outer lid 
contains subunits that bind the polyubiquitin chains plus two deubiquitinating enzymes (also 
called isopeptidases) that disassemble the Ub chain so that the Ub can be reused in the 
degradation of other proteins [6]. There is growing evidence that additional factors associate 
with the 19S particle and actually help to deliver ubiquitinated proteins into the particle [8]. 
 
 
Figure 3. Structure and function of the 26S proteasome. (A) Structure and components of the 
26S proteasome. (B) Location of active sites in the 20S proteasome core. There are three 
types of proteolytic sites in the 20S proteasome’s central chamber, and each β ring contains 
three active sites.  
Much has been learned about the mechanisms by which a ubiquitinated protein is degraded. 
After it binds to the 19S component, the polyubiquitin chain is cleaved off the substrate and 
disassembled. The protein is unfolded somehow by the six ATPases in the base of the particle 
[7]. Linearization of the folded protein is essential for it to be translocated through the gated 
entry channel into the 20S particle because this pore, even in its open state, is too narrow for 
globular proteins (i.e., most cell proteins) to enter [4]. The ATPases also act as a “key in a 
lock” to cause opening of the gated, substrate entry channel of the 20S outer ring and into its 
central degradative chamber [9]. After the substrate enters the 20S’s central chamber, the 
polypeptide is cleaved by its six proteolytic sites on the inner face of the changer, forming 
small peptides that range from three to 25 residues in length [10]. Unlike traditional proteases, 
which cut a protein once and release the fragments, the proteasome digests the substrates all 
the way to small peptides that exit the particle. Peptides that are released by the proteasome 
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only exist in the cell for seconds, because they are quickly digested into amino acids by the 
abundant cytosolic endopeptidases and aminopeptidases. The amino acids can be reutilized to 
synthesize new proteins or metabolized, yielding energy [11]. 
 
1.3!!Proteasome Inhibitors and Cancer Therapy 
“This is an exciting time for cancer therapeutics. The identification of promising molecular 
targets has led to the development of many exciting new drugs for which an antitumor 
mechanism of action has been clearly delineated. Given the recent major advances in our 
understanding of the biology of cancer cells, one might surmise that an era of truly rational 
therapeutics has arrived. Nevertheless, we continue to find new therapeutic agents that target 
unforeseen molecular pathways” (The proteasome-an emercing therapeutic target in cancer 
by B.S.Mitchell). 
 
The UPS pathway is responsible for degradation of the majority of regulatory proteins in 
eukaryotic cells, including proteins that control apoptosis, cell-cycle progression and DNA 
repair, and for that reason plays a critical role in preserving normal cellular homeostasis. 
Inhibition of the proteasome leads to stabilization and accumulation of its substrates, resulting 
in a concomitant activation of pro- and anti-proliferative signals, disruption of cell-cycle 
regulation, and, ultimately, activation of apoptotic pathways and cell death [12, 13]. 
Neoplastic cells usually have higher levels of proteasome activity compared with normal cells 
and, in addition, are more sensitive to the proapoptotic effects of proteasome inhibition than 
normal cells for reasons that are not entirely understood. This is in part due to the high 
replication rate of malignant cells, which implies rapid protein synthesis and turnover, but 
also because of the genetic changes that accompany transformation that disable diverse 
protective checkpoint mechanisms. Accordingly, the proteasome has emerged as an attractive 
target for cancer therapy [12, 14]. 
Based on promising preclinical results, proteasome inhibition has been widely explored as a 
therapeutic strategy and proteasome inhibitors (PIs) now form a keystone of anticancer 
treatment. On a cellular level, blocking the proteasome generally stresses cancer cells by 
jamming them with proteins. Therefore, cancer cells may be selectively vulnerable to PIs 
because they can't handle the stress of the protein buildup as easily as normal cells can. This 
stress causes “catastrophic signaling events, which drive the tumor cell to die. A normal, 
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untransformed cell can withstand the stress response, at least for short periods of time” (cit. 
Julian Adams). 
Clinical validation of the proteasome as a cancer therapeutic target was established by 
Bortezomib (Velcade; Millennium Pharmaceuticals/Takeda Pharmaceuticals), the first PI 
approved by the US Food and Drug Administration for the treatment of relapsed multiple 
myeloma (MM) [15]. Bortezomib-induced cell death is related with induction of endoplasmic 
reticulum stress and activation of the unfolded protein response, inhibition of the nuclear 
factor kappa B (NF-κB) inflammatory pathway, activation of caspase-8 and apoptosis, and 
augmented generation of reactive oxygen species [16]. Bortezomib, a boronic acid dipeptide, 
inhibits the proteasome pathway rapidly and in a reversible manner primarily acting on the 
CT-L activity of the proteasome and blocking its enzymatic activity.  
Proteasomal chymotrypsin-like activity is considered the most important because associated 
with the survival of tumor cells, and then considered the first important target for the 
development of anticancer drugs. Even if the approval of Bortezomib has modified treatment 
of MM, there are restrictions to the use of this drug including toxicity, limited activity in solid 
tumors and resistance. A large amount of patients fail to respond to Bortezomib therapy, and 
almost all patients relapse from this drug, either when it is used alone or as combination 
therapies. This prompted the development of a new generation of structurally distinct 
proteasome inhibitors with diverse mechanisms of action, in an effort to overcome resistance 
to Bortezomib and its toxicity. These additional PIs include drugs that bind either reversibly 
or irreversibly to the active sites of the proteasome (mainly β5 subunit) , as well as molecules 
(es. Chloroquine and 5AHQ) that allosterically inhibit the function of the proteasome by 
binding the complex outside (α ring) of the active site (Figure 4) [17].! The “second 
generation” PIs, representing distinct structural classes (peptidyl epoxyketones, beta-lactones, 
peptidylboronic acids, and salinosporamides), with diverse mechanisms of action and 
affinities for the catalytic sites within the proteasome core,  have now entered clinical 
development. 
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Figure 4. Sites of action of proteasome inhibitors. 5AHQ and chloroquine act at the interface 
between the alpha and the beta subunits outside of the active site of the proteasome. 
Bortezomib, Carfilzomib, Marizomib, Oprozomib, Ixazomib and Delazomib bind the active 
site of the proteasome at the β5 subunits of the 20S core particle. 
1.3.1 Mechanism of action of proteasome inhibitors  
The UPS pathway is the principal mechanism of degradation for several short-lived cellular 
regulatory proteins, including p53, cyclins and the cyclin-dependent kinase (CDK) inhibitors 
p21 and p27 and the inhibitor (IκB) of nuclear transcription factor kappa B (NF-κB). Some of 
these mechanisms are summarized below. 
Ø Nf-κB pathway: from innocent bystander to major culprit  
A primary rationale for the therapeutic use of PIs in oncology relies on their ability to inhibit 
the nuclear transcription factor kappa B (NF-κB) activity through stabilization of its inhibitor 
IκB.!According to Hanahan and Weinberg, tumorigenesis requires six essential alterations to 
normal cell physiology: self-sufficiency in growth signals; insensitivity to growth inhibition; 
evasion of apoptosis; immortalization; sustained angiogenesis; and tissue invasion and 
metastasis [18]. NF-κB is able to induce several of these cellular alterations and  it is 
19S RP
19S RP
20S 
proteasome
α-ring
α-ring
β-ring
β-ring
Bortezomib
Carfilzomib
Marizomib
Oprozomib
Ixazomib
Delanzomib
Chloroquine
5AHQ
"/+-0123+40/!
"$!
!
constitutively active in a large proportion of advanced cancers [19] playing a role in resistance 
to chemotherapeutic agents. 
NF-κB regulates various immune and inflammatory responses and it is also involved in 
tumorigenesis by inducing angiogenesis, proliferation, migration and suppression of 
apoptosis. Inactive NF-κB is sequestered in the cytoplasm bound to its inhibitory regulator 
IκB. Following activation of NF-κB by various stresses stimuli, IκB is degradated by UPS and 
NF-κB translocates to the nucleus inducing the expression of a variety of genes encoding 
several growth and antiapoptotic factors, which promote the survival of cancer cells and 
actually propagate the tumor [20]. Inhibition of proteasome activity prevents degradation of 
IκB and subsequent activation and translocation of NF-κB to the nucleus (Figure 5).  
 
Figure 5. Bortezomib and nuclear factor-kappa B (NF-κB) inhibition. Bortezomib prevents 
the degradation of I-κB and, thereby, inhibits NF-κB activation.  
Ø  Cell cycle 
The principal, immediate consequence of proteasome inhibition is a decrease of overall rates 
of protein breakdown in cells [21, 22]. Various proteins involved in the processes of 
carcinogenesis and cancer survival have been identified as targets of the UPS, including the 
proteins related  to cell cycle process like cyclins A, B, D and E [21, 23], tumor suppressor 
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protein p53 [24], pro-apoptotic factor Bax [25], cyclin-dependent kinase inhibitor (CKI) p27 
[26, 27], and the inhibitor of NF-κB, IκB-α [28]. Progression of cell cycle occurs through 
tightly controlled interplay between cyclins and cyclin dependent kinases (CDKs) [29]. Loss 
of cell cycle control is a critical step in oncogenesis. In fact, cyclin proteins are found to be 
highly upregulated (particularly cyclins D and E) in cases of aberrant cell division in cancer 
cells, [30, 31]. Cyclin D binds to CDK 4/6 in the initial phase of G1 , where it performs two 
major functions, hypophosphorylation of retinoblastoma protein (Rb) [32] and protection of 
cyclin E/ CDK2 complex from inhibitory effect of p21 and p27 [30] (Figure 6). 
 
 
Figure 6. Regulation of NF-κB, E2F/Rb and p53/p21 pathways of cell cycle arrest by PIs.    
The upregulation of cyclins is further supported by the down regulation of another class of 
CDK regulatory proteins, the CKIs, which bind, inactivate and degrade the cyclin/CDK 
complex. Rapid proteasomal degradation of CKIs in subsequent cell cycle phases contribute 
to the uncontrolled cell division in cancer cells.  
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There are a number of ways in which proteasome inhibitors may induce cell cycle arrest by 
interfering with the degradation of cyclins and cell cycle regulatory proteins in malignant 
cells. CKIs, p21 and p27 are known to be suppressed in several cancer types and are attributed 
to cancer progression [33, 34]. Bortezomib, along with other PIs has been reported to 
significantly increase the expression of p21 and p27 proteins in many cancers thereby causing 
cell cycle arrest [35-37]. On the other side, proteasome inhibition also causes accumulation of 
the tumor suppressor p53, which is a crucial component of cell cycle regulation, abrogating its 
degradation and reactivating its function in G1/S and G2/M arrest [38]. Proteasomal 
inhibition allows accumulation of p53 and its nuclear export in cancer cells and thereby 
increases the expression of its transcriptional target gene p21, a potent CDK inhibitor, which 
binds and inactivate cyclin E and the CDK2 complex. This complex is essential for late G1 
phase mediating entry in the S phase of cell cycle. However, activation of p53 and p21 
proteins leads to G0/G1 cell cycle arrest. For this reason, p53/p21 pathway blocks the 
doorstep of cell cycle entry. Finally, administration of PIs mediates retinoblastoma (Rb) 
protein escape from proteasomal degradation. Rb acts as a tumor suppressor protein playing a 
crucial role in cell cycle regulation, DNA replication, DNA damage repair and many other 
cellular processes. Another key component of PI mediated growth arrest, is the inhibition of 
NF-κB signaling and its downstream target proteins mainly cyclin D, responsible for G1/S 
transition and commitment to DNA synthesis.  
Ø Regulation of apoptosis 
Programmed cell death, or apoptosis, is necessary to the survival of all multicellular 
organisms playing an important role in normal growth and development. The discovery that a 
family of proteases, the caspases, mediates the execution of apoptosis, generated interest in a 
possible involvement of the proteasome in this process. Apoptosis is regulated by the 
opposing activities of pro-apoptotic and anti-apoptotic molecules. Cancer cells often have 
disregulated apoptotic signaling pathways which give malignant cells a survival advantage 
and can confer resistance to chemotherapeutic agents. The proteasome is involved in the 
control of apoptosis by modulating the levels of pro- and anti-apoptotic factors. Specifically, 
inhibition of proteasome activity results in an upregulation of pro-apoptotic factors such as 
p53 and Bax while reducing levels of anti-apoptotic proteins such as Bcl-2 [39]. The Bcl-2 
family is the best characterized protein family involved in the regulation of apoptotic cell 
death. Bcl-2 protein prevents apoptosis either by sequestering proforms of death-driving 
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cysteine proteases called caspases (a complex called the apoptosome) or by preventing the 
release of mitochondrial apoptogenic factors such as cytochrome c into the cytoplasm. After 
entering the cytoplasm, cytochrome c directly activates caspases that cleave a set of cellular 
proteins to cause apoptotic changes. In contrast, pro-apoptotic members of this family, such as 
Bax, induce the release of mitochondrial apoptogenic factors into the cytoplasm thereby 
leading to caspase activation. Thus, the Bcl-2 family of proteins acts as a critical life–death 
decision point within the common pathway of apoptosis. Moreover, p53 is a transcription 
factor capable of binding DNA in a sequence-specific fashion and directly activate the 
transcription of genes known to promote apoptosis [40-43]. Specifically, the most intuitive 
link between p53-mediated transactivation and apoptosis comes from its ability to control 
transcription of pro-apoptotic members of the Bcl-2 family, such as Bax, Noxa [44] and Bid 
[45] (Figure 7).  
 
Figure 7. Cytosolic and mitochondrial p53 apoptotic pathways. 
1.4 Ubiquitin-proteasome pathway and oxidative stress 
The past decade has seen an exponential increase in the number of cancer therapies with 
defined molecular targets. Interestingly, many of these new agents are also documented to 
raise levels of intracellular reactive oxygen species (ROS) in addition to inhibiting a 
biochemical target. The first report that proteasome inhibitors cause oxidative stress came 
from a study examining Bortezomib action in lung cancer cell lines [46]. In support of a 
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strong role for redox modulation by proteasome inhibitors, there are numerous observations 
that other classes of proteasome inhibitors also induce an oxidative stress [47].  
Oxidative stress is a complex and dynamic situation characterized by an imbalance between 
the productions of so called ROS (reactive oxygen species)- and the availability and action of 
antioxidants. Oxygen is one of the greatest blessings and perhaps curses to complex life, this 
is what is often referred to as the ‘Oxygen Paradox’ [48]. Higher eukaryotic aerobic 
organisms cannot exist without oxygen; nevertheless oxygen is fundamentally dangerous to 
their existence. This ‘disadvantage’ of oxygen relates to the fact, that molecular oxygen has 
two unpaired electrons in its outer electron shell. This electronic structure makes oxygen 
reactive. Besides molecular oxygen, a number of even more reactive species, the ROS, are 
derived from molecular oxygen. ROS refer to oxygen-containing breakdown products of 
molecular oxygen that are highly reactive and are able to damage lipid membranes, proteins, 
and DNA when present in high amounts, thus leading to aberrant molecular activities and 
resulting in dysfunction of bioprocesses [49-51]. The main endogenous source of ROS 
production is the mitochondrial metabolism. Other sources are the cytochrome P450 
metabolism, different environmental influences and inflammation processes (Figure 8). 
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Figure 8. The occurrence of oxidative stress depends on the interaction between the cellular 
antioxidative system and the formation of ROS.  
Because proteins are most abundant in cells, it is not surprising that they are  the major targets 
for oxidative modifications. ROS can attack proteins in different ways: directly at the protein 
backbone, amino acid residue side chains or they can lead to the formation of protein 
carbonyls. As a result of this damage, the affected proteins lose their biochemical 
functionality, protein expression is altered and finally aggregate formation occurs, resulting in 
different consequences for the cells. Therefore, to maintain cell viability and normal 
homeostasis, aerobic organisms have evolved multistep defense mechanisms for reducing the 
deleterious effects of oxidative stress. The first step is the direct scavenging and detoxification 
of reactive chemicals by antioxidants (e.g. glutathione) and cytoplasmic antioxidative 
enzymes (e.g. superoxide dismutase SOD, catalase, and glutathione peroxide) (Phase 1). The 
second step is the restoring of reversibly denatured proteins by chaperones (Phase 2). The 
final step is the elimination of irreversibly denatured proteins (Phase 3), catalyzed by several 
cytoplasmic proteases. One of those is the proteasomal system that is essential for cells to 
cope with oxidative stress [52] and prevent cytotoxicity. Therefore, inhibition of proteasomal 
"/+-0123+40/!
"+!
!
function can lead to an accumulation of damaged (e.g., oxidized) proteins which produce 
oxidative stress-dependent toxicity and contribute to induction of cell death. Specifically, 
ROS have been suggested as regulating the process involved in the initiation of apoptotic 
signaling [53]. For these reasons, redox status may be an element to consider in trying to 
maximize the utility of the proteasome inhibitors and oxidative stress can be a relevant and 
requisite outcome of many new cancer therapies.  
Finally, inhibition of NFκB activity, altered degradation of cell cycle related proteins, pro-
apoptotic and anti-apoptotic protein unbalance and inhibition of DNA repair, have all been 
reported to contribute to the apoptotic effects of proteasome inhibitors in tumor cells. These 
mechanisms are summarized in Figure 9. 
 
Figure 9. Critical targets for proteasome inhibitors in malignant cells 
Much emphasis has been placed on the identification of specific and targeted molecular 
therapy for the treatment of many cancer types. To establish a new targeted therapy, at least 
two criteria have to be met: a validated therapeutic target, and a highly specific inhibitor (or 
activator) towards that target. In the UPS, few targets have been well-established and 
validated, including proteasomal β1, β2 and β5 subunits. One should keep in mind that 
although the UPS is ubiquitously present in all cell types, the identification of a novel 
therapeutic target within this system could still prove to be tumor type-specific or at least 
superior in one tumor type over another. For example, the current clinical application of 
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proteasome inhibitors is still limited to multiple myeloma and lymphomas with limited 
success in solid tumors. Moreover, in spite of all its successes, the proteasome inhibitors 
currently in use often have severe disadvantages. As a result of their high reactivity they 
attack other proteins, thereby damaging not only cancer cells but also other healthy cells. For 
these reasons, several studies have suggested that the targeting of functionally related, up-
stream or down-stream proteasome effectors [54], can be an alternative and a safer way to 
recover proteasome dysfunction associated with pathological conditions. Specifically, one of 
this target could be identified in a specific serine-pepdidase, the Acylpeptide hydrolase 
(APEH), which has been hypothesized acting in coordination with proteasome in the protein 
turnover processes, opening new important and challenging perspectives for the development 
of novel strategies in cancer therapy.  
 
1.5 Acylpeptide hydrolase  
Acylpeptide hydrolase (APEH), also referred as oxidized protein hydrolase (OPH) or 
acylaminoacyl peptidase, is a member of a novel class of serine-type peptidases namely the 
prolyl oligopeptidase (POP, clan SC, family S9) [55], unique in the family for its substrate 
preference. It is a cytoplasmic exopeptidase that catalyzes the removal of N-acylated amino 
acids from blocked peptides, producing an acylamino acid and a peptide with a free N-
terminus shortened by one amino acid residue [56]. In eukaryotes, N-acetylation is one of the 
most common protein modifications occurring on approximately 85% of proteins, both co- 
and post-translationally [57]. The acetylation of proteins and peptides serves to protect the 
aminopeptidases present in eukaryotic cells from proteolytic degradation, and thus increases 
their half-life. Therefore, APEH has a broad role in regulating the basal N-terminal 
acetylation states of many proteins in the proteome but its cellular functions have been still 
unclear and the mechanism underlying the intracellular catabolism of N-acetylated proteins 
has not yet been elucidated. It is assumed that the intracellular catabolism of N-acetylated 
proteins is regulated by the cooperative action of the ubiquitin-proteasome system and APEH. 
Therefore, this enzyme has been postulated to be important in the endpoint of the ubiquitin 
system and thus in the breakdown of proteins into free amino acids (Figure 10) [58]. 
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Figure 10. Proposed scheme of the intracellular catabolism of α-NH2-acetylated protein. 
aa: amino acid, Ac-: acetyl- 
APEH is an ubiquitous enzyme but few members of this family have been characterized to 
date; specifically, these enzymes have been studied in a number of eukaryal organisms [59], 
in some Archaea [60, 61], in a bacteria [62] and, more recently, also in plant [63].  
APEH displays a broad spectrum of specificity with respect to the blocking group, (acetyl, 
chloroacetyl, formyl, and carbamoyl moieties) and the most notable property is its selectivity, 
which is restricted to oligopeptides comprising not more than about 30 amino acid residues 
Mammalian APEH is composed of four identical subunits and, like all members of the POP 
family, contains a catalytic site identical to that of serine peptidases,!but it hydrolyzes short 
peptides only. From a structural point of view, this enzyme  has the expected domain 
architecture of the POP family: a C-terminal catalytic domain with an α/β hydrolase fold and 
its catalytic triad (Ser, Asp and His) is covered by the central tunnel of an unusual seven-
bladed β-propeller at the N- terminal that hides the active site. This domain makes the enzyme 
an oligopeptidase by excluding large, structured peptides from the active site. In this way, the 
propeller operates as a gating filter and protects large peptides and proteins from proteolysis 
in the cytosol. Indeed, unlike POP members, this entrance has a diameter wide enough to 
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allow passage of a peptide substrate in a random coil conformation. There is a second smaller 
opening located between blades 1 and 2, suggesting the possibility of separate substrate entry 
and product exit sites for APEH. The only 3D structure available to date is that of the 
hyperthermophilic enzyme from the archaebacterium Aeropyrum pernix K1 (ApAAP) [61]. 
This crystal structure allowed to obtain the enzyme model of an APEH from Sulfolobus 
solfataricus (APEHSs) which shares a significant sequence identity (34%) with ApAAP [64]. 
APEHSs, unlike the tetramer mammalian enzymes, is a symmetrical homodimer with each 
subunit made up of a seven-bladed β-propeller domain and α-peptidase domain, which are 
characteristic of this enzyme family (Figure 10).  
 
 
Figure 10.!APEHSs dimer model. The two monomeric subunits are displayed in different 
colors as cartoon. For only one of the two subunits the catalytic triad residues (Ser425, 
Asp505, His537) are shown in yellow (ball-and-stick mode); the red and green arrows 
indicate the β-propeller tunnel opening and the interdomain side-opening, respectively. 
1.5.1 Role of Acylpeptide hydrolase in human diseases 
Like the other members of the POP family, APEHs are believed to be important targets for 
drug design, being involved in the development of several diseases such as neurodegenerative 
disorders and cancer. Despite the broad distribution of APEH in animal tissues including 
blood, brain and liver, its physiological functions have not been well understood other than its 
involvement in the degradation of N-acylated proteins. 
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Ø Recently, it has been suggested that APEH may play an important role in 
inflammatory diseases providing the first line of defense against unwanted 
inflammatory responses at tissue sites that are in continuous contact with commensal 
bacteria (e.g., intestines) [65, 66]. Mammalian large intestine is constantly exposed to 
bioactive and immunoreactive N-formyl peptides, a potent chemoattractants for 
phagocytes, derived from proteolytic degradation/processing of bacterial and 
mitochondrial proteins [67, 68]. Thus, to prevent unwanted immune response to 
commensal bacteria, mammals must possess enzymes that can effectively degrade the 
N-formyl peptides such as APEH.  
Ø Shimizu et al. demonstrated that APEH [69] may contribute to the elimination of the 
oxidized proteins, acting as secondary antioxidant defense systems in coordination 
with proteasome [70]. Strongly oxidized proteins are known to be poor substrates for 
the proteasome, since they easily form covalent cross-links and aggregates [71]. 
Therefore, APEH may play a homeostatic role in sustaining the cytoplasmic 
antioxidative system and in the clearance of such oxidized proteins [63], against which 
it has been biochemically demonstrated to have endopeptidase activity [72, 73]. As a 
fact, APEH may represent a promising therapeutic target for a wide array of human 
diseases in which oxidative stress increases such as diabetes mellitus. Specifically, it 
has been hypothesized that APEH might have a preventive or at least delaying role in 
the development and progression of diabetes mellitus, due to its ability to 
preferentially degrade oxidized and glycated proteins [74]. In this context, it is 
important to emphasize that glycated proteins, which increase in diabetes, are not 
readily degraded by 20S proteasome [75] and that the proteasome activity decreases in 
diabetes while a concomitant increase in APEH activity has been observed [76]. These 
events suggest that APEH takes part in a biological defense mechanism against 
oxidative stress and could represent a potential therapeutic target for the treatment of 
these type of pathologies. 
Ø There are many evidences indicating an involvement of APEH in the development of 
several human cancers. Human APEH is encoded by the DNF15S2 locus on the short 
arm of chromosome 3 at region 21 [77], which suffers deletions in small cell lung 
carcinomas and renal carcinomas, resulting in deficiency in the expression of the 
enzyme [78-80]. In addition, it has been demonstrated that downregulation of the 
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enzyme induces apoptosis in human monoblastic U937 cells suggesting that APEH 
may play a vital role for the survival of eukaryotic cells [81], although its involvement 
in the malignant state of these cell lines has not yet been established.   
Ø A lot of interest was aimed at the role of APEH in neurodegenerative diseases such as 
Alzheimer's. It has been reported that porcine brain APEH is implicated in synaptic 
plasticity processes that are responsible for mediating the organophosphorous-induced 
cognitive effects. Therefore, this enzyme has been proposed as alternative non-
cholinergic target in the treatment of neurodegenerative diseases [82].  
 
For these reasons, modulation of APEH activity appears to be an important event in 
controlling the UPS dysfunction associated with a wide array of human diseases, opening new 
important and challenging perspectives for the development of novel strategies in the 
therapeutic field. Moreover, the discovery of small bioactive molecules able to specifically 
and efficiently inhibit APEH may represent a valuable starting point to study the biological 
function by ‘‘knocking-out” its activity. 
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2.1 Peptide design and characterization 
s previously described, APEH inhibition could represent a novel strategy to 
regulate proteasome activity, with potential applications in biomedical fields. 
Therefore, the knowledge of the enzyme–inhibitor binding sites at the molecular 
level could be pivotal for our understanding of the underlying mechanisms, as well as for the 
design of novel and more efficient inhibitors. 
The identification and characterization of an endogenous inhibitor protein of APEH from S. 
solfataricus, named SsCEI (Sulfolobus solfataricus chymotrypsin-elastase inhibitor) [64, 83], 
was the starting point for the present study. SsCEI, obtained in recombinant form, belongs to 
phosphatidylethanolamine-binding protein (PEBP) family. SsCEI is a monomer protein with a 
molecular mass of 19.0 kDa and a pI of 6.7, which is able to inhibit the serine proteases α-
chymotrypsin and elastase but not trypsin, a distinct feature of all the members belonging to 
the family PEBP. In addition, in vitro inhibition studies showed that the isolated SsCEI was 
the first protein inhibitor able to efficiently interact and inhibit the APEHs from different 
sources. Homology modeling and site-specific mutagenesis techniques of the gene codifying 
SsCEI (sso0767) allowed the identification of the “reactive site loop” (RSL) of the inhibitor, 
located on the surface at the C-terminal region of SsCEI and responsible for the interaction 
with the protease targets. Such site shows an amino acid sequence never found in any protease 
inhibitor so far characterized. On the basis of the RSL of SsCEI, a set of four peptides, 
differing in size and nature at their P1 site, were designed and synthesized. Peptides SsCEI 1 
and SsCEI 2 correspond to residues 119–134 and 123–134 of the SsCEI protein, respectively, 
and include the P1-P’1 (L126-E127) binding site which is reportedly involved in protease 
inhibition (Figure 1).  
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Figure 1 Amino acid sequence of SsCEI protein. The sequence of SsCEI 1 and SsCEI 2 are 
indicated in red and blue boxes, respectively (A). Model of RSL of SsCEI (B). 
The shorter variant (SsCEI 2), starting with the N-terminus of RSL, was designed to minimize 
peptide length while maintaining intact the RSL binding site. Two further peptides were 
projected, SsCEI 3 and SsCEI 4, to replace the P1 residue Leu with Ala, which is the 
preferred amino acid in the substrates of mammalian APEHs. The sequences of these peptides 
are reported in Table 1.  
 
Table 1. Synthetic peptides designed. Peptides were synthesized with a free amino group at 
the N terminus and an amidic group at the C terminus. The apparent MWs of SsCEI peptides 
were determined by gel filtration chromatography. Data reported are the result of three 
independent determinations.   
Peptide Theoretical mass 
value (Da) 
Measured mass 
value (Da±SD) 
             P1P’1 
SsCEI 1 1818.12 n.d. YAIDTILLEIKNINAD 
SsCEI 2 1355.61 1961±265       TILLEIKNINAD 
SsCEI 3 1766.04 2012±150 YAIDTILAEIKNINAD 
SsCEI 4 1313.53 1986±28           TILAEIKNINAD 
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Amidation at the C-terminal end was introduced to mimic the amino acid stretch within the 
protein backbone, whereas the amino termini of peptides were not acetylated to prevent 
substrate-like effects when in contact with APEH. Peptide structures within SsCEI protein 
inhibitor are predicted to be random/extended, as they have to be free in adopting the best 
conformation needed to dock the target proteases. Circular dichroism (CD) spectroscopy 
analyses were carried out to obtain information on the secondary structures of peptides 
outside the context of the native protein. Interestingly, the CD spectra measured between the 
190 nm and 250 nm demonstrated that, except for SsCEI 4, which was largely unstructured 
(Figure 2), these peptides have well defined secondary structures in aqueous solution. 
Specifically, CD spectra of SsCEI 2 and SsCEI 4 at 37 °C, despite the single mutation, 
showed markedly different profiles, suggesting that the Leu→Ala substitution at the P1 site 
induces significant conformational alterations. CD spectra of SsCEI 2 featured canonical ‘α-
helix’ curves with surprising fidelity (Figure 2). These data are in agreement with the role 
that the RSL has in the native inhibitor protein, and suggest a strong tendency of these 
peptides to adopt different conformations following even minimal sequence modifications. 
CD spectra were also recorded in the temperature range between 37 °C and 77 °C, with 
increasing temperature steps of 10 °C. Under these conditions, SsCEI 2 and SsCEI 3 showed 
considerable structural stability, as seen by the poor influence of temperature on their 
conformations (Figure 2). SsCEI 1 was not examined due to its poor stability in aqueous 
solution at the concentrations required for these analyses. These findings indicate that, in our 
model, the backbone architecture of the inhibitory loop is imposed by its specific amino acid 
sequence, and that the protein scaffold does not constrain the conformation of the RSL. Given 
the relevant contents of β-sheet structures observed in SsCEI 2 and SsCEI 3, we next 
investigated the oligomerization properties of these peptides to exclude the occurrence of 
macroscopic aggregates. For this purpose, 100 µM solutions of peptides SsCEI 2, SsCEI 3 
and SsCEI 4 were analyzed by size-exclusion chromatography, and their apparent molecular 
masses were extrapolated from a calibration curve. As shown in Table 1, SsCEI 2, SsCEI 3 
and SsCEI 4 were essentially monomers, suggesting that the secondary structures detected by 
CD were not a result of non-specific self-association, but seemed to be an intrinsic property of 
the peptides. 
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Figure 2. Far-UV CD spectra of the SsCEI peptides at different temperatures. SsCEI 1-4 at 
37°C (A), SsCEI 2 (B), SsCEI 3 (C), SsCEI 4 (D), in the temperature range of 37 °C to77 °C 
(as indicated). All the spectra were taken in aqueous solution. 
2.2 Mammalian APEHs are specifically and efficiently inhibited by SsCEI peptides. 
The inhibition activity of SsCEI peptides was assessed using mammalian APEH purified from 
porcine liver (hereafter APEHpl), which shares more than 90% sequence identity with the 
human APEH, as calculated by the ClustalW algorithm 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). Ac-Ala–pNA was used as the preferential 
substrate for the mammalian APEH. Inhibition analyses were performed by pre-incubating the 
enzyme with increasing amounts of these compounds and their half-maximal inhibitory 
concentrations (IC50) were determined. As shown in Figure 3A, both SsCEI 2 and SsCEI 4 
dose-dependently decreased porcine APEH activity, although to different extents (IC50 
values were 142±30 µM and 84±16 µM, respectively). Notably, APEH activity followed a 
Michaelis–Menten kinetic, both in the absence and in the presence of SsCEI 4 but only the 
Michaelis constant (Km) was affected by increasing concentrations of substrate, suggesting 
that SsCEI 4 behaved as a typical competitive inhibitor. It was confirmed by plotting the data 
according to the Lineweaver–Burk equation (Figure 3B). The straight lines obtained at 
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different inhibitor concentrations, all intersecting in one point corresponding to 1/Vmax, 
indicate a typical competitive mechanism. Therefore, these results demonstrated that an 
increase in substrate concentration induced a displacement of SsCEI bound to the APEH 
resulting in Enzyme-Inhibitor (EI) dissociation. In fact, competitive inhibition is a mechanism 
where binding of the inhibitor to the active site of the enzyme prevents binding of the 
substrate and vice versa in a dynamic equilibrium-like process. Analysis of the data obtained 
yielded a dissociation constant (Ki) value of 4.0±0.8 µM for the SsCEI 4–APEH complex. 
The greater efficacy of SsCEI 4 over SsCEI 2, can be ascribed to the preference for an Ala 
residue, with respect to leucine, at the P1 site, assuming that the SsCEI 4–APEH association 
occurs in a substrate-like manner. Data also suggested that the additional N-terminal residues 
in SsCEI 3 (Table 1), negatively affected the inhibition capacity towards mammalian APEH 
(Figure 3A). 
 
 
Figure 3. Kinetic analysis of SsCEIs. Binding of SsCEI peptides towards porcine APEH 
using Ac-Ala-pNA as substrate (A). The hyperbolic curves indicate the best fits for the data 
obtained, with IC50 values calculated from the graphs. Inhibition kinetics analyses with 
porcine APEH (0.5 nM) at increasing SsCEI 4 concentrations: 100 µM (triangles) and 150 
µM (squares). Enzyme incubated without inhibitors were used as control (diamonds) (B). The 
inhibition constants, Ki, were determined by the Lineweaver–Burk equation for competitive 
inhibition. 
2.3 SsCEI 4 is a selective and non-covalent APEH inhibitor 
In order to confirm the specificity of SsCEI 4 towards APEH, a panel of eukaryotic serine 
proteases comprising trypsin, α-chymotrypsin, elastase, carboxypeptidase Y, subtilisin and 
proteinase K, was analyzed in biochemical assays. Results showed that SsCEI 4 has no 
A B
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detectable effects on the proteases tested. Moreover, to further examine the SsCEI 4 
selectivity, its inhibition activity was determined in a reaction mixture containing the entire 
set of proteases reported above including APEHpl. Under these conditions, the inhibition 
efficiency and the Ki of SsCEI 4 towards APEHpl were comparable to those measured in the 
presence of the APEHpl alone (data not shown). Moreover, to exclude the formation of 
adducts or degradation products between SsCEI 4 and its protease target APEHpl, we 
investigated the incubation mixtures by reverse-phase HPLC chromatography. The lack of 
new peaks in the HPLC chromatogram and invariability of peak area corresponding to SsCEI 
4, suggested that neither peptide degradation nor covalent binding with APEHpl occurred 
under the assay conditions (Figure 4). Data thus demonstrated that SsCEI 4 is a highly 
selective, and non-covalent inhibitor of APEH. 
 
 
Figure 4. Representative chromatogram from RP C18 column analysis of SsCEI 4 
incubated with or without porcine APEH for different times as indicated. 
2.4 SsCEI 4 downregulates APEH and proteasome activities in adenocarcinoma cell 
lines 
Proteasome inhibition represents a validated, although challenging, anticancer approach. 
However, to prevent the adverse effects deriving from indiscriminate cell death, inhibition of 
the proteasome needs to be tightly controlled or selectively induced in cancer tissues. 
Therefore, the concept that proteasome activity could be decreased via APEH inhibition was 
investigated in a cancer cell line to confirm the inhibitory activity of SsCEI 4 in a more 
complex assay system. To this end, differentiated human colon carcinoma Caco-2 cells have 
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been used as preliminary model system. The parental cell line, originally obtained from a 
human colon adenocarcinoma, undergoes in culture a process of spontaneous differentiation 
that leads to the formation of a monolayer of cells, expressing several morphological and 
functional characteristics of the mature enterocyte. For these reasons, Caco-2 cell line has 
been extensively used over the last twenty years as a model of the intestinal barrier. The 
choice of using such model system was given to us by the data reported in the literature [65]. 
Indeed, among the top-ranked proteases associated with inflammatory bowel disease, one of 
the most important is APEH, which is highly expressed in the intestinal mucosa where it is 
able to cleave N-formyl peptides derived from bacteria, a potent pro-inflammatory chemo-
attractant for phagocytes [66].  
Therefore, Caco-2 cells were treated with SsCEI 4 or with a specific proteasome inhibitor (PI) 
MG132 for 48 h. As shown in Figure 5A, the peptide markedly reduced APEH activity in a 
dose-dependent manner, reaching their maximum effect at 200 µM, where enzyme activity 
was decreased by 70%. Under the same conditions MG132 treatment had no detectable 
effects. We next examined the inhibitory effects of SsCEI 4 on the chymotrypsin-like 
proteasomal (CT-like) activity in Caco-2 cells and in cell-free assays. In these latter 
experiments, partially purified proteasome fractions from Caco-2 cells were used instead of 
the commercially available 20S proteasome. Indeed, it has been reported that in neoplastic 
cell lines the CT-like activity, as well as the sensitivity to different PIs, is greatly influenced 
by the highly variable proteasome subunit composition [84]. Therefore, cell exposure to 
SsCEI 4, produced a dose-dependent decrease (up to 45% of the residual activity) of the CT-
like activity with respect to the untreated cultures, whereas partially purified proteasome was 
not affected by these compounds (Figure 5B), thus confirming that it is not directly targeted 
by these inhibitors. 
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Figure 5. Downregulation of the proteasome/APEH enzymes by SsCEI 4 in Caco-2 cells. 
APEH activity was measured in Caco-2 cells incubated with 50 µM, 100 µM and 200 µM 
SsCEI 4 (white bars) for 48 h (A). CT-like activity was measured in cell-free system (a 
partially purified proteasome fraction from differentiated Caco-2 cells, gray bars) and in 
Caco-2 cells (white bars) treated with increasing concentrations of SsCEI 4 (B). Cell-free 
protein mixtures, or Caco-2 cell cultures, treated with DMSO alone (black bars) or with 
MG132 (10 µM) (striped black bars) were used as positive controls. The data are expressed 
as means±SD. *Significantly different (P<0.005) from respective controls. 
Next, we evaluated the effects of SsCEI 4 treatment on the activation of caspases. As shown 
in Figure 6A, caspase-3 activity, a key effector of apoptosis, was improved at increasing 
doses of SsCEI 4. These data are in agreement with the well-established association between 
proteasomal inhibition and apoptosis induction. Moreover, this was not associated with any 
cytotoxic effect even at the highest concentration (200 µM), as indicated by the lactate 
dehydrogenase (LDH) activity levels in culture broth, which remained comparable to those of 
controls (Figure 6B). The toxicity resulting from the APEH-mediated inhibition of 
proteasome activity, as indicated by the treatment with SsCEI 4, was significantly lower than 
that observed in cultures incubated with MG132.  
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Figure 6. Treatment with SsCEI 4 triggers apoptosis in Caco-2 cells without any 
cytotoxicity. Caspase-3 activities and LDH release were measured upon 48 h incubations of 
Caco-2 cells with increasing concentrations of SsCEI 4 (white bars) (A). The cytotoxic effect 
of the different treatments was evaluated by measuring the LDH release in the culture media 
(B). Cell-free protein mixtures, or Caco-2 cell cultures, treated with DMSO alone (black 
bars) or with MG132 (10 µM) (striped black bars) were used as positive controls. The data 
are expressed as means±SD. *Significantly different (P<0.005) from respective controls. 
Therefore, our results, consistently with the reporting coordinated functions of proteasome 
and APEH in protein turnover [70], add the relevant information that proteasome modulation 
could occurs via a complex pathway which has APEH like an important and regulative factor. 
Moreover, since APEH activity is not influenced by cell treatment with the specific PI 
MG132 (Figure 5A), proteasome modulation should be hierarchically down-stream of APEH 
inhibition. This view is also corroborated by the observation that APEH and proteasome seem 
to have no direct interactions, as they are distinctly eluted from gel filtration columns loaded 
with protein extracts obtained from SsCEI 4-treated or untreated Caco-2 cells. 
 
2.5 SsCEI 4 increases the level of UPS substrates in Caco-2 cells 
To finally confirm the reliability of the APEH-mediated strategy to affect the ubiquitin-
proteasome system (UPS), several readouts were evaluated in differentiated Caco-2 cells 
treated with SsCEI 4 (200 µM) for 48 h. The commercially inhibitor of APEH (ebelactone) or 
the PI MG132, were used as positive controls. The immunoblot analysis showed that the 
levels of APEH in cells were not affected by any of these treatments while a significant 
increase of well-known proteasome substrates (p21Waf1 and NF-κB, two-fold or four-fold, 
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respectively; Figure 7A, B) was revealed. These findings are consistent with the idea that the 
relationship between apoptosis and the accumulation of damaged or short-lived regulatory 
proteins has a prominent role in controlling the homeostasis of cancer cells [85]. Cytoplasmic 
increase of NF-κB levels is indeed regarded as a major hallmark of different cell death 
mechanisms including apoptotis, since NF-κB nuclear translocation, following IκB 
degradation by UPS and gene transcription, is a well-established signal of cell growth. 
Proteasome inhibition in cancer cells leads to a reduced rate of IκB degradation, and to a 
longer persistence of NF-κB in the cytoplasm [86]. In the same way, accumulation of 
p21Waf1, a negative regulator of the cell division cycle, is a direct evidence of increased 
apoptosis and of reduced proteasome function, since it has been reported that its degradation 
occurs through N-terminal as well as internal lysine ubiquitinylation [87]. Polyubiquitinylated 
proteins are normally degraded by UPS, and downregulation of proteasome activity has been 
shown to substantially suppress bulk intracellular protein turnover [55]. As evidenced in 
Figure 7C, following incubation with SsCEI 4, ebelactone or MG132, we detected in cell 
extract the presence of high-molecular mass immunoreactive species (66 kDa to 160 kDa) 
which were absent in untreated cultures. These signals are indicative of polyubiquitin 
conjugates in the treated cells, confirming that the three tested compounds deregulate UPS in 
cancer cells. As a whole, our in vitro results demonstrate that APEH inhibition by SsCEI 4 
treatment is associated with increased levels of the typical markers of proteasome inhibition 
without any cytotoxic effect.  
 
7,829+8!)/1!$48328840/!
$'!
!
 
Figure 7. Evaluation of proteasome inhibition markers in Caco-2 cells incubated with 
SsCEI 4. Representative immunoblots of the expression of p21Waf1, NF-kB, and APEH in 
Caco-2 cell exposed for 48 h to 10 µM MG132 (MG), 100 µM ebelactone (Ebel) or 200 µM 
SsCEI 4 (S4) (A). Data on Western blot analysis are expressed as the density ratio of target to 
control (β-actin) in arbitrary units. The values were expressed as average relative intensity as 
compared to untreated cultures and expressed as means±SD of measurements performed in 
triplicate (B). Protein ubiquitinylation in Caco-2 cell exposed for 48 h to MG, Ebel or S4 (C, 
upper panel). Upon the immunodetection, the membrane was stained with Coomassie blue. 
The lane loaded with molecular mass markers [MW kDa] was shown (C, lower panel). 
In this study we showed for the first time that, by using APEH inhibitors, proteasome activity 
can be regulated through an APEH-mediated mechanism which represents a novel strategy to 
control UPS functions. Beside these findings, we demonstrated that the stable, a selective and 
non-toxic inhibitor of APEH (the peptide SsCEI 4) is able to produce a noticeable 
downregulation of UPS in tumor cells. Moreover, this molecule represents an attractive 
template for the design of more potent inhibitors, with potential applications as anticancer and 
anti-inflammatory agents.  
 
2.6 CF3-lmph is a selective inhibitor of APEH having an uncommon mechanism of 
inhibition and a stable bent conformation 
With the aim of developing new compounds able to modulate APEH activity and to further 
investigate the role played by APEH in cell viability, we have undertaken the screening of a 
complex library of short synthetic peptides modified on the N terminus by a set of diverse 
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chemical groups; this to prevent undesired substrate-like behaviors of the peptides exposed to 
the enzyme. After five iterative rounds of screening and resynthesis needed to elucidate the 
whole peptide structure, we identified in the N-terminally modified tetrapeptide of sequence 
TFA-D-Leu-D-Met-D-Pro-D-His-NH2 (hereafter termed  CF3-lmph), the one best molecule 
able to inhibit the APEHpl activity, in a dose-dependent manner (Figure 8A) with an IC50 
value of 98.0±6.4 µM.  The selectivity of CF3-lmph was initially evaluated in biochemical 
assays using a panel of eukaryotic proteases (trypsin, α-chymotrypsin, elastase, 
carboxypeptidase Y, subtilisin and proteinase K). Results showed that the best protein target 
for CF3-lmph was APEH with a maximum of  72% inhibition reached at 150 μM. This 
inhibition did not increase even using the peptide at 1 mM. Moreover, in the presence of 
increasing amounts of CF3-lmph, both the Vmax of APEHpl that Km were affected, indicating 
a uncompetitive inhibition mechanism, with a Ki value of 24.0 ± 0.8 μM. This mechanism 
was confirmed by the Lineweaver−Burk plot, that reveals a series of parallel lines, which is 
the hallmark of uncompetitive inhibition (Figure 8B).!This very uncommon type of inhibition 
takes place when an enzyme inhibitor binds only the complex formed between the enzyme 
and the substrate (the E-S complex).!This reduction in the effective concentration of the E-S 
complex increases the enzyme's apparent affinity for the substrate (Km is lowered) and 
decreases the maximum enzyme activity (Vmax), as it takes longer for the substrate or 
product to leave the active site.  
 
 
Figure 8. Kinetic analysis of CF3-lmph towards APEH. Binding of CF3-lmph to porcine 
liver APEH (APEHpl) using Acetyl-Ala-pNA as substrate (A). The hyperbolic curve indicates 
the best fit for the percentage inhibition data obtained, and the IC50 value was calculated 
7,829+8!)/1!$48328840/!
$)!
!
from the graph. Double-reciprocal plots of the velocity against substrate (Ac-Ala-pNA) 
concentration at three different CF3-lmph concentrations (no inhibitor ?, 50 μM ■, and 100 
μM ▲) (B). The velocity of the reaction is expressed as μmol of p-nitroaniline 
released/min/mL of enzyme on incubation at 37 °C. Ki value was determined from the 
equation of the uncompetitive inhibition (see insert for a plot of [(1 +i/Ki)/Vmax] vs inhibitor 
concentration). 
Also the activity of the acetylated and nonacetylated variants was tested against APEHpl to 
assess the role of the N-terminal trifluoroacetyl group. The presence of this moiety confers a 
high specificity to peptide activity, because no enzyme inhibition was seen with the acetylated 
and the NH2-free peptides. Finally, a structural analysis of the peptide, carried out by circular 
dichroism (CD) and NMR spectroscopy, revealed that the molecule in solution adopts a well-
organized and stable (twisted or bent) conformation induced by the presence of a D-proline on 
position 3. The molecular model obtained by restrained molecular dynamics simulations 
showed a good agreement with experimental NMR data and were chosen as representative of 
peptide structures (Figure 9). 
 
 
Figure 9. Backbone superposition of ten molecular frames collected during the last 2 ns of 
restrained molecular dynamics for CF3- lmph. 
 
2.7 APEH and proteasome expression at both mRNA and protein level correlates with 
their enzyme activity in cancer cell lines. 
To deepening the ability of the two peptides under investigation to reduce cell proliferation, 
we decided to test the molecules on a collection of tumoral cell lines. 
Initially, we decided to examine the basal expression/activity levels of these enzymes in 
fourteen cancer cell lines and in normal human fibroblasts (at their pre-confluent stage), 
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among those most commonly used in laboratory practice, to select the best cellular candidate 
for further investigations. The pre-confluent stage was chosen for practical considerations 
altought, in some cases, it do not provide suitable cell models for drug testing.  
As shown in Figure 10, when basal specific APEH activity was plotted against the 
corresponding proteasomal chymotrypsin-like (CT-like) activity, a significant positive 
correlation was found (r
2
=0.81, P=<0.01), supporting the idea of a functional relationship 
between these two enzymes which could act in cooperation for degradation of damaged 
proteins [70, 88].   
 
 
Figure 10. Human cancer cell lines may be grouped according to the basal enzyme activities 
of APEH and proteasome. Cells from fourteen human cancer lines  and non-cancerous cells 
(BHk21, fibroblasts) were harvested at the pre-confluent stage. Basal APEH and proteasomal 
CT-like activities were measured in cytoplasmic extracts.!Results are presented as the mean 
values ±SD of triplicate analyses from at least three different experiments. 
On the basis of the basal levels, we identified two groups of cells displaying high (Group I) 
or low (Group II) APEH and proteasome activity values. The analysis of gene expression 
and intracellular protein levels of APEH and proteasome (β-5) in the different cell lines 
confirmed the existence of the two groups (Figure 11A-B). In light of results obtained, we 
decided to undergo to further investigations the cells of Group I, in good accordance with the 
hypothesis that cells exhibiting high activity and expression levels of APEH and proteasome 
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could be highly dependent on these enzyme functions and therefore more sensitive to their 
specific downregulation.  
!
!
Figure 11. Expression and protein levels of APEH and proteasome. Cells from fourteen 
human cancer lines were harvested at the pre-confluent stage and used for cytoplasmic or 
mRNA extract preparation. The mRNA levels of APEH and β-5 subunit were evaluated by 
qRT-PCR and expressed as fold change in comparison to expressed levels in human 
fibroblast (A). Intracellular levels of β-5 and APEH were detected by immunoblotting (B). 
Data from three different analyses were normalized to the density of control protein (β-actin) 
and expressed as ratio over control (B). Results are presented as the mean values ±SD of 
triplicate analyses from at least three different experiments. 
 
2.8 SsCEI 4 inhibits proliferation and decreases APEH-proteasome activity in U2OS 
osteosarcoma cell lines 
The susceptibility of cell lines belonging to Group I to the growth inhibitory effects of SsCEI 
4 and CF3-lmph was estimated up to 48 h exposure at two different concentrations (50 and 
100 µM).  
As shown in Figure 12,  the treatment of cells with SsCEI 4 caused a marked dose and time-
dependent reduction in cell viability of osteosarcoma cell lines (U2OS and SaOS) respect to 
untreated cells, reaching a maximum reduction of viability of 63% and 40%, respectively to 
the highest concentration used (100 -M) and at 48 h. In addition, exposure of cells to the 
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peptide CF3-lmph resulted in a significant dose-dependent anti-proliferative effect only on the 
osteosarcoma cell lines SaOS at 48 h, reaching a maximum inhibition of 40% . 
It is worth to note that, in these experimental conditions, Caco-2 cells were unaffected by 
SsCEI 4 treatment, possibly because the differentiation stage could be a necessary requisite 
for the susceptibility of these cells to the SsCEI 4 anti-proliferative effects. 
 
Figure 12. Human cancer cells exhibit differential sensitivity to the anti-proliferative 
activity of peptides SsCEI 4 and CF3-lmph . The effects of peptides on cell viability were 
assessed in six cancer cell lines exposed for 24 and 48 h to increasing concentrations of 
SsCEI 4 or CF3-lmph. Data are expressed as means ±SD values of triplicate data from three 
independent experiments.  
These results suggest that the high basal levels of proteasome and APEH may be a  necessary 
but not sufficient condition to identify cancer cells sensitive to APEH inhibition.  Moreover, 
the ability of the two peptide molecules to induce a marked anti-proliferative effect on 
osteosarcoma cell lines could indicate the existence of a tumor target specificity linked to 
diversity of response and physiology of these cell lines. 
On the basis of the proliferation assay (Figure 12), we selected SsCEI 4 and U2OS 
osteosarcoma cell line as model system for investigation on the role played by APEH in the 
multiple cancer cell anti-proliferative pathways. In order to define the dose accountable for 
50% decrease of cell viability (IC50), U2OS cells were incubated for different time (24, 48 
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and 72 h) with increasing concentrations of SsCEI 4 (ranging from 100 nM to 200 μM), using 
human fibroblasts as control and the viable cell number was determined using an MTT assay. 
The resulting isobolograms (Figure 13) revealed that SsCEI 4 reduced the cell viability of 
U2OS in a concentration- and time-dependent manner with an IC50 value of 50.0±1.0 μM. 
Moreover, proliferation data obtained from fibroblasts, even at higher concentration of SsCEI 
4, supported the lack of toxic effects (data not shown). As the maximal effect of cell viability 
inhibition was observed at 72 h, this time was chosen to set up our further experiments. 
 
 
 
Figure 13. SsCEI 4 inhibits cell growth in U2OS cells in a dose- and time-dependent 
manner. To measure the anti-proliferative activity of SsCEI 4, U2OS cells were cultivated in 
the presence or absence of increasing concentrations of the peptide (0.1-200 µM) for 24, 48 
or 72 h. Inhibition of cell growth was assessed by MTT assay and values represent the means 
±SD of triplicate data from three independent experiments. 
To assess the cytotoxicity of SsCEI 4 on the cancer cells considered, LDH activity was 
measured in spent media following 72 h exposure to 50 and 100 μM, using DMSO and 10 nM 
Bortezomib (BTZ) as controls . As expected, substantial cell death resulted from BTZ 
supplementation while the LDH activity in cultures exposed to SsCEI 4 was comparable to 
that of control, indicating that the reduction of cell viability induced by SsCEI 4 was not 
associated with any cytotoxic effect (Figure 14). 
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Figure 14. LDH release in the culture media was measured to study the cytotoxic of SsCEI 
4. U2OS cell cultures, treated with DMSO alone or with BTZ (10 nM), were used as positive 
controls. U2OS cell cultures were treated with cell lysis buffer to induce maximum LDH 
leakage (LDH control), DMSO alone or with Bortezomib (BTZ, 10 nM) as controls.  LDH 
activity was determined by a fluorescent assay (n = 3). Data are reported as percentage of 
maximum LDH release and values are presented as means±SD.  
 
2.9 U2OS exposure to high SsCEI 4 doses increases the level of UPS substrates in 
association with APEH/proteasome downregulation  
Proteasome inhibition represents a validated, although challenging, anticancer approach. 
However, to prevent the adverse effects deriving from indiscriminate cell death, inhibition of 
the proteasome needs to be tightly controlled or selectively induced in cancer tissues. 
Therefore, the concept that proteasome activity could be decreased via APEH inhibition was 
investigated in U2OS cancer cell line.!To this end, U2OS cells were incubated with increasing 
SsCEI 4 doses (50 or 100 μM) or with a specific PI (MG132) for 72 h. As shown in Figure 
15, SsCEI 4 markedly reduced proteasome activity in a dose-dependent manner, reaching its 
maximum effect at 100 µM, where enzyme activity was decreased by 54%. Under the same 
conditions, a less marked dose-dependent inhibition of APEH activity (32%) was observed. 
Notably, MG132 treatment had no detectable effects on APEH activity, suggesting that 
proteasome modulation should be hierarchically down-stream of APEH inhibition. We next 
examined the inhibitory effects of SsCEI 4 on the CT-like activity in cell-free assays, to 
confirm that it is not directly targeted by this inhibitor. In these experiments, partially purified 
proteasome from U2OS cells or the commercially available 20S proteasome from 
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erythrocytes, were used. As shown in Figure 16, SsCEI 4 do not directly downregulate 
proteasome (either purified from U2OS or from human erythrocytes) function thus 
demonstrating that its dysfunction occurs via a more complex pathway that is triggered by 
APEH inhibition and has APEH like an important and regulative factor.  
 
 
Figure 15. Dose-dependent anti-proliferative activity of SsCEI 4 correlates with 
downregulation of APEH and proteasomal CT-like subunit at activity level in U2OS cells. 
Pre-confluent U2OS cultures were incubated for 72 h with 50 or 100 μM SsCEI 4. Cells 
untreated or treated with 10 µM MG132 were used as negative or positive controls, 
respectively. Measurement of APEH or proteasomal CT-like activities were performed on 
cytoplasmic extracts. 
 
Figure 16. SsCEI 4 not exhibits inhibitory ability towards chymotrypsin-like (CT-like) 
proteasome activity. The inhibitory effects of SsCEI 4 or Bortezomib were evaluated on 
commercially 20S proteasome using the synthetic fluorescent substrate N-Suc-LLVT-AMC 
(0.080 mM) for the measurement of the CT-like activity. Results are presented as the mean ± 
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standard deviation (SD) of triplicate analyses from three independent experiments. SD values 
lower than 5% were not shown. 
To gain insights into the mechanism by which SsCEI 4 induces its anti-proliferative effect, we 
performed a gene expression analysis of APEH and proteasome on osteosarcoma cell line by 
qRT-PCR, following treatment with 50 and 100 µM at 72 h, demostrating that it did not cause 
any significant variation of both gene transcripts (Figure 17). 
 
 
Figure 17. Dose-dependent anti-proliferative activity of SsCEI 4 does not correlate with 
downregulation of APEH and proteasomal CT-like subunit at mRNA level in U2OS cells. 
The mRNA levels of APEH and β-5 subunit were evaluated by qRT-PCR and expressed as 
fold change in comparison to untreated cells (k). 
Conversely, analysis of protein levels by Western blot revealed that SsCEI 4 caused a marked 
reduction of APEH and proteasome (40 and 56%, respectively) in osteosarcoma cell line, 
possibly indicating that the specific downregulation of the APEH and proteasome activities 
could induce their protein degradation thus contributing to the dysfunction of degradative 
machinery and to the inhibitory effect of SsCEI 4 on the U2OS viability (Figure 18). 
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Figure 18. Intracellular levels of β-5 and APEH in U2OS cell lysates exposed for 72 h to 
SsCEI 4 were detected by immunoblot analysis (A). Typical Western blot was shown and data 
from three different analyses were normalized to the density of control protein (β-actin) and 
expressed as ratio over control (B). Results are presented as the mean values ±SD of 
triplicate analyses from at least three different experiments. 
To finally confirm the reliability of the APEH-mediated strategy to affect UPS activity, the 
cytoplasm levels of the polyubiquitinylated proteins, which represent the classic hallmark of a 
direct effect of proteasome inhibition, were evaluated in U2OS cells treated for 72 h with 
SsCEI 4 at the indicated concentrations (50 and 100 µM). Polyubiquitinylated proteins are 
normally degraded by the cellular proteasomes, and downregulation of proteasome activity 
has been shown to substantially suppress bulk intracellular protein turnover [55]. As 
evidenced in Figure 19, following incubation with SsCEI 4, we detected in cell extract a 
dose-dependent increase in the levels of high molecular-mass immunoreactive species (66 
kDa to 160 kDa), which are absent in untreated cultures. These signals are indicative of 
polyubiquitin conjugates in the treated cells, confirming that SsCEI 4 deregulates UPS 
activity in cancer cells.  
A B
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Figure 19. Evaluation of proteasome inhibition marker in U2OS cells incubated with 
SsCEI 4.!Polyubiquitinated proteins in U2OS cells untreated (K) and treated with SsCEI 4 for 
72 h. The membrane PVDF was stained with Coomassie blue after immunodetection. The 
lane loaded with molecular mass markers [kDa] was shown. 
On the basis of these results, we hypothesized that APEH and proteasome can be functionally 
related and act as components of a new pathway controlling protein homeostasis and cancer 
cell proliferation.   
 
2.10 SsCEI 4 induces cell death and G0/G1 phase cell cycle arrest in osteosarcoma cell 
lines through inhibition of Nf-κB signaling.  
To further examine the relationship between SsCEI 4 and the APEH-proteasome pathway, we 
investigated on the mechanism of cell death involved in the anti-proliferative effect of SsCEI 
4 and activated in response to inhibition of APEH-proteasome system in U2OS.  
Ø Apoptosis 
The correct functioning of the UPS pathway is essential for the degradation of the majority of 
intracellular proteins. Several key regulatory proteins involved in cell proliferation and 
differentiation are regulated by proteasome-mediated proteolysis resulting in the activation or 
inhibition of speciﬁc cell signaling pathways [14]. Therefore, it is not surprising that a myriad 
of cell responses and pathways are perturbates as a result of proteasome inhibition. In vitro 
and in vivo studies have demonstrated that proteasome inhibitors affect tumor growth by 
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inducing apoptosis, a genetically programmed mechanism(s) that allows the cell to commit 
suicide, in several human cancer cells [89]. Indeed, caspases, the key proteases activated 
during apoptosis, are also regulated by the proteasome.  
To this end, to examine the contribution of an apoptotic event in SsCEI 4-induced 
decline of cancer cells viability, caspase 3 activation was measured. Interestingly, results 
revealed that caspase 3 activity was not improved at increasing doses of SsCEI 4, as shown in 
Figure 20.   
 
 
Figure 20. Caspase 3 activity was measured in U2OS cells treated with SsCEI 4. Pre-
confluent U2OS cultures were incubated for 72 h with 50 or 100 μM SsCEI 4. Thereafter, 
cells were harvested, and used for cytoplasmic extracts preparation. Caspase 3 activity values 
are expressed as fold increase in comparison to untreated cells. Results were presented as 
means±SD of triplicate data from three independent experiments.  
This result was further confirmed by Western blot analysis which showed that SsCEI 4 
treatment failed to induce the proteolytic cleavage of caspase 3 and the poly(ADP-ribose) 
polymerase (PARP), two critical events that are a hallmark of apoptosis (Figure 21). 
Therefore, our findings demonstrated that the U2OS anti-proliferative effect elicited by SsCEI 
4 does not trigger apoptosis. 
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Figure 21. U2OS cells were treated 72 h with or without 50 and 100 μM SsCEI 4. Cleaved 
PARP and caspase 3 were evaluated by western blot. Jurkat cells treated with Etoposside 
(ETP) were used as positive controls. 
 
Ø  Autophagy 
The cells have evolved a multitude of pathways that can be used to promote cell killing under 
appropriate conditions. In this context, apoptosis is the best-characterized form while 
autophagy, as part of the lysosomal system, is an evolutionarily conserved cellular strategy to 
engulf and degrade long-lived cytosolic proteins and organelles to provide substrates for 
energy metabolism and to recycle amino acids, fatty acids, and nucleotides for the 
biosynthetic needs of cells [90]. Generally, autophagy plays dual roles in cellular death or 
survival: one is to induce type II programmed cell death, which is different from apoptosis 
and is often termed autophagic cell death, whereas the other is to recycle cellular components 
to sustain metabolism and to prevent the accumulation of damaged, toxic proteins and 
organelles during stress [91]. A recent study reported that inhibition of the proteasome can 
induce autophagy in human SHG-44 glioma cells, and inhibition of autophagy increases cell 
death [92]. Typical markers of this mechanism are Beclin 1 and LC3-I/LC3-II. Beclin 1 is a 
Bcl-2-interacting protein that promotes autophagy and has an important role in cellular 
proliferation and tumorigenesis. Specifically, Beclin 1 is required for the initiation of the 
formation of the autophagosome. Microtubule-associated protein light chain 3 (LC3) is 
synthesized as a proform that is cleaved by a protease to become LC3-I. Indeed, LC3 exists in 
cells in two forms; one is cytoplasmic, LC3-I (18 kDa) and the other, LC3-II (16kDa) is 
associated with the autophagosome membrane. Upon initiation of autophagy, the C-terminal 
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glycine of LC3-I is modified by addition of a phosphatidylethanolamine (PE) to form LC3-II, 
which translocates rapidly to nascent autophagosomes. The expression level of LC3-II 
generally correlates with the number of autophagosome. Western blot assessment of the 
increase in either the LC3-II forms or of the relationship between LC3-II and LC3-I content is 
currently considered as a simple, quick procedure to verify the presence of cell autophagy 
[93]. LC3 antibody was able to recognize both the upper LC3-I band and the lower LC3-II, 
which has a faster mobility on immunoblots as a result of the greater hydrophobicity. 
To determine the role of autophagy in anti-proliferative effect of SsCEI 4, Western blot 
analyses were performed. As shown in Figure 22A, SsCEI 4 did not affect the expression of 
Beclin 1 in U2OS cells. In addition, as shown in Figure 22B, after 72 h incubation with 
SsCEI 4 no alteration in the conversion of LC3-I to LC3-II was found.!U2OS treated with 
chloroquine (CQ), which causes accumulation of the lipid-modified LC3, were used as a 
positive control to confirm the identity of LC3-I and LC3-II. These results suggest that 
autophagy was not responsible for the anti-proliferative effect of SsCEI 4 observed in U2OS 
cells. 
 
 
Figure 22. Western blot of Beclin 1 (A) and LC3 (B) after treatment of U2OS cells with 
SsCEI 4 (50 and 100 µM). All the treatments were carried out for 72 h. Results of 
densitometry of Beclin 1 bands (left panel) are expressed as the mean of relationships 
between densitometries of Beclin 1 and α actin bands ± SD for three different experiments. 
The image (right panel) is representative of three different experiments.  
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Ø  Oxidative stress: ROS accumulation 
It was recently reported that proteasome inhibition by bortezomib increased the levels of 
intracellular ROS levels [53]. Therefore, we next investigated whether SsCEI 4 triggered an 
alteration of the redox status by increasing the intracellular ROS in osteosarcoma cancer cells.!
U2OS were treated with 50 and 100 µM SsCEI 4 from 1 to 48 h and then stained with DCF-
DA and analysed by FACS to identify cells bearing ROS. As shown in Figure 23, the levels 
of intracellular ROS did not increase in U2OS cells after exposure to SsCEI 4 for 1 h but 
same results were obtained upon 48 h treatment (data not shown), suggesting that the 
alteration of the redox status is not associated with the antiproliferative effect of SsCEI 4. 
 
Figure 23. Analysis of intracellular ROS levels by FACS.  U2OS cells were treated with 
SsCEI 4 (50 and 100 !M) from 1 to 48 h and analyzed respect to untreated cells (green line).  
!
Ø Cell cycle arrest 
To determine whether the antiproliferative activity induced by SsCEI 4  was caused by cell 
cycle arrest, we examined the effect of SsCEI 4  on cell cycle of U2OS. The percentages of 
cells in the G0/G1, S and G2/M phases were determined by flow cytometric analysis of 
propidium iodide stained cells. For these experiments, U2OS cells were exposed to increasing 
concentrations of SsCEI 5 (50 and 100 -M) and cell cycle profile was evaluated after 24, 48 
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and 72 h. Preliminary data revealed that, in the presence of peptide, the percentage of cells in 
G0/G1 phase increased in a time and dose-dependent manner, reaching a maximum already at 
48 h and at 100 -M (Figure 24). Further analyses will be need to investigate the changes in 
G0/G1 phase-related cycle regulators in response to SsCEI 4 treatment. 
 
 
Figure 24. SsCEI 4 induces a G0/G1 cell cycle arrest  in U2OS cells. Cell cycle analysis was 
performed after exposing U2OS to SsCEI 4  (50 and 100 µM) for 24 h, 48 and 72 h. The 
experiment shown is a representative example from three different experiments. CNT, control. 
It is reported that a key component of PI mediated growth arrest is inhibition of NF-κB 
signaling. NF-κB signaling in cancer cells is controlled by the ubiquitin proteasome pathway, 
which directs the ubiquitination and proteolysis of its inhibitory partner, IκB. Once freed from 
its inhibitor, NF-κB gets localized in the nucleus where it allows transcription of many genes 
driving cancer cell proliferation. To confirm the G0/G1 cell cycle arrest, we analyzed the 
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cytoplasmatic levels of NF-κB in U2OS cells treated with SsCEI 4 by Western Blot. As 
shown in Figure 25, treated U2OS cells exhibited a higher levels of the target protein than 
control cells, suggesting  that this transcription factor could be responsible for the cell-cycle 
arrest induced by SsCEI 4. 
  
!
Figure 25. SsCEI 4 increases the cytoplasmic level of NF-κB in U2OS cells. Cells were 
treated with SsCEI 4 (50 and 100 !M) for the indicated times and cell extracts were prepared 
and analyzed by western blot. β-actin was used as a loading control. The values were 
expressed as average relative intensity as compared to untreated cultures and expressed as 
means±SD of measurements performed in triplicate. 
2.11 Proteasomal degradation of the cystic fibrosis transmembrane conductance 
regulator (CFTR) mutated protein is prevented by SsCEI 4  
In light of a recently proposed cooperative role for the APEH–proteasome system in the 
control of protein turnover [70], we hypothesised that APEH could be used as a target to 
indirectly control/modulate proteasome functions. To support this idea, we conducted in vitro 
experiments using the selected APEH inhibitor (SsCEI 4) on the Baby Hamster Kidney 
(BHK) cell line, stably expressing a mutant protein of the cystic fibrosis transmembrane 
conductance regulator (CFTR), known as ΔF508 CFTR-3HA (hereafter called CFTR-M), 
bearing the deletion of Phe508, one of the most common modification in patients with cystic 
fibrosis. Many of the mutations in the CFTR gene that cause cystic fibrosis interfere with the 
folding and biosynthetic processing of CFTR molecules in the endoplasmic reticulum. 
Specifically, some mutations, including the common ΔF508, decrease the efficiency of CFTR 
folding, reduce the probability of its dissociation from molecular chaperones, and largely 
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prevent its maturation through the secretory pathway to the plasma membrane. These mutant 
CFTR molecules are rapidly targeted for proteolysis via the UPS [85, 94].!Accordingly, BHK 
and human bronchial epithelial cells (CFBE41o-DF) expressing CFTR-M were used in this 
study as a model system to confirm the role of APEH in the coordinated protein-degradation 
machinery, and steady-state levels of the core glycosylated CFTR-M form (140 kDa) were 
evaluated by immunoblot analysis. Remarkably, the SsCEI 4 peptide efficiently prevented 
degradation of CFTR-M at the time intervals considered (24 h and 48 h). As a fact, exposure 
of BHK cells to 100 -M SsCEI 4 for 48 h induced a marked increase of CFTR-M levels 
(twenty-fold) (Figure 26A, B),without any cytotoxic effects (data not shown).  
 
 
 
 
Figure 26. Analysis of the CFTR-M protein accumulation in BHK cells treated with the 
SsCEI 4. Representative Immunoblots and associated densitometric analysis for cytosolic 
CFTR-M accumulation in BHK cells following 24 h and 48 h exposure to 50 !M or 100 !M 
SsCEI 4 (A) Bands were quantified using densitometric analysis and normalized against α-
tubulin. The values were expressed as average fold increase as compared to untreated culture 
(B).  
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In addition, a dose-dependent inhibition of APEH and proteasome CT-like activities was 
observed upon 48 h of incubation (similar data on APEH and proteasome activities were 
measured after 24 h cell exposure) with peptide, as shown in Figure 27 (C, D) consistent with 
the immunoblot results.  
 
 
Figure 27. APEH activity was measured in BHK cells incubated with 50 !M and 100 !M 
SsCEI 4 (white bars)for 48 h (C). CT-like proteasome activities were measured in BHK cells 
incubated with 50 !M and 100 !M SsCEI 4 (white bars) for 48 h (D). Untreated cultures 
were used as controls (black bars); the data are expressed as means±SD. 
Finally, siRNA technique was used to directly correlate APEH to the protein degradation 
processes via UPS. For this purpose, the accumulation of CFTR-M was evaluated in 
CFBE41o-DF cells following transfection with APEH siRNA. As shown in Figure 28, APEH 
siRNA-transfected cells exhibited a considerable reduction of APEH protein levels and a 
marked accumulation of CFTR-M (eight-fold, data not shown), in contrast to cells transfected 
with a not specific siRNA which displayed basal levels of APEH and neglectable level of 
CFTR-M. Therefore, APEH can be seen as an alternative target, whose inhibition by 
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competitive inhibitor is accompanied by a parallel downregulation of proteasome activity 
through a yet unknown mechanism. 
 
 
Figure 28. Analysis of the CFTR-M protein accumulation in APEH siRNA transfected 
CFBE41o-DF cells. Representative Immunoblots of APEH and CFTR-M accumulation in 
CFBE41o-DF cells transfected with APEH siRNA. A scrambled, non-targeted siRNA, was 
used as negative control and α-tubulin was used as loading control. 
 
!&(!
!
!
!
!
!
!
:5!'0/392840/8!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
'0/392840/8!
&)!
!
roteasome is an abundant multi-enzyme complex that provides the main pathway for 
the protein turnover or the elimination of misfolded and aggregated proteins. As 
such, it controls the levels of proteins involved in cell-cycle progression and 
apoptosis in normal and malignant cells, and has become an important target in anticancer 
therapies [95]. A large number of specific PI molecules have been developed to date [96], but 
despite their indisputable efficacies all of these suffer for negative side-effects. These events 
represent the major drawback of impairing the activity of a target largely involved in 
important physiological processes. For these reasons, several studies have suggested that the 
targeting of functionally related, up-stream or down-stream proteasome effectors [9], can be 
an alternative and a safer way to recover proteasome dysfunction associated with pathological 
conditions [11, 55]. In this study we showed for the first time that, by using a specific APEH 
inhibitor, proteasome activity could be regulated through an APEH-mediated mechanism, 
which represents a novel strategy to control UPS functions. Beside these findings, we 
demonstrated that the stable, selective and non-toxic inhibitor of APEH (SsCEI 4) is able to 
produce a noticeable downregulation of UPS activity in different cancer cells. Moreover, this 
molecule represents an attractive template for the design of more potent inhibitors, with 
potential applications as anticancer and anti-inflammatory agents. APEH has been postulated 
to serve as a key regulator of N-terminally acetylated proteins [58] but the biological effects 
of disrupting APEH has not been completely understood. As more than 80% of proteins in 
human cells are N-terminal acetylated [97] and protein acetylation is implicated in a variety of 
essential cellular pathways [98], it is thus likely feasible that APEH is involved in these 
processes. As reported in previous studies, proteasome and APEH act cooperatively in protein 
turnover [70, 88], although the biochemical mechanisms remain to be clarified. In this regard, 
in contrast to the general idea that N-terminal acetylation protects from degradation, in certain 
proteins some sequences, which include acetyl groups at the N terminus, were recently found 
to be involved in degradation signals [99]. On the basis of our preliminary results, a direct 
interaction between APEH and proteasome might be excluded, whereas the hypothesis that 
APEH can activate or stabilize the proteasome by uncovering the N-tail of a yet unknown 
negative effector protein cannot be ruled out. Of note, we showed that whereas APEH 
inhibition triggered an impairment of the proteasome activity, its selective inhibition did not 
affect APEH functions, likely suggesting that APEH could be an up-stream modulator of the 
proteasome. Studies aimed at achieving a better understanding of the mechanism/s 
P 
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responsible for the APEH mediated downregulation of proteasome and at the evaluation of 
APEH inhibitors in animal cancer model are currently in progress. 
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5.1 Conjugated linoleic acid  
n the last decade, conjugated linoleic acid (CLA) has been studied intensively because of 
its unusual biological activities [1]. Conjugated LA was discovered quite accidentally 
when Pariza and Hargraves [2] were investigating the carcinogenic properties of grilled 
beef. To their surprise, the fatty acids present in grilled beef exhibited anticarcinogenic rather 
than procarcinogenic properties. CLA is a mixture of geometric and positional isomers of 
linoleic acid (18;2 n-6 or 9,12-cis,cis-octadecadienoic acid, LA) in which the double bonds 
are conjugated, instead of being in the typical methylene interrupted configuration [3]. They 
are found naturally in ruminant food products such as beef, lamb and dairy because of the 
process of bacterial biohydrogenation of LA in the rumen [4-6]. During the biohydrogenation 
of linoleic acid to stearic acid, CLA is synthesized as an intermediate by gram-negative 
bacteria, Butyrivibrio fibrisolvens [7]. Although 28 different CLA isomers are found in 
natural food, the major isomer is the cis9-trans11- (c9,t11)-CLA accounting for more than 
90% CLA intake in the diet [8]. CLA isomers can be prepared commercially by heating LA 
under alkaline conditions or by partial hydrogenation of LA [9]. Health benefits of CLA have 
been attributed to mainly two of its isomers: c9,t11-CLA and trans10-cis12 (t10,c12)-CLA, 
which are contained in equal levels (approximately 40–45%) in the mostly common used 
CLA. Structures of the parent LA, c9,t11- and t10,c12-CLA isomers are shown in Figure 29. 
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Figure 29. Chemical structures of linoleic acid and isomers of conjugated acid (CLA) 
 
In recent years, with the advent of technology, enriched of purified c9,t11-CLA and t10,c12-
CLA preparations have become commercially available, leading to studies examining the 
effects of these individual isomers in health-related disorders using animal models and cell 
cultures. Most of the studies have used CLA isomer mix, but recent evidence suggests that 
c9,t11-CLA and t10,c12-CLA may have myriad effects in different biological systems, which 
often may be similar or opposite. Specifically, CLAs have been shown to have antiadipogenic 
[1], anticarcinogenic [10], antiatherogenic [11], antidiabetogenic [12] and anti-inflammatory 
properties [13] (Table 2).  
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Anti-carcinogenic effects · Growth Inhibition 
· Metastasis reduction 
· Antiproliferative effect 
· Inhibition angiogenesis 
· Induction of apoptosis 
Anti-adipogenic  effects                                                         · Reducing lipid accumulation 
· Reduction of fat mass 
· Increasing adipocyte apoptosis 
Anti-inflammatory effects · Antiinflammatory cytokines 
inhibition 
· Antiinflammatory ecoisanoid 
inhibition 
       Table 2. Biological effects of CLAs in health 
 
5.2  Biological activities of CLA 
The biological role of CLA and its purified isomers (c9,t11 and t10,c12) in different models 
of health-related disorders in cell culture, animals and clinical studies are summarized below 
[14, 15]: 
 
Ø Body fat reduction by CLA 
One aspect of CLA that has drawn much attention is its ability to reduce body fat in animals, 
first reported in 1995 [16].!The availability of purified isomers or CLA enriched in either 
c9,t11-CLA or t10,c12-CLA isomers prompted new in vivo and in vitro studies, which 
identified t10,c12-CLA isomer to be primarily involved in reduction of fat mass, and not the 
c9,t11-CLA isomer [17]. CLA’s effect on body fat reduction is suggested to be the result of 
multiple mechanisms: increasing energy expenditure, reducing lipid accumulation in adipose 
tissues and/or adipocytes differentiation, increasing adipocyte apoptosis and increasing fatty 
acid β-oxidation in skeletal muscle [17]. 
 
Ø Prevention of cardiovascular diseases 
CLA has been reported to reduce atherosclerotic lesions in rabbits and hamsters [18]. CLA 
decreases total cholesterol, triacylglycerides (TG), LDL-cholesterol and increased HDL-
cholesterol in a number of animal models [14]. CLA affects these parameters through 
involvement of peroxisome proliferator-activated receptor (PPAR, key for lipogenesis), sterol 
regulatory element-binding proteins (SREBPs, key for fatty acid synthesis and elongation), 
"/+-0123+40/!
($!
!
and/or steroyl-CoA desaturase (SCD, key for TG and cholesterol formation) [14, 19]. 
Peroxisome proliferator-activated receptors are ligand-activated nuclear receptors regulating 
the expression of genes that control lipid and glucose homeostasis, thus modulating the major 
metabolic disorders predisposing to atherosclerosis [20]. Studies with pure isomers suggest 
that c9,t11-CLA isomer is more effective than t10,c12-CLA isomer in controlling key 
modulators of lipid metabolism [21]. Sterol regulatory element-binding protein 1 isoforms 
regulate fatty acid and TG synthesis [22]. Studies suggest that c9,t11-CLA isomer positively 
influences lipid metabolism by reduced synthesis and cleavage of hepatic SREBP-1, which in 
turn is regulated by hepatic LXRa expression [23].  
Hypertension is also a common pathological state associated with an increased risk of 
cardiovascular diseases. Nagao et al. have consistently shown that CLA or the t10,c12-CLA 
isomer decreases blood pressure and hypertension in various rat models prone to develop 
obesity, diabetes and obesity together, or hypertension [24]. 
Ø Inflammatory response and CLA 
Anti-inflammatory properties of CLA have been reported by reducing inflammation, and 
modulating the production of cytokines, prostaglandins, and leukotrien B4 [14, 25, 26]. 
However, Poirier et al. (2006) reported that the t10,c12-CLA isomer induced inflammatory 
responses in white adipose tissue [27]. Proinflammatory cytokines (TNF-α, IL-β, IL-1, etc.), 
anti-inflammatory cytokines [IL-10, interferon-γ (IFN-γ), etc.], eicosanoids (prostaglandins, 
leukotrienes) and nitric oxide (NO) are key inflammatory mediators that are regulated by 
dietary intake of polyunsaturated fatty acids (PUFA) including ω-6 and ω-3 fatty acids. 
Specifically, CLA decreases production of inflammatory mediators like prostaglandin PGE2, 
TNF-α,!IL-1β, IL-6 and NO. 
Ø Anticancer effects by CLA 
CLA has been shown to reduce cancer in a number of animal models, such as skin, colon, 
mammary, and liver [14, 28]. It has been suggested that CLA not only decreases initiation, 
promotion, and progression steps of cancer development, but also reduces metastasis of 
cancer [14, 28]. Mechanisms of inhibition of carcinogenesis may include antiproliferative 
effects, alterations in the components of the cell cycle and induction of apoptosis as well as 
inhibition of angiogenesis [28, 29-31].  
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Recent work by Ip and colleagues [32] demonstrated that CLA reduces the expression of 
cyclins A and D, that regulate the conversion of G1→S phase of the cell cycle. In addition, 
diets with CLA moderately increased levels of p16 and p27 cdk inhibitors. CLA feeding is 
also shown to up-regulate the expression of p53 [33], the protein product of a tumor 
suppressor gene that is frequently mutated in many tumor cells [34]. p53 is involved in 
monitoring the quality of DNA after G1 phase and, if DNA is damaged, will block entry of 
the cell into S phase by altering the expression of genes involved in growth arrest and 
promotion [35]. Together, these data suggest that CLA could reduce tumor cell proliferation 
by modifying cell cycle proteins that regulate this process. In addition, dietary CLA induces 
apoptosis in numerous tissues but the exact mechanism is not established. Specifically, it has 
been reported that CLA can decrease expression of bcl-2, a gene involved in suppression of 
apoptosis [36] and interfere with redox homeostasis inducing ROS formation [37]. Moreover, 
there is evidence in animal studies that fatty acids can decrease protein degradation through 
the inhibition of proteasome activity, although the exact mechanism is not known [38]. Of 
note, in several studies the prooxidant activity of CLA was associated to its pro-apoptotic 
effects on cancer cells [39] and to the modulatory ability of proteasomal chymotrypsin-like 
(CT-like) activity.  
Potential ways in which CLA could influence tumor cell growth is shown in  Figure 30. 
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Figure 30. Schematic diagram of how CLA may modulate the cell cycle and apoptosis. 
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6.1 t10,c12-, t9,t11- and c9,t11-CLA isomers differentially inhibit APEH and proteasome 
ecent studies have suggested that some fatty acids are able to disrupt the 
chymotrypsin (CT)-like proteasome activity. Among these, the two major isomers 
of conjugated linoleic acid (CLA), cis9-trans11 CLA (c9,t11-CLA) and trans10-
cis12 CLA (t10,c12-CLA), have shown pro-apoptotic activities in a number of cancer cell 
lines [40] and strong anticancer effects in numerous animal models [15]. Interestingly, 
although the mechanisms are yet poorly understood, their ability to inhibit the proteasome 
activity in vitro [38] suggests that this complex enzyme could be their ultimate target. On this 
background, we have investigated the molecular mechanisms that underlie the 
interrelationship between APEH and the proteasome, and their eventual regulation by natural 
compounds including the CLA isomers. 
A preliminary investigation of the potential inhibitory effect of CLA isomers on 
chymotrypsin-like (CT-like) activity of 20S proteasome isoform  was carried out. Inhibition 
analyses were performed by pre-incubating the purified enzyme with increasing amounts of 
each compound and their half-maximal inhibitory concentrations (IC50) were determined. 
The curves followed a hyperbolic pattern reaching 100% inhibition with all CLA isomers 
tested (Figure 31A-C), althought t10,c12- and c9,t11-CLA were the best effectors 
(IC50=14.8±2.0 μM and 31.2±8.8 μM on 20S isoform, respectively). Similar experiments 
were carried out by using the proteasome inhibitor bortezomib (BTZ) (Figure 31D) because 
of its recognized anti-proliferative activity on cancer cells. As expected, BTZ appeared to 
target 20S isoform (IC50=1.4±0.3 nM), reaching about 60% of inhibition, while octanoic acid 
(data not shown), used as a negative control, gave only negligible effects.!Next, before to 
investigate the possible mechanisms underlying the CLA-reduced viability of cancer cells, the 
potential contribution of APEH was explored. When the ability of these compounds to 
modulate porcine APEH (APEHpl) in cell-free assays was evaluated (Figure 31E), only 
t10,c12-CLA was revealed to affect the enzyme activity in a dose-dependent manner, 
reaching a maximum inhibition of about 41% (IC50=110.1±11.7 μM), whilst c9t11-CLA was 
ineffective. In addition the Ki of t10c12- CLA towards APEHpl was 140±20 -M and the 
Lineweaver-Burk plot revealed a non–competitive inhibition mechanism. Indeed, in the 
presence of increasing amounts of t10c12-CLA isomer, only the Vmax of APEHpl was 
affected (Figure 31F).  
R 
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This is the first evidence of a direct inhibition of APEH by a CLA isomer. Moreover, a 
stereoselective binding in the interaction with APEH and proteasome isoform of the CLA 
isomers can be proposed together with a specific ability of t10,c12-CLA to inhibit all these 
enzymes. 
!!!
!
 
Figure 31. CLA isomers exhibit dissimilar inhibitory ability towards chymotrypsin-like (CT-
like) proteasome and APEH activities. The inhibitory effect of different CLA isomers, namely 
c9,t11- (A), t9,t11- (B), t10,c12-CLA (C), bortezomib, BTZ (D), was evaluated on 
commercially available pure 20S (black circles) proteasome. The synthetic fluorescent 
substrate N-Suc-LLVT-AMC (0.080 mM) was used for the measurement of the CT-like activity 
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of the proteasome. The hyperbolic curves indicate the best fits for the data obtained, with 
IC50 values calculated from the graphs by SigmaPlot 10.0 software. Mixtures treated with 
DMSO alone were used as blank. The dose-dependent inhibitory effect of c9,t11-, t9,t11-, 
t10,c12-CLA isomers, octanoic acid or bortezomib on APEH activity was shown (E). 
Inhibition kinetic by increasing t10c12-CLA concentrations: 50 µM (squares) and 100 µM 
(triangles) (F). Enzyme incubated without inhibitors were used as control (diamonds). The 
inhibition constants, Ki, was determined by the Lineweaver–Burk equation for non-
competitive inhibition. Results are presented as the mean ± standard deviation (SD) of 
triplicate analyses from three independent experiments. SD values lower than 5% were not 
shown. 
6.2 Cancer cell proliferation is significantly inhibited and associates with caspase 3 
activation in melanoma cells exposed to t10,c12-CLA 
In evaluating the involvement of APEH and proteasome in the anti-cancer activity of CLA 
isomers, the growth inhibitory effects were estimated up to 48 h exposure in cell lines 
belonging to Group I and Group II (Figure 10-Chapter I), at two different concentrations (50 
and 100 µM). Data shown in Figure 32 refer to four Group I-cell lines (A375, A375M, Caco-
2 and HepG2) and four Group II-cell lines (MDA-MB, Hela, U87 and MCF7), which were 
chosen for comparative analyses. It is worth to note that the results obtained with all the other 
Goup I-cell lines (Figure 10-Chapter I) did not show any variation in cell viability upon 
treatments and, therefore, they were not considered for further investigations. Interestingly, 
the most marked anti-proliferative effect was observed following exposure with t10,c12-CLA 
on A375 (63%) (Figure 32B). A375 cell viability was also greatly influenced by t9,t11-CLA 
(about 50%) (Figure 32C), whereas no significant results were obtained on all cancer cells by 
octanoic acid (up to 200 μM) treatment, which was used as a negative control (data not 
shown). To assess if the cytotoxicity was associated to the anti-proliferative events observed 
on the cancer cells considered, LDH activity was measured in spent media following 24 h 
exposure to 200 μM c9,t11-, t10,c12-CLA (the most abundant CLA isomers) or to 10 nM 
BTZ, using octanoic acid as negative control. As expected, substantial cell death resulted 
from BTZ supplementation while the LDH activity in cultures exposed to CLA isomers was 
comparable to that of control (Figure 33A). Moreover, to examine the contribution of an 
apoptotic event in CLA-induced decline of cancer cells viability, caspase 3 activation was 
measured. Unespectedly, results revealed that while caspase 3 activation varied slightly 
between the different tumor cell lines upon exposure with c9,t11-CLA, a more marked 
variation was observed by t10,c12-CLA treatment (Figure 33B), leading to inversely 
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correlated measures of cell viability and caspase 3 activation (r
2
=0.78; P<0.01) (Figure 33C). 
It’s worth to note that, although CLA reduced cell viability in the considered cell lines with 
no cytotoxicity (LDH release), nevertheless its pro-apoptotic activity couldn’t be accounted 
for the observed cell death, therefore a cytostatic effect cannot be excluded. In addition, 
proteasome activity was differently downregulated by CLA isomers (data not shown) but it 
was not significantly correlated with cell viability decrease (r
2
=0.046; data not shown), 
suggesting that proteasome inhibition alone was not liable for the observed anti-proliferative 
activity of CLAs. Hence, it appears reasonable to hypothesize that an enzyme machinery, 
such as APEH/proteasome system, could be involved in the marked anti-proliferative and pro-
apoptotic activity exerted by t10,c12-CLA through its specific capacity to downregulate both 
enzymes in cell free assays (Figure 31). 
 
Figure 32. Human cancer cells exhibit differential sensitivity to the anti-proliferative 
activity of CLA isomers. The effects of c9,t11 (A), t10,c12- (B) or t9,t11-CLA isomers (C) on 
cell viability were assessed in eight cancer cell lines exposed for 24 h to increasing 
concentrations of the CLA isomers. Data are expressed as means ±SD values of triplicate 
data from three independent experiments. SD values lower than 5% were not shown. 
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Figure 33. Anti-proliferative ability of t10,c12-CLA correlates with caspase 3 activation. 
LDH release (A) and caspase 3 activity (B) were measured to study the cytotoxic and pro-
apoptotic ability of 200 μM of t10,c12- (red bars) or c9,t11-CLA (light blue bars). Cell 
cultures exposed to octanoic acid (200 μM, violet bars) or to BTZ (10 nM, green bars) were 
used as negative or positive controls, respectively. Average caspase 3 activity values (fold 
increase) in cancer cells exposed for 24 h to 200 μM t10,c12- (C upper panel) or to c9,t11- 
CLA (C lower panel) were plotted against cell viability (%). 
6.3 t10,c12-CLA decreases glutathione level and APEH/proteasome activity in A375 cells 
triggering apoptosis in a dose-dependent fashion 
On the basis of the marked cell viability reduction (Figure 32B) induced by t10,c12-CLA on 
A375 melanoma cell line, we decided to use this model system for investigations on the 
different cellular factors (redox status, caspase 3, APEH and proteasome) involved in the 
apoptotic pathway. In order to define the dose accountable for 50% decrease of cell viability 
(IC50), A375 cells were exposed for 24 h to a concentration range of t10,c12-CLA or BTZ 
(from 10 nM to 400 μM), using human fibroblasts as control. The resulting isobologram 
revealed that the IC50 values were 1.0±0.02 μM or 10.0±0.02 nM for t10,c12-CLA or BTZ, 
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respectively. Moreover, proliferation data obtained from fibroblasts, even at higher 
concentration of t10,c12-CLA, further supported the lack of toxic effects (Figure 34A). Next, 
cultures were incubated with increasing t10,c12-CLA doses (50, 100 or 200 μM) and the 
possible additive effect elicited by sub-toxic amount of BTZ (5 nM) was evaluated in cells co-
incubated with t10,c12-CLA for 24 h. The results obtained (Figure 34B) demonstrated that 
the dose-dependent activation of caspase 3 was triggered by t10,c12-CLA, reaching an 
eightfold increase compared to the control culture. Notably, pro-apoptotic induction, 
associated with a significant decline in intracellular GSH, was not further improved by BTZ 
supplementation (Figure 34C). Similarly, APEH and proteasome mRNA levels were strongly 
downregulated by 200 μM t10,c12- CLA treatment (Figure 35A, right panel) and only minor 
alterations were produced by the addition of BTZ (data not shown). Interestingly, while a 
dose-dependent inhibition of APEH activity was observed, the proteasomal CT-like activity 
was inhibited to 46 and 50% by 50 and 100 μM t10,c12-CLA, respectively and a less marked 
effect resulted from cells exposed to 200 μM CLA (25%) (Figure 35A, left panel). Moreover, 
the decline of APEH and β-5 protein expression only occurred at the higher CLA dose 
(p<0.05) (Figure 35B). In addition, the noticeable decrease of the anti-apoptotic protein Bcl-2 
expression, reaching the maximum reduction of 80%, further supported the role of apoptosis 
in the anti-proliferative effect of t10,c12-CLA (Figure 35B). Finally, we showed that cell 
exposure to high t10,c12-CLA doses markedly down-regulated the Nrf2 pathway, as 
evidenced by the declined mRNA levels of some target genes (NQO1 and γGCL), expressed 
as fold change in comparison to untreated cells (Figure 36). These findings support the 
hypothesis that the combined downregulation of antioxidant/detoxifying defences, 
APEH/proteasome system and Bcl-2 levels, may play an important role in apoptosis induction 
triggered by t10,c12-CLA in A375 cells. 
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Figure 34. Dose-dependent pro-apoptotic activity of t10,c12-CLA correlates with 
downregulation of GSH in A375 cells. Isobologram of A375 cells treated with t10,c12-CLA 
or BTZ for 24 h is reported in panel A. Human fibroblasts exposed to the same t10,c12-CLA 
concentrations were used as control. Data are expressed as means ±SD values of triplicate 
data from three independent experiments. Pre-confluent A375 cultures were incubated for 24 
h with 50, 100 or 200 μM t10,c12-CLA. Thereafter, cells were harvested, and used for 
cytoplasmic or mRNA extracts preparation. Cells untreated or treated with 10 nM BTZ were 
used as negative or positive controls, respectively. Measurement of caspase 3 activity (B) and 
GSH concentration (C) were performed on cytoplasmic extracts. Results were presented as 
means±SD of triplicate data from three independent experiments. *Significantly different (P < 
0.01) from respective controls. 
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Figure 35. Dose-dependent pro-apoptotic activity of t10,c12-CLA correlates with 
downregulation of APEH and proteasomal CT-like subunit at both mRNA and activity level 
in A375 cells. Pre-confluent A375 cultures were incubated for 24 h with 50, 100 or 200 μM 
t10,c12-CLA. Thereafter, cells were harvested, and used for cytoplasmic or mRNA extracts 
preparation. Cells untreated or treated with 10 nM BTZ were used as negative or positive 
controls, respectively. Measurement of APEH or proteasomal CT-like activities (A left panel) 
were performed on cytoplasmic extracts. The mRNA levels of APEH and β-5 subunit were 
evaluated by qRT-PCR and expressed as fold change in comparison to untreated cells (A 
right panel). Intracellular levels of Bcl-2, APEH and β-5 were detected by immunoblotting (B 
upper panel). Data on Western blot analysis were normalized to the density of control (β-
actin) and the values were expressed as percent value as compared to untreated cultures (K) 
on triplicate measurements (B lower panel). Results were presented as means±SD of 
triplicate data from three independent experiments. *Significantly different (P < 0.01) from 
respective controls. 
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Figure 36. mRNA levels of GCL and NQO1 in A375 cells treated with 50 or 200 μM of 
t10,c12-CLA for 24 h. The mRNA levels were evaluated by RT-PCR and expressed as fold 
change in comparison to untreated cells. *Significantly different (P < 0.01) from respective 
controls. 
6.4 A375 exposure to high t10,c12-CLA doses increases ROS production in association 
with apoptotic events and APEH/proteasome downregulation in time-dependent fashion 
Time-dependent monitoring of ROS production, APEH and proteasome (β-5) at mRNA and 
enzyme activity level, was performed to evaluate the effects produced by the exposure to 
lower (50 μM) or higher (200 μM) t10,c12-CLA concentrations, on pre-confluent A375 cells. 
Sudden decrease (2 h) of APEH and proteasomal CT-like activities in cells exposed to low 
doses, correlated with a transient reduction of their mRNA expression. Upon this early 
response, enzyme activities recovered, reaching a plateau after 8h with values corresponding 
to 80 or 70% of their starting values, respectively (Figure 37A). Similarly, mRNA profiles 
showed a short-lived gene repression, which quickly recovered towards the stable final 
values, being approximately one-fold lower than their initial expression level (Figure 37B). 
Conversely, the higher concentration of t10,c12-CLA produced a downshift of APEH activity 
reaching a plateau with average values of 70% compared to its starting level, whereas a long-
term downregulation of proteasomal activity persisted up to 16 h (Figure 37C). Interestingly, 
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two transient minima of mRNA levels were observed after 2 and 6 h, followed by a 
significant increase until 16 h. After 24 h of incubation, APEH and β-5 expression decreased 
again reaching the corresponding lowest values (Figure 37D). The time-dependent ROS 
production indicated that the early downregulation of APEH /proteasome enzyme activities 
could be induced by ROS yield (Figure 37A), while a direct modulation of the CLA isomer 
on both enzymes can possibly contribute to the following decrease of the activity/mRNA 
levels observed at 200 μM (Figure 37C, D). Cell pre-incubation with the antioxidant N-acetyl 
cysteine (NAC, 5 mM) before the 200 μM CLA exposure (2 or 24 h) resulted in a marked 
cytotoxic effect (data not shown).  
 
 
Figure 37. Time-dependent effects of t10,c12-CLA on APEH/proteasome system and on 
ROS production in A375 cells. Preconfluent A375 cells were incubated with 50 μM or 200 
μM of t10,c12-CLA for the indicated times. After treatments, cytoplasmic cell-extracts were 
used for the measurement of APEH and proteasomal CT-like activities (A,C). The ROS 
profiles were compared with the time courses of proteasomal CT-like and APEH activity 
levels (A,C). ROS production was assessed as described in materials and methods. cDNAs 
were synthesized and used for qRT-PCR amplification of APEH and β-5 (B,D) at the 
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indicated times. The mRNA levels were finally expressed as fold change in comparison to 
untreated cells. Results were presented as means±SD of triplicate data from three 
independent experiments and SD values lower than 5% were not shown. *Significantly 
different (P< 0.01) from respective controls. 
Finally, time-dependent effects elicited by 200 μM t10,c12- CLA on GSH concentration and 
caspase 3 activity, together with γGCL mRNA levels, were measured. As shown in Figure 
38A, the decline of intracellular GSH was followed by caspase 3 activation (after 6-8 h). To 
investigate the mechanism underlying the pro-oxidant activity of t10,c12-CLA, the mRNA 
expression of the rate-limiting enzyme responsible for cellular GSH synthesis (namely γGCL) 
was monitored. As expected, the early activation triggered by CLA isomer (after 2 h) was 
followed by a transient decrease in mRNA (peaking after 4 h), which temporarily recovered 
before leading to the downregulation (1.5 fold) of mRNA levels (Figure 38B). 
 
 
Figure 38. Time-dependent effects of t10,c12-CLA on caspase 3 and cyto-protective 
defences on A375 cell. Pre-confluent A375 cultures were incubated with 200 μM t10,c12-
CLA  for the indicated times. After treatments, cytoplasmic cell-extracts were used for the 
measurement of GSH concentration and caspase 3 activity (A). GSH and caspase 3 activities 
were expressed as percent variation in comparison to cells harvested at the beginning or at 
the end of the incubation, respectively. cDNAs were synthesized and used for qRT-PCR 
analysis of γGCL transcripts (B) at the indicated times. The mRNA levels were finally 
expressed as fold change in comparison to untreated cells. Results were presented as 
means±SD of triplicate data from three independent experiments. SD values lower than 5% 
were not shown. *Significantly different (P < 0.01) from respective controls. 
6.5 Putative APEH binding site for t10,cis12-CLA isomer 
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In a previous work [41], the structural model of the inhibition complex APEHSs-SsCEI protein 
corroborated by mutagenesis studies, indicated an involvement of the SsCEI RSL (shown in 
paragraph 2.1 Peptide design and characterization-Chapter 1) in the interaction with the 
active site of the enzyme target. The surprising downregulation of APEH by t10,c12-CLA 
prompted us to undertake a molecular modelling study to look for potential APEH-CLA 
binding sites. Protein-fatty acid docking analyses were carried out starting from the 
previously reported structural model of APEHSs [41], herein used for the biochemical 
investigation. The APEHSs 3D model, built on the X-ray structure of APEH from Aeropyrum 
pernix [5], shows the typical features of a POP family member: a α/β hydrolase catalytic 
domain with the (Ser-Asp-His) catalytic triad, covered by a central tunnel of an unusual β-
propeller domain. 
Docking calculations were performed by using the AutoDock simulation package [43]. The 
docked conformations of t10,c12-CLA suggested two putative binding modes that were 
characterised by different anchoring points for the carboxylate group of the CLA isomer: the 
positively charged side-chains of either R62 or R507. However, the binding involving the 
residue R507 appeared to be in conflict with the non-competitive inhibition mechanism 
indicated by the experimental data, as R507 belongs to the active site of APEHSs [41]. Thus 
we did not consider this binding approach further. binding of t10,c12-CLA involving R62 
residue of the enzyme is in agreement with the non-competitive mechanism of inhibition 
resulting from cell-free assays. In this case, t10,c12-CLA occupies the β-propeller tunnel, 
eventually obstructing the passage of the substrate and/or the product (Figure 39). Details of 
the binding mode involving R62 are shown in Figure 40: t10,c12-CLA carboxylate group 
interacts with the side-chains of R62 and S273 of APEHSs, while the long hydrophobic carbon 
tail of t10,c12-CLA is stabilised by van der Waals interactions with some of the hydrophobic 
residues that line the b-propeller tunnel of APEHSs. Of note, the interaction mechanism 
suggested by this docking analysis shares common characteristics with the fatty-acid-binding 
proteins (FABP) [44, 45]. X-ray structural studies have shown that the fatty acid molecule 
binds to the relatively large FABP inner cavity, and is anchored to a positively-charged 
arginine residue and a polar amino acid (usually serine or threonin), with the hydrophobic tail 
again stabilised by van der Waals interactions 
with hydrophobic residues. The lack of structural information and the difficulty to predict a 
sufficiently accurate 3D model for any mammalian APEH have prevented us from performing 
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modelling studies on mammalian APEHs. However, the functional properties indicate 
significant similarity between mammalian and archaeal APEHs, showing that both are 
inhibited by t10,c12-CLA through a non-competitive mechanism (Figure 31F), with 
comparable Ki values. Therefore, we hypothesize that the enzymes from archaeal and 
mammalian sources could share some common features in their modes of interaction with this 
inhibitor. 
 
 
Figure 39. Binding mode of the t10,c12-CLA with APEHSs. Binding mode suggested by 
docking analysis for t10,c12-CLA (blue; ball-and-stick mode) with APEHSs (cartoon 
representation; green, left). Protein residues involved in stabilising the interactions with the 
carboxylic group of the t10,c12-CLA are represented as sticks. The Ser-Asp-His catalytic 
triad residues are shown as black lines; R507 is shown in yellow. (right) View rotated 90u 
along the x-axis (the horizontal axis parallel to the image plane). 
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Figure 40. Suggested binding site on APEHSs by docking analysis for the t10,c12-CLA 
(blue; ball-and-stick mode) isomer. The relevant APEHSs residues are shown in ball-and-stick 
representation.  
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wing to their enhanced metabolic activity, cancer cells require elevated levels of 
energy to maintain a high rate of cell growth and proliferation. This is also 
guaranteed by an improved activity of the Ubiquitin-Proteasome System, which is 
the major pathway for protein turnover in eukaryotes [46], providing a secondary antioxidant 
defence mechanism, in combination with APEH [47, 48]. Indeed, protein homeostasis is 
critically involved in cancer cell survival; thus, one of the major focus in cancer research is 
targeting the balance between the production and destruction of proteins mediating cell 
proliferation. In this context, proteasome inhibition represents a novel strategy against many 
tumoral diseases, triggering an increase in apoptosis and decrease in cellular growth. 
Accordingly, in the last decade, research and development of new compounds able to down-
regulate proteasome functions have attracted growing attention. It is known that the pro-
apoptotic ability of CLA mixture (c9,t11- and t10,c12-CLA; 50:50) or its individual isomers, 
affects tumor cell proliferation via different biochemical pathways involving apoptotic or 
survival genes (Bcl-2, p21, p53). The efficacy of these isomers in inhibiting the cancer cell 
viability was highly influenced by the model system used, within a concentration range of 1-
200 μmol/L and treatment lasting 1-11 days [28]. Specifically, t10,c12-CLA has revealed a 
more efficient activity, respect to c9,t11-CLA isomer, in modulating apoptosis or cell cycle. 
In human prostatic carcinoma cells, t10,c12-CLA anticancer effect associates to decreased 
Bcl-2 and increased p21(WAF1/Cip1) mRNA levels [49] while in human colon or bladder 
cancer cells it was accompanied by the activation of ATF/NAG-1 [50] or Insulin Growth 
Factor signaling [51]. Moreover, it was reported that t10,c12-CLA was able to down-regulate 
Fatty Acid Synthase [52] or antioxidant defence systems [53-55] in different human cancer 
cells. In such a context, the purpose of this study was to explore the relationship between the 
anti-proliferative properties and the ability of CLA isomers to down-regulate the 
APEH/proteasome system in cancer cells, taking into account the role of cellular redox status 
in these processes. We firstly evaluated the effects of CLA isomers on purified proteasome 
and APEH in cell free assays, showing that t10,c12-CLA was the only isomer able to 
efficiently inhibit both enzymes, which appeared functionally correlated, in a cancer cell 
panel. Intriguingly, the link observed between caspase 3 activation and cell viability in 
t10,c12-CLA treated cells, supported the apoptosis role in the anti-proliferative effects 
specifically induced by this isomer. The higher susceptibility to the t10,c12-CLA treatment of 
A375 melanoma cell line, showing the highest basal levels of APEH/proteasome, is consistent 
O 
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with the involvement of this system in cell survival. Unfortunately, this hypothesis cannot be 
extended to all the tested cell lines showing high constitutive enzymatic levels. In addition, 
we demonstrated that early ROS production triggered by higher t10,c12-CLA doses, along 
with the combined downregulation of NF-E2-related factor 2-Antioxidant responsive 
elements (Nrf2-ARE) pathway and proteasome-APEH activity/expression levels, was likely 
responsible for the programmed A375 cell death. However, these results couldn’t be further 
investigated by using antioxidants (NAC) and t10,c12-CLA combination in cell treatment 
(data not shown) due to NAC toxicity on A375 cells [56]. The endogenous oxidative stress 
rarely leads to damage, because a healthy cell generally possesses a powerful antioxidant 
defence to inactivate ROS. However, when cellular antioxidants are compromised, as occurs 
in the context of external environmental challenges, cell death is the expected outcome. By 
contrast, in several tumoral cells, hyperactivation of endogenous sources of ROS, which 
generates the observed increased levels of these molecules, results in a state of chronic 
oxidative stress [57, 10]. It is well established that GSH plays an important role in cancer 
development and treatment, as it can protect against DNA damages produced by ROS and 
electrophilic chemicals [58]. Generally, in various types of cancerous cells and solid tumors, 
elevated GSH levels are observed, making these cells and tissues less susceptible to 
chemotherapy by increasing the resistance to oxidative stress. However, although chronic 
ROS exposure confers several advantages to cancer cells, by stimulating proliferation and 
maintaining the transformed phenotype [59], excessive ROS yield may induce cell cycle 
arrest and apoptosis. Therefore, redox state modulation in tumoral cells has been indicated as 
a possible target for cancer [60] or, specifically, for melanoma treatment [61]. 
In this context, our results, showing the increased intracellular GSH levels in A375 cells, were 
in agreement with studies reporting the central role played by redox homeostasis in the 
control of melanoma survival, proliferation and invasiveness [62]. Moreover, the association 
of pro-oxidant activity of t10,c12-CLA with anti-proliferative effect, was consistent with 
literature [53, 54] and conformed to the activities of recently discovered proteasome 
inhibitors, triggering ROS production in melanoma cells through oxidative stress activation 
[63, 64]. In addition, although the downregulation of the Nrf2 pathway, was accompanied by 
the caspase 3 activation in cells exposed to high t10,c12-CLA doses, nevertheless there is not 
necessarily a direct cause/effect between these two events. In accordance with the importance 
of Nrf2 downregulation in tumor growth reduction and in enhancing the efficacy of 
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chemotherapeutic agents [65], the use of t10,c12-CLA in combination with specific 
APEH/proteasome inhibitors could represent an effective strategy for melanoma treatment. 
To sum up, t10,c12-CLA-induced oxidative stress was detectable at very early times, as 
revealed by the increase of DCF fluorescence (Figure 37C), downregulation of γGCL 
expression (Figure 38B) and the following decline of intracellular thiols (Figure 38A). 
Hence, it is reasonable to hypothesize that the oxidative stress and the Nrf2-activation, 
triggered by t10,c12-CLA, are upstream processes contributing to the APEH/proteasome 
downregulation (Figure 41) [66-68] which culminate in activation of caspase 3. The finding 
of time progression events provides additional insights toward understanding the CLA-
activated mechanisms, which are involved in the anticarcinogenic effects of these compounds, 
particularly the t10,c12-CLA isomer, in melanoma cancer cells. Further research are needed 
to support the role played by APEH in the downregulation of cancer cell viability. 
 
Figure 41. Summary diagram. In the scheme early ROS yield (after 1 h), triggered by cells 
exposure to 200 μM t10,c12-CLA, led to the transient decline of the detoxifying 
APEH/proteasome system and the improved γGCL expression, following the increased 
nuclear translocation of Nrf2. During the next 10 h, the partial recovery of β-5 and APEH 
transcription paralleled the reduced GCL expression and intracellular GSH levels resulting 
in the increased apoptosis (caspase 3 activity, casp3). After 24 h incubation, the simultaneous 
decline of β-5, APEH, γGCL and NQO1 transcriptional levels and of intracellular GSH are 
associated with decreased cell viability likely via apoptosis enhancement (as evidenced by 
increased casp3 activity and Bcl-2 degradation). 
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In conclusion, in the light of all the results reported, it can be assumed that the selected APEH 
inhibitors t10,c12-CLA and SsCEI 4 are able to activate different cellular responses in diverse 
tumor cell lines. This could be due to the specific nature of these compounds. Indeed, t10,c12-
CLA isomer is a natural molecule which is known to exert multiple functions and therefore 
several fundamental processes, including not only protein degradation machinery but also 
apoptotic pathways and antioxidative defence systems, could be strongly altered in melanoma 
A375 cells. Conversely, SsCEI 4 is a synthetic and very selective peptide designed as APEH 
inhibitor and, for this reason, possibly involved in the specific downregulation of APEH-
proteasome system and protein turnover processes in osteosarcoma U2OS cells. Hovewer, 
further analysis will be necessary to deepen the molecular mechanisms activated in response 
to APEH-proteasome inhibition. 
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9.1 Reagents  
Pure fatty acids (octanoic acid, c9,t11-, t9,t11- and t10,c12-CLA isomers), caspase-3 
fluorometric Assay Kits were purchased from Sigma-Aldrich. DMEM/F12, DMEM, L-
glutamine, penicillin-streptomycin and FBS were from Gibco-BRL. Porcine liver APEH was 
obtained by Takara. 20S human proteasome was purchased from Boston Biochem. 
Bortezomib (BTZ) was obtained by Santa Cruz Biothecnology. Chemicals of the highest 
purity were from Sigma-Aldrich or Calbiochem. 
 
9.2 Peptide design, synthesis and characterization 
The peptides were prepared as amidated derivatives by solidphase synthesis (synthesis scale, 
0.1 mmoles), following standard Fmoc/tBu protocols. A rink amide resin (substitution, 0.57 
mmol/g) and amino acid derivatives with standard protection were used in all of the 
syntheses. Cleavage from the solid support was performed by treatment with a trifluoroacetic 
acid (TFA)/triisopropylsilane/ water (90:5:5, v/v/v) mixture for 90 min at room temperature. 
The crude peptides were precipitated in cold ether, dissolved in a water/acetonitrile (1:1, v/v) 
mixture and lyophilised. The peptides were purified by reverse-phase HPLC using a 
semipreparative 561 cm ID C18 monolythic Onyx column, applying a linear gradient of 
0.05% TFA in acetonitrile from 10% to 70% over 8 min at a flow rate of 15 mL/min. Peptide 
purity and identity were confirmed by liquid chromatography–mass spectrometry analysis. 
 
9.3 Gel filtration analysis of synthetic peptides 
Gel filtration chromatography was performed on a BioSep SEC-S2000 column equilibrated 
with 50 mM phosphate buffer pH 6.8, at a flow rate of 1.0 mL/min. A standard curve was 
built using a set of synthetic peptides with molecular weights between 1.500 amu and 2.500 
amu. For this purpose, peptide aliquots were injected onto the column and a plot of KD versus 
log10 molecular weights (MW) was obtained, where KD=(Ve-Vo)/(VTVo), Ve is the elution 
volume of the sample, and VT and Vo are the total and void volumes of the column, 
respectively. 
 
9.4 Circular dichroism spectroscopy 
CD spectra were obtained on a Jasco J-715 spectropolarimeter with 400 µL of 8.0x10
-7
 M 
protein in 5 mM Tris–HCl pH 7.5. Hellman quartz cells of 0.1-cm-path length were used in 
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the far UV (190–250 nm). The temperature of the sample cell was regulated by a PTC-348 
WI thermostat and thermal CD was performed from 250 to 195 nm by raising the cell 
temperature from 37 °C to 77 °C. The thermal CD spectra were signal-averaged by combining 
three scans and the baseline was corrected by subtracting a buffer spectrum. The samples 
were then cooled back to 37 °C to monitor the final folding of the peptides. 
 
9.5 Enzyme assays 
APEH activity was measured spectrophotometrically using the chromogenic substrate acetyl-
Ala-pNA (Bachem). The reaction mixture (1 mL) containing pure APEH (38 ng) or an 
appropriate amount of cell extract in 50 mM Tris-HCl buffer pH 7.5 (Tris Buffer), was 
preincubated at 37 °C for 2 min. Then, 1 mM acetyl-Ala-pNA was added and the release of p-
nitroanilide (ɛ410 = 8800 M
-1
 cm
-1
) was measured by recording the absorbance increase at 
410 nm on a Cary 100 Scan (Varian) UV/Vis spectrophotometer, equipped with a 
thermostated cuvette compartment. APEH activity was expressed in IU. The synthetic 
fluorescent substrate N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (N-Suc-
LLVT-AMC) was used for the measurement of the CT-like activity of the proteasome, at a 
final concentration of 0.080 mM. The reaction mixture (0.9 mL) containing appropriate 
amount of proteasome was preincubated as above, in Tris buffer. N-Suc-LLVT-AMC was 
added, and the release of the fluorescent product (7-AMC) was monitored for 5 min in a 
Perkin–Elmer LS 50B fluorimeter. The excitation and emission wavelengths were 380 nm 
and 460 nm, respectively. 
The carboxypeptidase Y, elastase, thrombin, trypsin and subtilisin activities were also 
evaluated according to previously published methods.  
 
9.6 Enzyme inhibitory assays 
Protease inhibitor activities of the peptides (SsCEI 4 and CF3-lmph) and fatty acids were 
carried out using a fixed amount of APEH or partially purified proteasome (3–5 nM and 0.12 
mg/mL, respectively), and increasing peptide or fatty acid concentrations. Mixtures were pre-
incubated for 30 min at 37 °C before the addition of the substrate, and the enzymatic activities 
were followed as described above. Inhibitory cell free assays were also performed on APEH 
and proteasome partially purified from Caco-2, A375 and U2OS cells at 37 °C in Tris 
buffer pH 7.5. 
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The time-dependent inhibition of SsCEI 4 towards APEH was assessed. Mixtures containing 
appropriate amounts of each inhibitor and APEH were pre-incubated for 20 min at 37 °C; 
they were then diluted (1:5) into the standard assay mixture, which contained the substrate 
only. The enzymatic activity was followed as described above. Control samples were 
prepared by pre-incubating the same amounts of APEH without the inhibitors and then diluted 
in the standard assay mixture. To determine the mechanisms of APEH inhibition (Ki), 
Lineweaver−Burk double reciprocal plots of data at  increasing inhibitor and substrate 
concentrations were constructed. 
 
9.7 Cells, culture conditions and treatments 
Human hepatoma cells (HepG2) were seeded (2x10
4
cells/cm
2
) and grown in MEM (Gibco 
Invitrogen; Milano) medium supplemented with 2 mM L-glutamine, 1% nonessential amino 
acids and 10% FBS. Colon carcinoma (Caco-2), cervical carcinoma (Hela), glioblastoma 
(U87), melanoma (A375, A375M, PNP, Sk-mel, LCM, LCP), osteosarcoma (U2OS, SaOS) 
and mammary adenocarcinoma (MCF7, MDA-MB) were seeded (1x10
4
cells/cm
2
) and grown 
in DMEM supplemented with 10% FBS, 2 mM L-glutamine. The cells were harvested at the 
pre-confluent stage and used for cytoplasmic or mRNA extract preparation. 
Differentiated Caco-2 cells were studied between passages 12 and 22. The cells were split 
using trypsin-EDTA solution and plated in 6-well plates at a density of 8x104 cells/mL and 
the medium was replaced every 2–3 days. Under these conditions, the cells reached visual 
confluence after 7 days and the differentiated stage two weeks later. Then, the differentiated 
cells were incubated for 48 h with the different substances. 
Normal human dermal fibroblast (NDHF) within 8th passage were seeded at a density! of 
2x10
4
 cells/cm
2
 and cultured in fibroblast growth medium (FGM-2; Lonza, Milan, Italy) 
containing 2% FBS, 50 μg/mL gentamycin and amphotericin B, 10μg/mL fibroblast growth 
factor and insulin. BHK21 cells (kindly donated by Dr. David Y Thomas, McGill University 
Montreal Canada) were cultured in DMEM/F12, 5% FBS, 1 mM L-glutamine, 200 μg/mL 
methotrexate, and 100units/mL penicillin-streptomycin. Cells were incubated in a humidified 
atmosphere at 37 °C in 5% CO2. Stock solutions of SsCEI peptides, fatty acids or bortezomib 
(BTZ) were prepared by dissolving in dimethyl sulphoxide (DMSO) and further dilutions 
were carried out in DMEM. Cells were treated with  fatty acids or BTZ and control culture 
were exposed to the same amount of DMSO. 
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BHK cells stably expressing CFTR-M (kindly donated by Dr. David Y Thomas, McGill 
University Montreal Canada) were plated in 12-well plates, to a confluence of 60% for the 24-
h incubations, and 40% for 48-h exposure to PIs. These treatments were initiated 24-h after 
the plating of the cells. Phase-contrast images of the cells were taken just before the lysis of 
the cells for protein analysis, using a Lica DM6000 inverted microscope.  
 
9.8 Antibodies 
The following antibodies were used: anti-APEH antibody (sc-102311; Santa Cruz 
Biotechnology); anti-NF-kB/p65 antibody (Thermo Scientific); anti-p21Waf1 antibody 
(Exbio); pan Ab-5 anti-actin antibody (clone ACTN05, Thermo Scientific); anti-Bcl-2 
(340576-BD PharmingenTM); anti-proteasome 20S β-5 subunit (BML-PW8895-0025; Enzo 
Life Science); anti-caspase 3 (Santa Cruz Biotechnology); anti-PARP (Abcam); anti-LC3 e 
anti-Beclin-1 (Autophagy Antibody Sampler Kit, Cell Signaling Technology) and monoclonal 
antibodies against polyubiquitinylated proteins conjugated with horseradish peroxidase 
(FK2H, Enzo, Life Science). The ΔF508CFTR-3HA protein was detected with an anti HA 
monoclonal antibody (Covance). 
 
9.9 Protein extraction and Western blotting analysis 
Following the treatments, the cells were washed three times with ice cold phosphate-buffered 
saline and collected immediately at 4 °C in lysis buffer (1% Triton X-100, 0.1% SDS, 20 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate and complete protease inhibitors 
[Roche]). The lysates were centrifuged at 10,000xg for 15 min at 4 °C. The protein 
concentrations in the clear supernatants were determined (BCA protein assay reagent kit; 
Pierce) before their use in enzymatic assays or SDS–PAGE. In brief, for Western blotting, 
aliquots  (30 -g) were run on SDS-PAGE (8% or 12.5%) and then electroblotted onto PVDF 
membranes (ImmobilonTM, Millipore). The membranes were next incubated with primary 
antibodies and then with the appropriate dilution of secondary antibody (1 h at 37 °C). At the 
end of this time, the immunocomplexes formed were visualised by enhanced 
chemiluminescence and autoradiography according to the manufacturer protocol (Amersham 
Biosciences) and quantified by densitometric analysis with ChemiDoc XRS (Bio-Rad). 
Protein expression data was quantified with Quantity One Software (Bio-Rad). 
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9.10 MTT-based cytotoxicity assay 
The colorimetric 3-(4,5-dimethylthiazol-2)-2,5- diphenyltetrazolium bromide (MTT) (Sigma 
Aldrich, Milan) assay was used to quantify cell viability. Briefly, cells were incubated in 96 
well microplates in the appropriate complete medium with standardized densities for 24 h as 
pre-incubation process. The medium was removed and replaced by medium containing 
different doses of the different compounds for 24h (CLA isomers) or 24, 48 and 72 h 
(peptides). Following treatment, the medium was removed and the cells were incubated with 
DMEM w/o red phenol with 0.5 mg/ml MTT for additional 2 to 4h at 37 °C. After removal of 
the medium and MTT, cells in each plate were incubated with 0.1 M HCl/ isopropanol to 
dissolve the MTT-formazan crystals. Absorbance at 590 nm was recorded with a plate reader 
(Bio Rad mod 680). The relative number of viable cells was expressed as a percentage of the 
control. 
 
9.11 Apoptosis assays 
The pro-apoptotic ability of the peptides or CLA isomers were assayed by measuring the 
caspase 3 activity using fluorometric kits, according to the manufacturer instructions. These 
assays were based on hydrolysis of the substrate acetyl-Asp-Glu-Val-Asp-7-amido-4-
methylcoumarin (Ac-DEVD-AMC) by caspase 3. The release of the 7-AMC moiety in 
protein extracts prepared from the differently treated cells was evaluated by fluorimetry 
(excitation 360 nm, emission 460 nm). Their amounts were calculated by means of a standard 
curve prepared with pure AMC, and following normalization for protein content, the activities 
were expressed as nmoles AMC/mg protein/min. 
 
9.12 Cytotoxicity assay 
The release of LDH (Lactate dehydrogenase) was used as the marker for cell toxicity [48]. 
The culture supernatants were sampled at the end of the incubations and centrifuged (4,000xg, 
5 min, and 4 °C). Aliquots of the clear supernatant (10 µL) were incubated with 190 µL 
reaction buffer (200 mM Tris/HCl, pH 8.0, 0.7 mM p-iodonitrotetrazolium violet, 50 mM L-
lactic acid, 0.3 mM phenazine methoxysulphate, 0.4 mM NAD,) for 30 min at 37 °C. 
Absorbance was measured at 490 nm and the results were expressed as percentages of total 
LDH release from control cultures treated with 1% (w/v) Triton X-100 and calculated as: 
[(experimental value - blank value)/(total lysis -blank value)-100]. 
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9.13 ROS detection 
DCF-DA (2’,7’-dichlorofluorescein diacetate) was used to determine the amount of ROS 
production. DCF-DA working solution was added to the medium to reach 10 μM and then 
incubated at 37 °C for 15 min in the dark. Cells were harvested by trypsinization, washed with 
PBS and kept on ice for detection by FACScan (Becton Dickinson, USA) equipped with a 
488 nm argon laser using a band pass filter of 530 nm. 
 
9.14 Cell cycle analysis  
U2OS cells were treated with the indicated concentrations of SsCEI 4 for 24, 48 and 72 h. 
The cells were then harvested, washed with PBS, and then stained with 50 -g ⁄mL of 
propidium iodide containing 0.1% Triton X-100 in citrate buffer, and 100 -g/mL RNase A. 
The stained cells were then analyzed for DNA content using a FACS Calibur flow cytometer 
(BD Biosciences) and differences in cell cycle between treated versus untreated cells were 
analysed using ModFit LT software. The experiment was performed in triplicate. 
 
9.15 Intracellular redox status and cell viability assessment 
Intracellular concentration of reduced and oxidized glutathione (GSH and GSSG, 
respectively) were quantified using the 5,5'-dithiobis(2-nitrobenzoic acid)-GSSG reductase 
recycling assay. GSSG content was preliminarily evaluated in cytosolic extracts of treated or 
untreated cells upon the addition of 10 mM 1-methyl-2-vinylpyridinium 
trifluoromethanesulfonate (a specific GSH scavenger). Notably, 
owing to the minor contribution given by GSSG (less than 5%) to the total intracellular thiol 
concentration, the latter was finally expressed as nmol GSH/mg protein. Pro-apoptotic and 
cytotoxic ability of CLA isomers were assayed by measuring caspase 3 and the activity of 
lactate dehydrogenase (LDH) in the spent media, respectively. The caspase 3 activity, 
measured at 37 °C and pH 7.5, was 
expressed as fold increase compared to the control culture. The LDH release, measured at 37 
°C and pH 8.2, was expressed as percentages of total LDH released from cultures treated with 
1% (w/v) Triton X-100 and calculated as: [(experimental value-blank value)/(total lysis-blank 
value)-100]. 
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9.16 Small interfering RNA transfection 
The siRNA is purchased from Sigma (siRNAID SASI_ Hs01_00240856 and 
SASI_Hs01_00240857), and CFBE41o-DF espressing ΔF508 CFTR were kindly provided by 
Dr. J. P. Clancy Department of Pediatrics, the University of Alabama at Birmingham, 
Birmingham, AL, USA. CFBE41o-DF cells at 5x10
4
 cells/well were cultured over-night on 
12-well plates and transfected 24 h after with APEH siRNA at a final concentration of 50 nM. 
using Lipofectamine 2000, according to the manufacturer’s instruction. Non-targeting siRNA 
was used as a negative control. After 72 hours of transfection, cells are lysed in RIPA buffer 
and protein levels were determined by western blotting. 
 
9.17 RNA isolation and quantitative real-time PCR analysis 
mRNA expression levels of APEH and β-5 proteasome subunit were determined in treated or 
untreated cells to investigate on the functional relationship existing between APEH and 
proteasome activities and on their involvement in the anticancer activity of APEH inhibitors. 
In addition, the mRNA expression of NADH quinone oxidoreductase (NQO1) and of gamma 
Glutamylcysteine Ligase (γGCL), which is the limiting enzyme in the GSH synthesis, were 
also measured to further demonstrate the CLA ability to down-regulate intracellular redox 
status via the Nrf2 pathway. 
Total RNA was isolated from the human cell lines (~106 cells aliquots) according to the SV 
Total RNA Isolation System (Promega) protocol, with an on column DNase I step. Total 
RNA concentrations were determined using a Qubit® Fluorometer (Invitrogen). RNAs were 
then reverse transcribed using the Transcriptor First Strand cDNA Synthesis Kit (Roche). 100 
ng of reverse transcribed complementary DNA, and its dilution series to calculate the efficacy 
of primers, were amplified by quantitative real-time PCR (qRT-PCR) on an iCycleriQ™ (Bio-
Rad) using 300 nM gene-specific primers, Maxima® SYBR Green/Fluorescein qPCR Master 
Mix (2X) (Fermentas) and the following PCR conditions: 1 cycle at 95 °C for 10min, and 40 
cycles of 95 °C for 15s , 60 °C for 30s, and 72 °C for 30s. The expression level of β-actin 
gene was used as an internal control for normalization (ref gene). Raw cycle threshold values 
(Ct values) obtained for the target genes were compared to the Ct value obtained for the ref 
gene. The final graphical data were derived from the R=(Etarget)ΔCt_target (control - 
sample)/(Eref)ΔCt_ref (control - sample) formula, where “control” cells were fibroblasts or 
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A375/U2OS line, and “sample” cells were the tumor lines. In time course analysis the 
expression levels were normalized to those of untreated cells at Time=0.  
Universal Probe Library Assay Design Center (https://www.roche-
appliedscience.com/sis/rtpcr/upl/index.jsp?id=UP030000) was used for designing primers. 
The primers utilized were: 
APEH, 5’-CCCCATTCATCCTTTGTCAC-3’ and 5’- 
AAAGCCCATCTTGCAAAGC-3’; 
β-5, 5’-CATGGGCACCATGATCTGT-3’ and 5’- 
GAAATCCGGTTCCCTTCACT-3’; 
γGCL, 5’-GACAAAACACAGTTGGAACAGC-3’and 5’- 
CAGTCAAATCTGGTGGCATC-3’; 
NQO1, 5’-CAGCTCACCGAGAGCCTAGT-3’ and 5’- 
GAGTGAGCCAGTACGATCAGTG-3’; 
β-actin, 5’-CCAACCGCGAGAAGATGA-3’ and 5’- 
CCAGAGGCGTACAGGGATAG-3’. 
 
9.18 Statistical analysis 
All data were obtained from triplicate analyses of three different preparations. Data were 
presented as means±SD. Statistical analysis and IC50 values were calculated with the 
SigmaPlot 10.0 software through a non-linear curve-fitting method and using a simple 
binding isotherm equation. Groups were compared by 
Student’s t test, and P<0.05 was considered as significant.!
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Abstract
Acylpeptide hydrolase (APEH), one of the four members of the prolyl oligopeptidase class, catalyses the removal of N-
acylated amino acids from acetylated peptides and it has been postulated to play a key role in protein degradation
machinery. Disruption of protein turnover has been established as an effective strategy to down-regulate the ubiquitin-
proteasome system (UPS) and as a promising approach in anticancer therapy. Here, we illustrate a new pathway
modulating UPS and proteasome activity through inhibition of APEH. To find novel molecules able to down-regulate APEH
activity, we screened a set of synthetic peptides, reproducing the reactive-site loop of a known archaeal inhibitor of APEH
(SsCEI), and the conjugated linoleic acid (CLA) isomers. A 12-mer SsCEI peptide and the trans10-cis12 isomer of CLA, were
identified as specific APEH inhibitors and their effects on cell-based assays were paralleled by a dose-dependent reduction
of proteasome activity and the activation of the pro-apoptotic caspase cascade. Moreover, cell treatment with the individual
compounds increased the cytoplasm levels of several classic hallmarks of proteasome inhibition, such as NFkappaB, p21,
and misfolded or polyubiquitinylated proteins, and additive effects were observed in cells exposed to a combination of both
inhibitors without any cytotoxicity. Remarkably, transfection of human bronchial epithelial cells with APEH siRNA, promoted
a marked accumulation of a mutant of the cystic fibrosis transmembrane conductance regulator (CFTR), herein used as a
model of misfolded protein typically degraded by UPS. Finally, molecular modeling studies, to gain insights into the APEH
inhibition by the trans10-cis12 CLA isomer, were performed. Our study supports a previously unrecognized role of APEH as
a negative effector of proteasome activity by an unknown mechanism and opens new perspectives for the development of
strategies aimed at modulation of cancer progression.
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Introduction
In all living cells, proteolysis is essential in the control of many
basic processes, including protein quality control, cell-cycle
progression, signal transduction, apoptosis, and gene expression.
One of the major players in the regulation of intracellular
proteolysis is the ubiquitin-proteasome system (UPS) [1]. This is a
complex enzymatic machine that primarily contributes to the
cytoplasmic turnover of a vast majority of proteins in mammalian
cells and it is tightly controlled by a number of endogenous
regulators. Due to the multiple roles of UPS, it is essential in
eukaryotes and its dysfunction can have deleterious effects in cells
and for the organism as a whole. UPS dysregulation has been
implicated in a number of pathologies such as autoimmune,
neurodegenerative diseases and viral infections, and it is
considered a novel therapeutic target for tackling tumoral diseases
[2–6]. Indeed, protein homeostasis is critically involved in cancer
cell survival thus, targeting the balance between the production
and destruction of proteins mediating cell proliferation, has
become a major focus in cancer research. Accordingly, over the
past decade, several studies have been focused on the development
of specific proteasome inhibitors (PIs), which have relevant
anticancer effects and particularly on those involving in the
repression of nuclear factor-k (NF-k B) signalling, and in the
promotion of apoptosis in transformant cells [7,8].
The first evidence of the pro-apoptotic activity of PIs was shown
in U937 human monoblast cells [9]. In 2003, the PI bortezomib
(VelcadeH or PS341) has been approved by the Food and Drug
Administration for the treatment of multiple myeloma, which
confirmed the efficacy of PIs in blocking cancer progression.
However, like other PIs, bortezomib has several relevant adverse
events [10,11] and, at present, increasing research efforts are
aimed at reducing these negative side-effects through the use of
inhibitors with reversible and time-limited binding activity and
increased bioavailability. Recent studies have suggested that some
fatty acids are able to disrupt the chymotrypsin (CT)-like
proteasome activity. Among these, the two major isomers of
conjugated linoleic acid (CLA), cis9-trans11 CLA (c9t11-CLA) and
trans10-cis12 CLA (t10c12-CLA), have shown pro-apoptotic
activities in a number of cancer cell lines [12] and strong
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anticancer effects in numerous animal models [13]. Interestingly,
although the mechanisms are yet poorly understood, their ability
to inhibit the proteasome activity in vitro [14] suggests that this
complex enzyme could be their ultimate target.
Acylpeptide hydrolase (APEH; also known as acylaminoacyl
peptidase or oxidised protein hydrolase) is one of the four
members of the prolyl oligopeptidase class (POP, clan SC, family
S9); it catalyses the removal of N-acylated amino acids from
acetylated peptides and has been recently recognised as having a
role in the coordinated protein-degradation machinery in Cos-7
cells [15], and in the modulation of cancer progression [16].
On this background, we have investigated the molecular
mechanisms that underlie the interrelationship between APEH
and the proteasome, and their eventual regulation by natural or
synthetic compounds including peptides reproducing the reactive
site loop (RSL) of an archaeal APEH inhibitor (SsCEI, Sulfolobus
solfataricus chymotrypsin-elastase inhibitor) [17], and the c9t11-CLA
and t10c12-CLA isomers. Two molecules that selectively inhibit
APEH and induce, in parallel, a down-regulation of proteasome
activity have been identified. Moreover, a direct correlation
between APEH inhibition and proteasome down-regulation has
been established using a specific APEH siRNA probe. A molecular
docking analysis has been also carried out to predict the CLA-
enzyme binding sites. Therefore, this study shows that proteasome
functions can be upstream regulated by APEH, and that inhibition
of APEH activity appears to be an important event in controlling
the proteasome dysfunction associated with pathological condi-
tions, opening new important and challenging perspectives for the
development of novel strategies in cancer therapy.
Results and Discussion
Peptide design and characterisation
The recent identification and characterisation of an endogenous
inhibitor protein of APEH in S. solfataricus (SsCEI) [17,18], was
the starting point for the present study and the S. solfataricus
APEH (APEHSs) was used, in a first instance, as a model protein
for molecular investigation. On the basis of the RSL of SsCEI, a
set of four peptides, differing in size and nature at their P1 site,
were designed and synthesized. Peptides SsCEI 1 and SsCEI 2
correspond to residues 119–134 and 123–134 of the SsCEI
protein, respectively, and include the P1-P91 (L126-E127) binding
site which is reportedly involved in protease inhibition (Figure S1).
The shorter variant (SsCEI 2), starting with the N-terminus of
RSL, was designed to minimise peptide length while maintaining
intact the RSL binding site. Two further peptides were projected,
SsCEI 3 and SsCEI 4, to replace the P1 residue Leu with Ala,
which is the preferred amino acid in the substrates of mammalian
APEHs. The sequences of these peptides are reported in Table 1.
Amidation at the C-terminal end was introduced to mimic the
amino acid stretch within the protein backbone, whereas the
amino termini of peptides were not acetylated to prevent substrate-
like effects when in contact with APEH. Peptide structures within
SsCEI protein inhibitor are predicted to be random/extended, as
they have to be free in adopting the best conformation needed to
dock the target proteases. Circular dichroism (CD) spectroscopy
analyses were carried out to obtain information on the secondary
structures of peptides outside the context of the native protein.
Interestingly, the CD spectra measured between the 190 nm and
250 nm demonstrated that, except for SsCEI 4 which was largely
unstructured (Figure S2), these peptides have well defined
secondary structures in water. Specifically, CD spectra of SsCEI
2 and SsCEI 4 at 37uC, despite the single mutation, showed
markedly different profiles, suggesting that the LeuRAla substi-
tution at the P1 site induces significant conformational alterations.
CD spectra of SsCEI 2 featured canonical ‘a-helix’ curves with
surprising fidelity (Figure S2). These data are in agreement with
the role that the RSLs have in the native inhibitor proteins, and
suggest a strong tendency of these peptides to adopt different
conformations following even minimal sequence modifications.
CD spectra were also recorded in the temperature range
between 37uC and 77uC, with increasing temperature steps of
10uC. Under these conditions, SsCEI 2 and SsCEI 3 showed
considerable structural stability, as seen by the poor influence of
temperature on their conformation (Figure S2). SsCEI 1 was not
examined due to its poor stability in aqueous solution at the
concentrations required for these analyses. These findings indicate
that, in our model, the backbone architecture of the inhibitory
loop is imposed by its specific amino acid sequence, and that the
protein scaffold does not constrain the conformation of the RSL.
Given the relevant contents of b-sheet structures observed in
SsCEI 2 and SsCEI 3, we next investigated the oligomerization
properties of these peptides to exclude the occurrence of
macroscopic aggregates. For this purpose, 100 mM solutions of
peptides SsCEI 2, SsCEI 3 and SsCEI 4 were analysed by size-
exclusion chromatography, and their apparent molecular masses
were extrapolated from a calibration curve. As shown in Table 1,
SsCEI 2, SsCEI 3 and SsCEI 4 were essentially monomers,
suggesting that the secondary structures detected by CD were not
a result of non-specific self-association, but seemed to be an
intrinsic property of the peptides.
APEHSs is specifically and efficiently inhibited by SsCEI 2
and t10c12-CLA isomer
Preliminary experiments were aimed at investigating the
possible interaction/inhibition between APEHSs and the peptides
SsCEI 2, SsCEI 3 and SsCEI 4. Inhibition analyses were
performed by pre-incubating the enzyme with increasing amounts
Table 1. Synthetic peptides used in this study.
Peptide Theoretical mass value (Da) Measured mass value (Da±SD) P1 P91
SsCEI 1 1818.12 n.d. YAIDTILL EIKNINAD
SsCEI 2 1355.61 19616265 TILL EIKNINAD
SsCEI 3 1766.04 20126150 YAIDTILA EIKNINAD
SsCEI 4 1313.53 1986628 TILA EIKNINAD
Peptides were synthesized with a free amino group at the N-terminus and an amidic group at the C-terminus. The apparent MWs of SsCEI peptides were determined by
gel filtration chromatography. The calibration curve (R2 = 0.995) was obtained using a set of synthetic peptides. Data reported are the result of three independent
determinations.
doi:10.1371/journal.pone.0025888.t001
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of these compounds and their half-maximal inhibitory concentra-
tions (IC50) were determined. The calibration curve for SsCEI 2
followed a hyperbolic pattern with an IC50 value of 9.861.0 mM
as calculated using Ac-Leu-pNA as reporter substrate; however, in
the presence of SsCEI 3 and SsCEI 4 no detectable decrease in the
APEHSs activity was observed (Figure 1A). Therefore, APEHSs
interacts with and is inhibited only by SsCEI 2 which has a Leu on
the P1 site, suggesting that the residue on this position has a major
role in the recognition with the target protease. Moreover, among
the fatty acids tested, only the t10c12-CLA isomer was able to
dose-dependently reduce APEHSs activity with an IC50 value of
8062.0 mM, whilst no significant modulatory effect was observed
using c9t11-CLA isomer (Figure 1B). Notably, APEHSs activity
followed a Michaelis–Menten kinetic, both in the absence and in
the presence of SsCEI 2 but only the Michaelis constant (Km) was
affected by increasing concentrations of substrate, suggesting that
SsCEI 2 behaved as a competitive inhibitor. It was confirmed by
plotting the data according to the Lineweaver–Burk equation (data
not shown), which allowed the calculation of a Ki value for SsCEI-
2 of 1.0060.02 mM. In contrast, in the presence of increasing
amounts of t10c12-CLA isomer, only the Vmax of APEHSs was
affected, indicating a non-competitive inhibition mechanism for
t10c12-CLA, with a Ki value of 140620 mM.
Mammalian APEHs are inhibited by SsCEI peptides and
t10c12-CLA
The inhibition activity of SsCEI peptides was also assessed using
mammalian APEHs purified from both porcine liver and human
colon carcinoma intestinal cells (Caco-2). These two enzymes
share more than 90% sequence identity, as calculated by the
ClustalW algorithm (http://www.ebi.ac.uk/Tools/msa/clustalw2/).
Ac-Ala–pNA was again used as the preferential substrate for these
mammalian APEHs. As shown in Figure 1C, both SsCEI 2 and
SsCEI 4 dose-dependently decreased porcine APEH activity,
although to different extents (IC50 values were 142630 mM and
84616 mM, respectively). Comparable IC50 values were obtained
using human APEH (data not shown). Moreover, the affinity of
SsCEI 4 towards porcine APEH was revealed by a Ki value of
4.060.8 mM, as determined by the Lineweaver-Burk plot, which
also showed that SsCEI 4 is a competitive inhibitor of this enzyme
(Figure 1E). The greater efficacy of SsCEI 4 over SsCEI 2, can be
ascribed to the preference for an Ala residue, with respect to leucine,
at the P1 site, assuming that the SsCEI–APEH association occurs in
a substrate-like manner. Data also suggested that the additional N-
terminal residues in SsCEI 3 (Table 1), negatively affected the
inhibition capacity towards both APEHSs and mammalian APEH
(Figure 1A, C).
Next, the modulatory effects of CLA isomers on porcine APEH
were investigated. The dose-dependent reduction of enzyme
activity followed a hyperbolic pattern in the presence of t10c12-
CLA isomer with an IC50 value of 105623 mM (Figure 1D),
whilst c9t11-CLA was ineffective. In addition the Ki of t10c12-
CLA towards porcine APEH was 140620 mM and the Line-
weaver-Burk plot revealed a non–competitive inhibition mecha-
nism. This is the first evidence of a direct inhibition of APEH by a
CLA isomer.
SsCEI 4 and t10c12-CLA are selective, time-dependent
and non covalent APEH inhibitors
The selectivity of SsCEI 2 and SsCEI 4 for porcine APEH
(hereafter APEH) were analysed in biochemical assays using
a panel of eukaryotic serine proteases comprising trypsin,
a-chymotrypsin, elastase, carboxypeptidase Y, subtilisin and
thrombin. Results showed that SsCEI 4 has no detectable effects
on the proteases tested. In contrast, SsCEI 2 displayed an
inhibition activity towards bovine a-chymotrypsin. The inhibition
curve also followed a hyperbolic pattern with increasing SsCEI 2
concentrations, and gave an IC50 value of 21.966.4 mM (Figure
S3). To further examine the SsCEI 4 specificity towards APEH, its
inhibition activity was determined in a reaction mixture containing
the entire set of proteases reported above. Under these conditions
the inhibition efficiency and the Ki of SsCEI 4 towards APEH
were comparable to those measured in the presence of the APEH
alone (data not shown).
To investigate the molecular inhibition mechanisms of SsCEI 4
and t10c12-CLA, time-dependent experiments were carried out.
Of note, SsCEI 4 and t10c12-CLA inhibited APEH (100% and
43%, respectively) only after pre-incubation with the enzyme for at
least 20 min, suggesting that they behave as time-dependent
inhibitors. Moreover, to exclude the formation of adducts or
degradation products between SsCEI 4 and its protease target
APEH, we analysed the incubation mixtures by reverse-phase
HPLC chromatography. The lack of new peaks in the HPLC
chromatogram and invariability of peak area suggested that
neither peptide degradation nor covalent binding with APEH
occurred under the assay conditions (Figure S3). Data thus
indicated that SsCEI 4 is a highly selective, time-dependent and
non covalent inhibitor of APEH.
Proteasomal degradation of the cystic fibrosis
transmembrane conductance regulator (CFTR) mutated
protein is prevented by SsCEI 4 and t10c12-CLA
The enzymatic stability of SsCEI 4 in 10% FBS was evaluated
as previously reported [19] and the peptide was completely stable
for at least one week under the assay conditions (data not shown).
In light of a recently proposed cooperative role for the APEH–
proteasome system in the control of protein turnover [15], we
hypothesised that APEH could be used as a target to indirectly
control/modulate proteasome functions. To support this idea, we
conducted in vitro experiments using the selected APEH
inhibitors (SsCEI 4 or t10c12-CLA) on the Baby Hamster
Kidney (BHK) cell line stably expressing a mutant protein of the
cystic fibrosis transmembrane conductance regulator (CFTR),
known as DF508 CFTR-3HA (hereafter called CFTR-M),
bearing the deletion of Phe508, one of the most common
modification in patients with cystic fibrosis. Many of the
mutations in the CFTR gene that cause cystic fibrosis interfere
with the folding and biosynthetic processing of CFTR molecules
in the endoplasmic reticulum. Specifically, some mutations,
including the common DF508, decrease the efficiency of CFTR
folding, reduce the probability of its dissociation from molecular
chaperones, and largely prevent its maturation through the
secretory pathway to the plasma membrane. These mutant
CFTR molecules are rapidly targeted for proteolysis via the UPS
[20–22].
Accordingly, BHK and human bronchial epithelial cells
(CFBE41o-DF) expressing CFTR-M were used in this study as a
model system to confirm the role of APEH in the coordinated
protein-degradation machinery, and steady-state levels of the core-
glycosylated CFTR-M form (140 kDa) were evaluated by
immunoblot analysis. Remarkably, the SsCEI 4 peptide and the
t10c12-CLA isomer efficiently prevented degradation of CFTR-M
at the time intervals considered (24 h and 48 h). As a fact,
exposure of BHK cells to 100 mM SsCEI 4 for 48 h or to 100 mM
t10c12-CLA for 24 h induced a marked increase of CFTR-M
levels (twenty- and five-fold, respectively) (Figure 2A, B, C),
without any cytotoxic effects (data not shown). In addition, a dose-
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Figure 1. Kinetic analysis of SsCEIs and CLA isomers towards APEHs. Binding of increasing concentrations of the SsCEI peptides (A), and CLA
isomers (B) to APEHSs. Binding of SsCEI peptides (C), and t10c12-CLA (D) to porcine APEH. The hyperbolic curves indicate the best fits for the data
obtained, with IC50 values calculated from the graphs. Inhibition kinetics analyses with porcine APEH (0.5 nM) at increasing SsCEI 4 concentrations:
100 mM (triangles) and 150 mM (squares) (E). Similarly, inhibition kinetics by increasing t10c12-CLA concentrations: 50 mM (squares) and 100 mM
(triangles) (F). Enzyme incubated without inhibitors were used as control (diamonds) (E, F). The inhibition constants, Ki, were determined by the
Lineweaver–Burk equation for competitive and non-competitive inhibition, respectively.
doi:10.1371/journal.pone.0025888.g001
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dependent inhibition of APEH and proteasome CT-like activities
was observed upon 48 h of incubation (similar data on APEH and
proteasome activities were measured after 24 h cell exposure) with
both compounds, as shown in Figure 2D, E consistent with the
immunoblot results.
Finally, siRNA technique was used to directly correlate APEH
to the protein degradation processes via UPS. For this purpose, the
accumulation of CFTR-M was evaluated in CFBE41o-DF cells
following transfection with APEH siRNA. As shown in Figure 2F,
APEH siRNA-transfected cells exhibited a considerable reduction
Figure 2. Analysis of the CFTR-M protein accumulation in BHK cells treated with the SsCEI 4 and t10c12-CLA and in APEH siRNA
transfected CFBE41o-DF cells. Representative Immunoblots and associated densitometric analysis for cytosolic CFTR-M accumulation in BHK cells
following 24 h and 48 h exposure to 50 mM or 100 mM SsCEI 4 (A), and to 50 mM or 100 mM t10c12-CLA (B). Bands were quantified using densitometric
analysis and normalized against a-tubulin. The values were expressed as average fold increase as compared to untreated culture (C). APEH activity
was measured in BHK cells incubated with 50 mM and 100 mM SsCEI 4 (white bars) or t10c12-CLA (grey bars) for 48 h (D). CT-like proteasome activities
were measured in BHK cells incubated with 50 mM and 100 mM SsCEI 4 (white bars) or t10c12-CLA (gray bars) for 48 h (E). Untreated cultures were
used as controls (black bars); the data are expressed as means6SD. *Significantly different (P,0.005) from the control (D, E). Representative
Immunoblots of APEH and CFTR-M accumulation in CFBE41o-DF cells transfected with APEH siRNA. A scrambled, non-targeted siRNA, was used as
negative control and a-tubulin was used as loading control (F).
doi:10.1371/journal.pone.0025888.g002
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of APEH protein levels and a marked accumulation of CFTR-M
(eight-fold, data not shown) (Figure 2F), in contrast to cells
transfected with a not specific siRNA which displayed basal levels
of APEH and neglectable level of CFTR-M. Therefore, APEH
can be seen as an alternative target, whose inhibition by
competitive as well as non-competitive inhibitors is accompanied
by a parallel down-regulation of proteasome activity through a yet
unknown mechanism.
SsCEI 4 and t10c12-CLA down-regulate APEH and
proteasome activities in cancer cells
Proteasome inhibition represents a validated, although chal-
lenging, anticancer approach. However, to prevent the adverse
effects deriving from indiscriminate cell death, inhibition of the
proteasome needs to be tightly controlled or selectively induced in
cancer tissues. Therefore, the concept that proteasome activity
could be decreased via APEH inhibition was investigated in a
cancer cell line. To this end, differentiated human colon
carcinoma Caco-2 cells were treated with SsCEI 4, t10c12-CLA
or with a specific PI (MG132) for 48 h. As shown in Figure 3A,
SsCEI 4 and t10c12-CLA markedly reduced APEH activity in a
dose-dependent manner, reaching their maximum effect at
200 mM, where enzyme activity was decreased by 70% and
50%, respectively. Under the same conditions MG132 treatment
had no detectable effects.
We next examined the inhibitory effects of SsCEI 4 and t10c12-
CLA on the CT-like proteasomal activity in Caco-2 cells and in
cell-free assays. In these latter experiments, partially purified
proteasome fractions from Caco-2 cells were used instead of the
commercially available 20S proteasome or immunoproteasome.
Indeed, it has been reported that in neoplastic cell lines the CT-
like proteasomal activity, as well as the sensitivity to different PIs, is
greatly influenced by the highly variable proteasome subunit
composition [23].
Therefore, cell exposure to SsCEI 4 and t10c12-CLA, produced
a dose-dependent decrease (up to 45% of the residual activity) of
the CT-like proteasome activity with respect to the untreated
cultures, whereas partially purified proteasome was not affected by
these compounds (Figure 3C, D), thus confirming that it is not
directly targeted by these inhibitors.
Next, we evaluated the effects of SsCEI 4 and t10c12-CLA
treatment on the activation of caspases. As shown in Figure 3B,
Figure 3. Down-regulation of the proteasome/APEH enzyme system by the SsCEI 4 and t10c12-CLA in Caco-2 cells. APEH activity was
measured in Caco-2 cells incubated with 50 mM, 100 mM and 200 mM SsCEI 4 (white bars) or t10c12-CLA (gray bars) for 48 h (A). Proteasomal CT-like
activity was measured in cell-free system (a partially purified proteasome fraction from differentiated Caco-2 cells, gray bars) and in Caco-2 cells
(white bars) treated with increasing concentrations of SsCEI 4 (C) or t10c12-CLA (D). Caspase-3 activities and LDH release were measured upon 48 h
incubations of Caco-2 cells with increasing concentrations of SsCEI 4 (white bars) and t10c12-CLA (striped grey bars) (B). The cytotoxic effect of the
different treatments was evaluated by measuring the LDH release in the culture media (B insert). Cell-free protein mixtures, or Caco-2 cell cultures,
treated with DMSO alone (black bars) or with MG132 (10 mM) (striped black bars) were used as positive controls. The data are expressed as
means6SD. *Significantly different (P,0.005) from respective controls.
doi:10.1371/journal.pone.0025888.g003
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caspase-3 activity, a key effector of apoptosis, was improved at
increasing doses of either SsCEI 4 or t10c12-CLA. This was not
associated with any cytotoxic effect even at the highest
concentration (200 mM), as indicated by the lactate dehydrogenase
(LDH) activity levels which remained comparable to those of
controls (Figure 3B insert).
Therefore, our results, consistently with the reporting coordi-
nated functions of proteasome and APEH in protein turnover
[15], add the relevant information that proteasome modulation
could occur via a complex pathway which has APEH like an
important and regulative factor. Moreover, since APEH activity is
not influenced by cell treatment with the specific PI MG132
(Figure 3A), proteasome modulation should be hierarchically
down-stream of APEH inhibition. This view is also corroborated
by the observation that APEH and proteasome seem to have no
direct interactions, as they are distinctly eluted from gel filtration
columns loaded with protein extracts obtained from SsCEI 4-
treated or untreated Caco-2 cells (Figure S4). Further investiga-
tions aimed at a better understanding of the molecular mechanism
underlying the proteasome inhibition by APEH are currently in
progress.
The combined use of SsCEI 4 and t10c12-CLA improves
the inhibition of proteasome activity, triggers apoptosis
and increases the level of UPS substrates in Caco-2 cells
To finally confirm the reliability of the APEH-mediated strategy
to affect UPS activity, several readouts were evaluated in
differentiated Caco-2 cells treated with SsCEI 4 and t10c12-
CLA, alone or in combination. Caco-2 cells were incubated for
48 h with SsCEI 4, t10c12-CLA (200 mM), or an equimolar
mixture (100 mM each) of both compounds. The commercially
inhibitors of APEH (ebelactone) or the proteasome (MG132) were
used as positive controls.
Cell exposure to SsCEI 4 or t10c12-CLA saw 40% reduction in
the proteasomal CT-like activity, with a more marked decrease
(about 73%) resulting from their combined use (Figure 4A). A
similar behaviour was observed when APEH activity was
monitored (data not shown), which supports the hypothesis of an
additive effect (combination index; CI = 1) [24] produced by
SsCEI 4 and t10c12-CLA on the target protease. However, due to
the difficulties in the setting-up the large number of variables
which possibly affect the formation of enzyme–inhibitor-substrate
complexes, we were unable to reproduce the additive effects on the
proteasome or APEH activities in cell-free assays.
To evaluate the pro-apoptotic effects arising from cell exposure
to a mixture of SsCEI 4 and t10c12-CLA, we measured caspase-3
and caspase-8 activities as these enzymes have been reported to be
essential for the proteasome-induced apoptosis cascade [6,25].
Specifically, caspase-3 was significantly increased by SsCEI 4 or
t10c12-CLA (about two-fold in both cases; P,0.01), with a further
improvement produced by their combination (about four-fold), in
comparison to untreated cultures. Although caspase-8 activity was
less intense, it showed a profile similar to that of caspase-3, further
supporting the view that cell death occurs by an apoptotic
mechanism (Figure 4B). These data are in agreement with the
well-established association between proteasomal inhibition and
apoptosis induction, and confirm the additive effects produced by
using a mixture of SsCEI 4 and t10c12-CLA on the caspase
cascade in cancer cells. Notably, the toxicity resulting from the
APEH-mediated inhibition of proteasome activity, as indicated by
the treatment with SsCEI 4, t10c12-CLA or ebelactone, was
significantly lower than that observed in culture incubated with
MG132 (Figure 4B insert).
Moreover, the immunoblot analysis, showing that the levels of
APEH in cells were not affected by any of these treatments, clearly
indicated that the APEH down-regulation resulted from an
enzyme inhibition process, rather than a reduction in protein
expression. Cell exposure to SsCEI 4 and t10c12-CLA, alone or in
combination, produced an increase of well-known proteasome
substrates (p21Waf1 and NF-kB, two-fold or four-fold, respective-
ly; Figure 4C, D). These findings are consistent with the idea that
the relationship between apoptosis and the accumulation of
damaged or short-lived regulatory proteins has a prominent role in
controlling the homeostasis of cancer cells [22]. Cytoplasmic
increase of NF-kB levels is indeed regarded as a major hallmark of
apoptotic cells, since NF-kB nuclear translocation, following I-kB
degradation by UPS and gene transcription, is a well-established
mechanism of cell growth. Proteasome inhibition in cancer cells
leads to a reduced rate of I-kB degradation, and to a longer
persistence of NF-kB in the cytoplasm [26,27]. In the same way,
accumulation of p21Waf1, a negative regulator of the cell division
cycle, is a direct evidence of increased apoptosis and of reduced
proteasome activity, since it has been reported that its degradation
occurs through N-terminal as well as internal lysine ubiquitinyla-
tion [28].
Polyubiquitinylated proteins are normally degraded by the
cellular proteasomes, and down-regulation of proteasome activity
has been shown to substantially suppress bulk intracellular protein
turnover [29]. As evidenced in Figure 4E, following incubation
with SsCEI 4, t10c12-CLA (alone or in combination), ebelactone
or MG132, we detected in cell extract the presence of high-
molecular-mass immunoreactive species (66 kDa to 160 kDa)
which are absent in untreated cultures. These signals are indicative
of polyubiquitin conjugates in the treated cells, confirming that
these compounds deregulate UPS activity in cancer cells.
As a whole, our in vitro results demonstrate that APEH
inhibition by SsCEI 4 and t10c12-CLA treatments is associated
with increased levels of the typical markers of proteasome
inhibition without any cytotoxic effect. Although pro-apoptotic
activities of CLA mixtures and their ability to induce an increase of
the cytoplasm levels of NF-kB and p21Waf1 have been previously
reported [30,31], to our knowledge this is the first study showing
that their effects are mediated, at least in part, by the APEH/
proteasome system, suggesting a possible mechanism by which
CLA isomers exert their anticancer activity.
Putative APEH binding site for t10cis12-CLA isomer
In light of these outcomes, APEH inhibition represents a novel
strategy to regulate proteasome activity, with potential applications
in biomedical fields. Knowledge of the enzyme–inhibitor binding
sites at the molecular level is pivotal for our understanding of the
underlying mechanisms, as well as for the design of novel and
more efficient inhibitors. In a previous work [17], the structural
model of the inhibition complex APEHSs-SsCEI protein corrob-
orated by mutagenesis studies, indicated an involvement of the
SsCEI RSL in the interaction with the active site of the enzyme
target. Therefore, it is conceivable to assume that the competitive
inhibition of APEHSs by SsCEI 4 peptide occurs through a similar
binding-mode.
The surprising down-regulation of APEH by t10c12-CLA and
the finding of additional non-competitive APEH binding pockets
apart from the active site, prompted us to undertake a molecular
modelling study to look for potential APEH-CLA binding sites.
Protein-fatty acid docking analyses were carried out starting from
the previously reported structural model of APEHSs [17], herein
used for the biochemical investigation. The APEHSs 3D model,
built on the X-ray structure of APEH from Aeropyrum pernix
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[32], shows the typical features of a POP family member: a a/b-
hydrolase catalytic domain with the (Ser-Asp-His) catalytic triad,
covered by a central tunnel of an unusual b-propeller domain.
Docking calculations were performed by using the AutoDock
simulation package [33]. The docked conformations of t10c12-CLA
suggested two putative binding modes that were characterised by
different anchoring points for the carboxylate group of the CLA
isomer: the positively charged side-chains of either R62 or R507.
However, the binding involving the residue R507 appeared to be in
conflict with the non-competitive inhibition mechanism indicated
by the experimental data, as R507 belongs to the active site of
APEHSs [17]. Thus we did not consider this binding approach
further. binding of t10c12-CLA involving R62 residue of the
enzyme is in agreement with the non-competitive mechanism of
inhibition resulting from cell-free assays. In this case, t10c12-CLA
occupies the b-propeller tunnel, eventually obstructing the passage
of the substrate and/or the product (Figure 5). Details of the binding
mode involving R62 are shown in Figure 6: t10c12-CLA
carboxylate group interacts with the side-chains of R62 and S273
of APEHSs, while the long hydrophobic carbon tail of t10c12-CLA
is stabilised by van der Waals interactions with some of the
hydrophobic residues that line the b-propeller tunnel of APEHSs.
Figure 4. Evaluation of proteasome inhibition markers in Caco-2 cells incubated with SsCEI-4 and t10c12-CLA, alone or in
combination. Caco-2 cells were treated (48 h) with 10 mM MG132 (MG), 100 mM ebelactone (Ebel), 200 mM SsCEI 4 (S4), t10c12-CLA (t10), or with a
mixture of both (t10+S4). Cells exposed to DMSO alone were used as the controls (black bar). The data are expressed as means6SD. *Significantly
different (P,0.005) from the control (A). Caspase-3 (white bars) and caspase-8 (grey bars) activities measured as fold increase in comparison to
untreated cells (B). The cytotoxic effect of the different treatments was evaluated by measuring the LDH release in the culture media (B insert).
Representative immunoblots of the expression of p21Waf1, NF-kB, and APEH in Caco-2 cell exposed for 48 h to MG, Ebel, S4, t10 or with a mixture of
both (t10+S4) (C). Data on Western blot analysis are expressed as the density ratio of target to control (b-actin) in arbitrary units. The values were
expressed as average relative intensity as compared to untreated cultures and expressed as means6SD of measurements performed in triplicate (D).
Protein ubiquitinylation in Caco-2 cell exposed for 48 h to MG, Ebel, S4, t10 or with a mixture of both (t10+S4) (E, upper panel). Upon the
immunodetection, the membrane was stained with Coomassie blue. The lane loaded with molecular mass markers [MW kDa] was shown (lower
panel).
doi:10.1371/journal.pone.0025888.g004
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Of note, the interaction mechanism suggested by this docking
analysis shares common characteristics with the fatty-acid-binding
proteins (FABP) [34,35]. X-ray structural studies have shown that
the fatty acid molecule binds to the relatively large FABP inner
cavity, and is anchored to a positively-charged arginine residue
and a polar amino acid (usually serine or threonin), with the
hydrophobic tail again stabilised by van der Waals interactions
with hydrophobic residues.
The lack of structural information and the difficulty to predict a
sufficiently accurate 3D model for any mammalian APEH have
prevented us from performing modelling studies on mammalian
APEHs. However the functional properties indicate significant
similarity between mammalian and archaeal APEHs, showing that
both are inhibited by SsCEI 4 peptide in a competitive manner
(Figure 1E) or by t10c12-CLA through a non-competitive
mechanism (Figure 1F), with comparable Ki values. Therefore,
we hypothesise that the enzymes from archaeal and mammalian
sources could share some common features in their modes of
interaction with these inhibitors suggesting that APEHSs can be
used as an initial model system for the early design of novel
inhibitors of mammalian APEH.
Conclusions
Proteasome is an abundant multi-enzyme complex that provides
the main pathway for the protein turnover or the elimination of
misfolded and aggregated proteins. As such, it controls the levels of
proteins involved in cell-cycle progression and apoptosis in normal
and malignant cells, and has become an important therapeutic
target in anticancer therapies. A large number of specific PI
molecules have been developed to date [36], but despite their
indisputable efficacies all of these suffer for negative side-effects.
These events represent the major drawback of impairing the
activity of a target largely involved in physiological processes. For
these reasons, several studies have suggested that the targeting of
functionally related, up-stream or down-stream proteasome
effectors [29], can be an alternative and a safer way to recover
proteasome dysfunction associated with pathological conditions
[29,37,38].
In this study we showed for the first time that, by using a set of
selected APEH inhibitors, proteasome activity can be regulated
through an APEH-mediated mechanism which represents a novel
strategy to control UPS functions. Beside these findings, we
demonstrated that the stable, selective and non toxic inhibitors of
APEH (a synthetic peptide and a CLA isomer) are able to produce
a noticeable down-regulation of UPS activity in cells. Moreover,
Figure 5. Binding mode of the t10c12-CLA with APEHSs. Binding mode suggested by docking analysis for t10c12-CLA (blue; ball-and-stick mode)
with APEHSs (cartoon representation; green, left). Protein residues involved in stabilising the interactions with the carboxylic group of the t10c12-CLA
are represented as sticks. The Ser-Asp-His catalytic triad residues are shown as black lines; R507 is shown in yellow. (right) View rotated 90u along the
x-axis (the horizontal axis parallel to the image plane).
doi:10.1371/journal.pone.0025888.g005
Figure 6. Suggested binding site on APEHSs.by docking
analysis for the t10c12-CLA (blue; ball-and-stick mode) isomer.
The relevant APEHSs residues are shown in ball-and-stick representation.
doi:10.1371/journal.pone.0025888.g006
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these molecules represent attractive templates for the design of
more potent inhibitors, with potential applications as anticancer
and anti-inflammatory agents. In addition, the synergistic effects
resulting from their combined use strongly suggest that chimeric
compounds, including competitive and non-competitive inhibitors,
with increased specificity and enhanced activity, can be investi-
gated and developed.
APEH has been postulated to serve as a key regulator of N-
terminally acetylated proteins [39] but the biological effects of
disrupting APEH has not been completely understood. As more
than 80% of proteins in human cells are N-terminal acetylated
[40–42] and protein acetylation is implicated in a variety of
essential cellular pathways [43], it is thus likely feasible that APEH
is involved in these processes.
As reported in previous studies, proteasome and APEH act
cooperatively in protein turnover [15,44], although the biochem-
ical mechanisms remain to be clarified. In this regard, in contrast
to the general idea that N-terminal acetylation protects from
degradation, in certain proteins some sequences which include
acetyl groups at the N-terminus were recently found to be involved
in degradation signals [45,46]. On the basis of our preliminary
results, a direct interaction between APEH and proteasome might
be excluded, whereas the hypothesis that APEH can activate or
stabilise the proteasome by uncovering the N-tail of a yet unknown
negative effector protein cannot be ruled out. Of note, we showed
that whereas APEH inhibition triggered an impairment of the
proteasome activity, its selective inhibition did not affect APEH
functions, likely suggesting that APEH could be an up-stream
modulator of the proteasome. Studies aimed at achieving a better
understanding of the mechanism/s responsible for the APEH-
mediated down-regulation of proteasome and at the evaluation of
APEH inhibitors in animal cancer model are currently in progress.
Materials and Methods
Reagents
Pure c9t11- and t10c12-CLA isomers and caspase-3 and -8
fluorometric Assay Kits were purchased from Sigma-Aldrich.
DMEM/F12, DMEM, L-glutamine, penicillin-streptomycin and
FBS were from Gibco-BRL. Porcine liver APEH was obtained by
Takara. Chemicals of the highest purity were from Sigma-Aldrich
or Calbiochem.
Peptide design, synthesis and characterisation
The peptides were prepared as amidated derivatives by solid-
phase synthesis (synthesis scale, 0.1 mmoles), following standard
Fmoc/tBu protocols [47]. A rink amide resin (substitution,
0.57 mmol/g) and amino acid derivatives with standard protection
were used in all of the syntheses. Cleavage from the solid support
was performed by treatment with a trifluoroacetic acid (TFA)/tri-
isopropylsilane/water (90:5:5, v/v/v) mixture for 90 min at room
temperature. The crude peptides were precipitated in cold ether,
dissolved in a water/acetonitrile (1:1, v/v) mixture and lyophilised.
The peptides were purified by reverse-phase HPLC using a semi-
preparative 561 cm ID C18 monolythic Onyx column, applying a
linear gradient of 0.05% TFA in acetonitrile from 10% to 70%
over 8 min at a flow rate of 15 mL/min. Peptide purity and
identity were confirmed by liquid chromatography–mass spec-
trometry analysis.
Gel filtration analysis of synthetic peptides
Gel filtration chromatography was performed on a BioSep
SEC-S2000 column equilibrated with 50 mM phosphate buffer
pH 6.8, at a flow rate of 1.0 mL/min. A standard curve was built
using a set of synthetic peptides with molecular weights between
1.500 amu and 2.500 amu. For this purpose, peptide aliquots
were injected onto the column and a plot of KD versus log10
molecular weights (MW) was obtained, where KD= (Ve-Vo)/(VT-
Vo), Ve is the elution volume of the sample, and VT and Vo are
the total and void volumes of the column, respectively.
Circular dichroism spectroscopy
CD spectra were obtained on a Jasco J-715 spectropolarimeter
with 400 mL of 8.0610-7 M protein in 5 mM Tris–HCl pH 7.5.
Hellman quartz cells of 0.1-cm-path length were used in the far
UV (190–250 nm). The temperature of the sample cell was
regulated by a PTC-348 WI thermostat and thermal CD was
performed from 250 to 195 nm by raising the cell temperature
from 37uC to 77uC. The thermal CD spectra were signal-averaged
by combining three scans and the baseline was corrected by
subtracting a buffer spectrum. The samples were then cooled back
to 37uC to monitor the final folding of the peptides.
Purification of APEHs and proteasome
APEH from Sulfolobus solfataricus was purified as previously
reported [17]. Partial purification of human APEH and proteasome
was carried out from protein extracts of Caco-2 cell. Briefly, protein
extracts (500 mg) were fractionated by gel filtration chromatography
on a Superdex 200 PC 3.2/30 column connected to a SMART
System (Pharmacia) equilibrated in buffer 50 mM Tris-HCl,
pH 7.5, 100 mM NaCl, at 0.1 mL/min. The eluted fractions were
assayed using the specific substrates for APEH and the proteasome.
The active fractions were collected and used for further analysis.
Enzyme assays
Porcine liver APEH activity was measured spectrophotometri-
cally using the chromogenic substrate acetyl-Ala-pNA (Bachem).
The reaction mixture (1 mL) containing pure APEH (38 ng) or an
appropriate amount of cell extract in 50 mM Tris-HCl buffer
pH 7.5 (Tris Buffer), was preincubated at 37uC for 2 min. Then,
1 mM acetyl-Ala-pNA was added and the release of p-nitroanilide
(e410= 8800 M-1 cm-1) was measured by recording the absor-
bance increase at 410 nm on a Cary 100 Scan (Varian) UV/Vis
spectrophotometer, equipped with a thermostated cuvette com-
partment. APEH activity was expressed in IU. The APEHSs
activity was measured using acetyl-Leu-pNA (0.1 mM) (Sigma) as
substrate. The reaction mixture (1 mL) containing the appropriate
amount of enzyme in 25 mM Tris-HCl buffer pH 7.5, was
preincubated at 80uC for 2 min. Then, 0.1 mM acetyl-Leu-pNA
was added and the release of p-nitroanilide was measured,
following the standard assay procedure described above.
The synthetic fluorescent substrate N-succinyl-Leu-Leu-Val-
Tyr-7-amido-4-methylcoumarin (N-Suc-LLVT-AMC) was used
for the measurement of the CT-like activity of the proteasome, at a
final concentration of 0.080 mM. The reaction mixture (0.9 mL)
containing appropriate amount of proteasome was preincubated
as above, in Tris buffer. N-Suc-LLVT-AMC was added, and the
release of the fluorescent product (7-AMC) was monitored for
5 min in a Perkin–Elmer LS 50B fluorimeter. The excitation and
emission wavelengths were 380 nm and 460 nm, respectively.
The carboxypeptidase Y, elastase, thrombin, trypsin and
subtilisin activities were also evaluated according to previously
published methods [18].
Enzyme inhibitory assays
Protease inhibitor activities of the SsCEI peptides and the CLA
isomers were carried out using a fixed amount of APEH or
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partially purified proteasome (3–5 nM and 0.12 mg/mL, respec-
tively), and increasing the SsCEI and CLA isomer concentrations.
Mixtures were pre-incubated for 30 min at 37uC before the
addition of the substrate, and the enzymatic activities were
followed as described above. Protease inhibitor activities of the
SsCEI peptides and the CLA isomers were determined towards
APEHSs. The protease and increasing concentrations of the
inhibitors were mixed and preincubated for 30 min at 80uC before
the addition of the specific substrate. The residual enzymatic
activity was determined using the assay procedure described
above.
The time-dependent inhibition of SsCEI 4 and t10c12-CLA
towards APEH was assessed. Mixtures containing appropriate
amounts of each inhibitor and of APEH were pre-incubated for
20 min at 37uC; they were then diluted (1:5) into the standard
assay mixture, which contained the substrate only. The enzymatic
activity was followed as described above. Control samples were
prepared by pre-incubating the same amounts of APEH without
the inhibitors and then diluted in the standard assay mixture.
The additive effects elicited by cell exposure to SsCEI 4 and
t10c12-CLA was calculated accordingly to the Chou and Talalay
equation (CI =D1/[(DM)16[fa/(1-fa)]1/m1+D2/[DM26[fa/(1-
fa)] 1/m2) [24].
HPLC analysis of SsCEI peptides incubated with the
target enzyme
The experiments were conducted at 37uC in 50 mM Tris
buffer, pH 7.5. Solutions of SsCEI 4 and porcine APEH were
incubated for up to 2 h at optimal concentrations (4 mM SsCEI 4
and 100 mM APEH) to guarantee a high degree of enzymatic
inhibition. At specific time intervals, 195 mL aliquots were taken,
and the reaction was stopped by addition of 5 mL TFA. The
samples were then analysed directly by reverse-phase HPLC
(Dionex BioLC) on a mBondapak C18 column (3.96300 mm,
Waters), eluted with a linear gradient (0–60% acetonitrile in 0.1%
TFA) at a flow rate of 1 ml/min. Control peptide samples were
incubated in the absence of the purified enzymes and run in
parallel.
Antibodies
The following antibodies were used: anti-APEH antibody (sc-
102311; Santa Cruz Biotechnology); anti-NF-kB/p65 antibody
(Thermo Scientific); anti-p21Waf1 antibody (Exbio); pan Ab-5
anti-actin antibody (clone ACTN05, Thermo Scientific); and
monoclonal antibodies against polyubiquitinylated proteins con-
jugated with horseradish peroxidase (FK2H, Enzo, Life Science).
The DF508CFTR-3HA protein was detected with an anti HA
monoclonal antibody (Covance).
Cell culture
BHK cells stably expressing CFTR-M (kindly donated by Dr.
David Y Thomas, McGill University Montreal Canada) were
cultured in DMEM/F12, 5% FBS, 1 mM L-glutamine, 200 mg/
mL methotrexate, and 100 units/mL penicillin-streptomycin, at
37uC in a humidified 5% CO2 atmosphere. The cells were plated
in 12-well plates, to a confluence of 60% for the 24-h incubations,
and 40% for 48-h exposure to PIs. These treatments were initiated
24-h after the plating of the cells. Phase-contrast images of the cells
were taken just before the lysis of the cells for protein analysis,
using a Lica DM6000 inverted microscope.
Caco-2 cells (ATCC) were cultivated in DMEM supplemented
with 10% FBS, 1 mM glutamine and 100 units/mL penicillin-
streptomycin at 37uC in a humidified 5% CO2 atmosphere. The
cells were studied between passages 12 and 22. The cells were split
using trypsin-EDTA solution and plated in 6-well plates at a
density of 86104 cells/mL and the medium was replaced every 2–
3 days. Under these conditions, the cells reached visual confluence
after 7 days and the differentiated stage two weeks later. The
differentiated cells were incubated for 48 h with the different
substances.
Protein extraction and Western blotting analysis
Following the treatments, the BHK and Caco-2 cells were
washed three times with ice cold phosphate-buffered saline and
collected immediately at 4uC in lysis buffer (1% Triton X-100,
0.1% SDS, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5%
sodium deoxycholate and complete protease inhibitors [Roche]).
The lysates were centrifuged at 10,0006g for 15 min at 4uC. The
protein concentrations in the clear supernatants were determined
(BCA protein assay reagent kit; Pierce) before their use in
enzymatic assays or SDS–PAGE. In brief, for Western blotting,
aliquots were run on SDS-PAGE (8% or 12.5%) and then
electroblotted onto nitrocellulose (Schleicher & Schuell) or PVDF
membranes (ImmobilonTM, Millipore). The membranes were next
incubated with primary antibodies and then with the appropriate
dilution of secondary antibody (1 h at 37uC). At the end of this
time, the immunocomplexes formed were visualised by enhanced
chemiluminescence and autoradiography according to the man-
ufacturer protocol (Amersham Biosciences) and quantified by
densitometric analysis with ChemiDoc XRS (Bio-Rad). Protein
expression data was quantified with Quantity One Software (Bio-
Rad).
Apoptosis assays
The pro-apoptotic ability of the peptides and the CLA isomers
were assayed by measuring the caspase-3 and caspase-8 activities
using fluorometric kits, according to the manufacturer instructions.
These assays were based on hydrolysis of the substrate acetyl-Asp-
Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC) or
acetyl-Ile-Glu-Thr-Asp-7-amino-4-methyl coumarin (Ac-IETD-
AMC) by caspase-3 and caspase-8, respectively. The release of
the 7-AMC moiety in protein extracts prepared from the
differently treated cells was evaluated by fluorimetry (excitation
360 nm, emission 460 nm). Their amounts were calculated by
means of a standard curve prepared with pure AMC, and
following normalisation for protein content, the activities were
expressed as nmoles AMC/mg protein/min.
Cytotoxicity assay
The release of LDH was used as the marker for cell toxicity
[48]. The culture supernatants were sampled at the end of the
incubations and centrifuged (4,0006g, 5 min, and 4uC). Aliquots
of the clear supernatant (10 mL) were incubated with 190 mL
reaction buffer (200 mM Tris/HCl, pH 8.0, 0.7 mM p-iodoni-
trotetrazolium violet, 50 mM L-lactic acid, 0.3 mM phenazine
methoxysulphate, 0.4 mM NAD,) for 30 min at 37uC. Absorbance
was measured at 490 nm and the results were expressed as
percentages of total LDH release from control cultures treated
with 1% (w/v) Triton X-100 and calculated as: [(experimental
value - blank value)/(total lysis -blank value)2100].
Docking calculations
The AutoDock (version 4.0) programme package [33] was
chosen to dock t10c12-CLA into the large inner cavity of the
APEHSs enzyme. The previously reported atomic coordinates of
the APEHSs model [17], were used in the calculations. Amber
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charges and polar hydrogens were added to the protein using the
PDB2PQR server (http://pdb2pqr-1.wustl.edu/pdb2pqr/). The
ligand coordinates were generated by the PRODRG server
(http://davapc1.bioch.dundee.ac.uk/prodrg/), and subsequently
energy minimised using the Insight II package; atom charges and
active torsions were defined using AutoDockTools. Affinity grids
with dimensions 80680690 points (with spacings of 0.375 A˚) were
centred approximately in the middle of the enzyme b-propeller
central tunnel and were large enough to cover the entire inner
cavity of the enzyme subunit. The Lamarckian genetic algorithm
and the pseudo-Solis and Wets methods were used for the
conformational search. The maximum number of energy
evaluations was set to 2.56107 and a maximum number of
2.76105 genetic algorithm operations were generated on a single
population of 150 individuals. The operator weights for crossover,
mutation, and elitism were set as the default parameters: 0.80,
0.02, and 1.0, respectively. One hundred runs were performed.
The resultant docked conformations of the ligand were clustered
and ranked according to the default AutoDockTools scoring
function using a RMSD deviation of 3.5 A˚. The MOLMOL
programme was used for the molecular visualisation and analysis
[49].
Small interfering RNA transfection
The siRNA is purchased from Sigma (siRNAID SA-
SI_Hs01_00240856 and SASI_Hs01_00240857), and CFBE41o-
DF espressing DF508 CFTR were kindly provided by Dr. J. P.
Clancy Department of Pediatrics, the University of Alabama at
Birmingham, Birmingham, AL, USA. CFBE41o-DF cells at
56104 cells/well were cultured over-night on 12-well plates and
transfected 24 h after with APEH siRNA at a final concentration
of 50 nM. using Lipofectamine 2000, according to the manufac-
turer’s instruction. Non-targeting siRNA was used as a negative
control. After 72 hours of transfection, cells are lysed in RIPA
buffer and protein levels were determined by western blotting
Statistical analysis
All data were obtained from triplicate analyses of three different
preparations. Data were presented as means 6S.D. Statistical
analysis and IC50 values were calculated with the SigmaPlot 10.0
software through a non-linear curve-fitting method and using a
simple binding isotherm equation. Groups were compared by
Student’s t test, and P,0.05 was considered as significant.
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10 ABSTRACT: Acyl peptide hydrolase (APEH) catalyzes the removal of acetyl-
11 amino acids from the N-terminus of peptides and cytoplasmic proteins. Due to
12 the role played in several diseases, and to the growing interest around N-
13 terminal acetylation, studies on APEH structure, function, and inhibition are
14 attracting an ever increasing attention. We have therefore screened a random
15 tetrapeptide library, N-capped with selected groups, and identified a
16 trifluoroacetylated tetrapeptide (CF3-lmph) which inhibits the enzyme with
17 a Ki of 24.0 ± 0.8 μM. The inhibitor is selective for APEH, shows an
18 uncommon uncompetitive mechanism of inhibition, and in solution adopts a
19 stable bent conformation. CF3-lmph efficiently crosses cell membranes,
20 blocking the cytoplasmic activity of APEH; however, it triggers a mild pro-
21 apoptotic effect as compared to other competitive and noncompetitive
22 inhibitors. The unusual inhibition mechanism and the stable structure make
23 the new compound a novel tool to investigate enzyme functions and a useful
24 scaffold to develop more potent inhibitors.
25 ■ INTRODUCTION
26 Acyl peptide hydrolase (APEH) is a ubiquitous enzyme that
27 belongs to the prolyl-oligopeptidase (POP) family of proteins.
28 It mostly catalyzes the removal of N-acetyl-amino acids from
29 the N-terminus of short peptides deriving from protein
30 degradation processes and bearing residues with small hydro-
31 phobic side chains on position 1.1 It has been also postulated
32 for many years that it could be a key regulator of protein N-
33 terminal acetylation; however, only very recently it has been
34 shown that APEH can process a large set of full length
35 cytoplasmic proteins, thus suggesting that their structure and
36 function can be tightly regulated by the activity of this enzyme.2
37 Indeed, treatment of cells with potent and highly specific APEH
38 inhibitors leads to an accumulation of N-terminal acetylated
39 proteins over the nonacetylated variants and to a sustained
40 proliferation of mouse T cells, an effect not observed in
41 untreated cells. Because a relevant fraction of cellular proteins is
42 N-terminally acetylated3 and this modification plays a critical
43 role in the protein folding/misfolding process, thus on protein
44 fate,4 an obvious involvement of APEH in the protein turnover
45 mechanism has been also hypothesized.2,5
46 We have recently demonstrated that APEH can influence the
47 activity of proteasomes,6 a well-established target for a number
48 of cancer diseases, including multiple myeloma.7,8 APEH
49 inhibitors have a potential as antitumor agents working as
50indirect regulators of the proteasome activity or more in general
51of the ubiquitin proteasome system (UPS).5,9 In particular, we
52have reported that competitive inhibitors of APEH derived
53from the reactive site loop (RSL) of the first protein inhibitor
54of APEH isolated from the archaeon Sulfolobus solfataricus,
55SsCEI,10 block the enzyme activity by a mechanism that leads
56to a concomitant downregulation of proteasome function,
57inducing a potent pro-apoptotic stimulus in human colon
58carcinoma cells (Caco-2). Remarkably, the same effects are
59seen using, alone or in combination with the peptide inhibitor,
60the trans10-cis12 isomer of conjugated linoleic acid (CLA),
61which instead shows a noncompetitive mechanism of APEH
62inhibition. These findings open a new important perspective for
63the development of APEH inhibitors, especially in the field of
64multiple myeloma, an incurable tumor disease whose current
65treatments are mainly based on the use of proteasome
66inhibitors.6 A further important role for APEH has been
67hypothesized in neurodegenerative diseases, such as Alzheim-
68er's disease (AD), because administration of the acetylcholi-
69nesterase inhibitor dichlorvos to rat hippocampal slices also
70efficiently inhibits enzyme activity, and this correlates with
71improved synaptic efficacy.11
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72 To further investigate the role played by APEH and their
73 inhibitors on cell activity, we have undertaken the screening of
74 a random library made of short synthetic peptides to select new
75 compounds able to modulate the enzyme functions. Peptides
76 are particularly suitable for this purpose for their capability to
77 mimic the structures of natural substrates and of modulating
78 enzyme activity by different mechanisms; in particular, small
79 linear peptides could best fit in catalytic pockets and, given the
80 high flexibility, they can adopt suitable conformations in an
81 effective and timely way. Random screenings are very useful in
82 this instance, as the protein structure is unknown and inhibitors
83cannot be designed on a rational basis. In addition, libraries of
84small peptides made of three to four residues and containing
85only subsets of amino acids are of particular interest for the
86rapid identification of small hits, which more favorably can be
87converted to more rigid and stable organic scaffolds.12
88In this study, we have identified N-terminally modified small
89peptides (average MW 500−600 amu), selected from
90completely random synthetic libraries, which inhibit APEH in
91a very specific manner. The most active molecule also exhibits
92an uncommon mechanism of inhibition and a bent
93conformation induced by the presence of a D-proline on
Figure 1. Iterative screening of the Yi-X1-X2-X3-X4 library to identify APEH inhibitors. The library was assembled in a simplified format (see
Marasco et al.12) using a reduced set of residues accounting for all the different chemical groups present on natural amino acid side chains. D-Amino
acids were used to obtain enzymatically stable peptides. Also the N-terminus was modified by a set of carboxylic acids in order to explore the
chemical space around the N-terminus where APEH is known to operate. In part a, a plot with inhibition by the first sublibraries, distinguishable by
the different carboxylic acids on the N-terminus, is reported. In part b, a plot with inhibition by the second set of sublibraries all N-terminally
trifluoroacetylated, distinguishable by the different residues on position X1, is reported. In part c, a plot with inhibition by the third set of
sublibraries, all having in common TFA-D-Leu, distinguishable by the different residues on position X2, is reported. In part d, a plot with inhibition
by the fourth set of sublibraries, all having in common TFA-D-Leu-D-Met, distinguishable by the different residues on position X3, is reported. In part
e, a plot with inhibition by the fifth set of sublibraries, all having in common TFA-D-Leu-D-Met-D-Pro, distinguishable by the different residues on
position X4, is reported. In part f, the binding of TFA-D-Leu-D-Met-D-Pro-D-His to porcine liver APEH using acetyl-Ala-pNA as substrate is reported.
The hyperbolic curve indicates the best fit for the percentage inhibition data obtained, and the IC50 value was calculated from the graph.
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94 position 3. The peptide is not toxic compared to the
95 commercially available APEH inhibitor ebelactone, efficiently
96 crosses cell membranes, and blocks the activity of APEH in
97 cancer cells. Although it exhibits only minor effects on cell
98 proliferation and caspase 3 activity, its novel mechanism of
99 action opens new perspectives for the understanding of the
100 cellular processes involving APEH and the mechanisms
101 associated to the parallel inhibition of proteasome activity.6
102 ■ RESULTS
103 Library Preparation and Characterization. After the
104 synthesis of the first library, an average 10 mg amount of
105 material was obtained. Assuming an average MW of 600 amu
106 and considering the synthesis scale of 20 μmoles, a rough 83%
107 yield could be calculated. Data from amino acid analysis of
108 peptide pools performed on the first (complexity 124 = 20 736
109 peptides) and second library (complexity 123 = 1728 peptides)
110 were in agreement with a pretty equimolar distribution of
111 peptide components within the mixtures. The third library
112 (complexity 122 = 144 peptides) was not characterized. LC-MS
113 analysis of a 12-component mixtures also suggested that
114 peptide components were essentially at the same concentration
115 within mixtures. The synthesis of single peptides proceeded
116 very smoothly. After HPLC purification, an average 50% yield
117 was obtained. After semipreparative purification, tetrapeptides
118 were all >95% pure, as determined by RP-HPLC as well as LC-
119 MS analyses.
120 Library Screening. After the first screening step, the
121 sublibrary trifluoroacetylated on the N-terminus was selected as
122 the most active in inhibiting the APEH activity. It indeed
123 provided an overall 78% enzyme inhibition at a concentration
f1 124 of 200 μM (see Figure 1a).
125 From the screening of the second library, tested at 40 μM,
126 pools having D-Leu, D-Pro, and D-Arg on position X1 were
127 selected as the most active. They provided inhibition of 67%,
128 64%, and 51%, respectively (Figure 1b). Testing of these
129 sublibraries in a range of concentrations between 10 and 200
130 μM allowed the selection of the library with D-Leu as the most
131 active (not shown). The 12 pools of the third library with TFA
132 and D-Leu at the N-terminus were assayed at 100 μM. Pools
133 with D-Cys(Acm), D-Met, and D-Leu were selected for the
134 dose−response test and, as shown in Figure 1c, the library with
135 D-Met on the X2 position was then selected for resynthesis.
136 The 12 pools of the fourth library having the N-terminal
137 common sequence TFA-D-Leu-D-Met were tested at 50 μM. In
138 this assay, only pools with D-Pro and D-Arg on position X3
139 inhibited the enzyme (both 21%, Figure 1d). A dose−response
140 test allowed selection of the pool with D-Pro as the candidate
141 for resynthesis (not shown). The fifth library, composed of
142 twelve single tetrapeptides, was tested at 50 μM. As reported in
143 Figure 1e, peptides having D-Arg, or D-His, or D-Phe, or D-Tyr
144 on position X4 were capable of inhibiting APEH for more than
145 25%; however, after testing in a dose−response assay, the
146 peptide of sequence TFA-D-Leu-D-Met-D-Pro-D-His-NH2
147 (hereafter termed only CF3-lmph), was the one selected as
148 an efficient inhibitor, as it was the only peptide able to block
f2 149 enzyme activity in a dose-dependent fashion. In Figure 2a the
150 drawing structure of the selected tetrapeptide is reported,
151 whereas in Figure 2b and 2c the structure of the inactive TFA-
152 D-Leu-D-Met-D-Pro-D-Ala-NH2 and TFA-D-Leu-D-Met-D-Pro-D-
153 Asp-NH2 (hereafter termed CF3-lmpa and CF3-lmpd, respec-
154 tively), used as negative controls in the subsequent experi-
155 ments, are reported.
156Assessment of Peptide Selectivity and Mechanism of
157Inhibition. The inhibition activity of CF3-lmph peptide was
158assessed using APEH purified from porcine liver, which shares
159more than 90% sequence identity with the homologous human
160enzyme. The selectivity of CF3-lmph toward APEH was initially
161evaluated in biochemical assays using a panel of eukaryotic
162proteases (trypsin, α-chymotrypsin, elastase, carboxypeptidase
163Y, subtilisin, and proteinase K). Results (Table 3) show that the
164best protein target for CF3-lmph was APEH with a maximum of
16572% inhibition reached at 150 μM. This inhibition did not
166increase even using the peptide at 1 mM. The inhibition curve
167of porcine APEH followed a hyperbolic pattern with increasing
168inhibitor concentrations and gave an IC50 value of 98.0 ± 6.4
169μM (Figure 1f). The affinity of CF3-lmph toward porcine
170APEH was witnessed by a Ki value of 24.0 ± 0.8 μM. Data
171indicated that the peptide was also able to slightly affect
172carboxypeptidase activity (Table 3), reaching a maximum of
17330% inhibition at 1.0 mM; the IC50 was only 210 ± 0.8 μM (see
174Figure SI 1 in Supporting Information). To determine the
175mechanism of APEH inhibition, we set out to use the peptide
176in several inhibition experiments, varying both substrate and
177 f3peptide concentrations. Data are reported in Figure 3 as the
178classical Lineweaver−Burk double reciprocal plot, and the
179straight lines obtained at different inhibitor concentrations
Figure 2. (a) Drawing structure of the selected active tetrapeptide
TFA-D-Leu-D-Met-D-Pro-D-His-NH2 (named CF3-lmph). (b and c)
The structures of the inactive variants TFA-D-Leu-D-Met-D-Pro-D-Ala-
NH2 and TFA-D-Leu-D-Met-D-Pro-D-Asp-NH2 (termed CF3-lmpa and
CF3-lmpd, respectively), used as negative control in the subsequent
experiments, are shown.
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180 resulted in a series of parallel lines, which indicate that the
181 tetrapeptide acts as a typical uncompetitive inhibitor. This very
182 uncommon type of inhibition is based on a mechanism where
183 the inhibitor binds to the enzyme, enhancing the binding of the
184 substrate (so reducing Km), but, due to a reduced reaction rate
185 of the resultant enzyme−inhibitor−substrate complex, Vmax is
186 also decreased.13
187 Also the activity of the acetylated and nonacetylated variants
188 was tested against porcine APEH to assess the role of the N-
f4 189 terminal trifluoroacetyl group. As reported in Figure 4, the
190 presence of this moiety confers a high specificity to peptide
191 activity, because no enzyme inhibition was seen with the
192 acetylated and the NH2-free peptides.
193 Circular Dichroism. CF3-lmph was characterized by CD
194 and NMR spectroscopy in order to determine its conforma-
195tional preferences and a possible correlation between its
196structure and the inhibition activity. For this purpose, CD
197spectra of the peptide at both pH 7.0 and pH 5.0 were acquired.
198In parallel also the CD spectrum of the N-terminally free
199variant was investigated under the same conditions. As can be
200 f5seen in Figure 5, the peptide adopted a well-organized structure
201with a minimum at 195 nm and a maximum at 220 nm.
202Considering the presence of all-D amino acids, which normally
203show inverted values, these spectra suggest that the peptide has
204a twisted or bent conformation at both pH values and that the
205structure is not grossly affected, at a qualitative level, by
206removing the trifluoroacetyl group.
207NMR Spectroscopy. NMR investigation was performed on
208both the tetrapeptide inhibitor CF3-lmph and on the inactive
209analogue CF3-lmpa. The ala
4 variant, instead of that used as
210control in biochemical as well as cellular assays, was chosen
211because of its higher solubility at millimolar concentration.
212NMR analyses in plain water showed that the two peptides
213CF3-lmph and CF3-lmpa adopt very similar conformations.
214Indeed, they showed comparable proton chemical shifts
215(Tables SI 1a, SI 1b of the Supporting Information), αCH
216chemical shifts deviations from random coil values14 (Figure SI
2172 of the Supporting Information) and NOE patterns.
218Interproton distances, evaluated from NOE intensities, were
219used in restrained molecular dynamics simulations to obtain
220solution molecular models of both peptides. Starting models
221were energy-minimized in a cubic box of water using Gromacs
2224.0 program, as described in the Supporting Information.
223Before starting the dynamics simulations, the systems were
224further energy-minimized adding the NMR restraints, and the
225solvent was relaxed by a 200 ps MD at 300 K. Then, for each
226peptide, two simulations were run for 10 ns with (r) and
227without (u) NMR restraints to evaluate the stability of the
228peptide structure. The backbone root-mean-square deviations
229(rmsd) of both peptides along the trajectory at 300 K show
230small deviations (∼1−1.5 Å) from the starting model, either for
231the restrained or for unrestrained molecular dynamics
232simulations, pointing to a stable structure over the observation
233time. The structural stability is well represented by the
234backbone superposition of molecular frames, collected during
235the last 2 ns of restrained MD simulations, of CF3-lmph (rmsd
2360.25 ± 0.10 Å) and CF3-lmpa (rmsd of 0.34 ± 0.24 Å), and
237 f6reported in Figure 6a and 6b. It should be noted that no
238structural differences were observed from restrained (r) and
239unrestrained (u) molecular dynamics simulations, and the
Figure 3. Double-reciprocal plots of the velocity against substrate (Ac-
Ala-pNA) concentration at three different CF3-lmph concentrations
(no inhibitor ◆, 50 μM ■, and 100 μM ▲). The velocity of the
reaction is expressed as μmol of p-nitroaniline released/min/mL of
enzyme on incubation at 37 °C. Ki value was determined from the
equation of the uncompetitive inhibition (see insert for a plot of [(1 +
i/Ki)/Vmax] vs inhibitor concentration).
Figure 4. APEH inhibition by CF3-lmph and the corresponding
acetylated and NH2-free peptides. Only the trifluoroacetylated peptide
shows inhibition.
Figure 5. CD spectra of CF3-lmph at pH 5.0 (solid line) and 7.0
(dashed line) at 200 μM. The spectrum of the NH2-free peptide at pH
7.0 and at the same concentration (dotted line) is also reported. CD
values at all wavelengths have been multiplied by −1 to take into
account for the presence of all D residues.
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240 comparison of the final r and u structures showed backbone
241 rmsd of 0.34 Å and 0.20 Å for CF3-lmph and CF3-lmpa,
242 respectively. The final molecular models obtained by restrained
243 molecular dynamics simulations showed a good agreement with
244 experimental NMR data and were chosen as representative of
245 peptide structures. They look very similar in the conserved
246 region (see Figure 6c) with a global backbone rmsd of 0.21 Å.
247 Cell Assays. The pro-apoptotic/cytotoxic effect produced
248 by APEH inhibition was preliminarily investigated in HeLa cells
249 exposed for 24 h to increasing concentrations of a widely used
250 noncompetitive APEH inhibitor (i.e., ebelactone).15 The
251 marked (5-fold) increase of caspase 3 was produced by cell
252 incubation with 30 and 50 μM ebelactone (P < 0.001) whereas
253 its maximum cytotoxic effect (28%) was produced by cell
f7 254 exposure to 100 μM concentration. (Figure 7a).
255 Next, to determine the influence of CF3-lmph or the control
256 peptide TFA-D-Leu-D-Met-D-Pro-D-Asp-NH2 (CF3-lmpd) on
257 cell viability, cell proliferation was evaluated upon exposure of
258 HeLa cells for 24 h to increasing concentrations of the selected
259 peptides. The dose-dependent antiproliferative effect was
260 produced by cell exposure to different ebelactone concen-
261 trations (positive control), but only minor changes were
262produced by the treatment with CF3-lmph or CF3-lmpd (Figure
2637b).
264In order to evaluate the ability of the peptide to inhibit
265APEH in in vitro experimental models, two cancer cell lines
266(A375 and HeLa) were exposed for 24 h with increasing
267concentrations of CF3-lmph or of the control peptide CF3-
268 f8lmpd. As shown in Figure 8a and 8b, CF3-lmph markedly
269reduced APEH activity in a dose-dependent manner, reaching
270their maximum effect at 150 μM, where enzyme activity was
271decreased in HeLa and in A375 cells by 80% and 50%,
272respectively. Notably, undetectable inhibition resulted from the
273treatment with CF3-lmpd control peptide.
274To determine the effects of CF3-lmph or CF3-lmpd on cell
275viability, their cytotoxic or pro-apoptotic effects were also
276studied. As apoptosis has been associated with APEH
277inhibition,16 the caspase 3 activity, a key enzyme in the
278apoptotic cascade, was measured upon the cell treatments.
279Specifically, cells exposed to 100 or 150 μM CF3-lmph,
280triggered a mild, but significant, increase in caspase 3 activity as
281compared with cells incubated with the same amount of control
282peptide (P < 0.01 or 0.005). In addition, undetectable toxicity,
283measured as LDH release in the medium, resulted from the
284CF3-lmph-mediated inhibition of APEH (Figure 8c, 8d insert).
285■ DISCUSSION AND CONCLUSIONS
286Aminopeptidases are known to be essential for basic
287physiological processes, such as protein maturation17 and cell
288cycle control.18 Their inhibition disrupts protein turnover,
289leading to decreased cell survival and proliferation; thus,
Figure 6. Backbone superposition of ten molecular frames collected
during the last 2 ns of restrained molecular dynamics for (a) CF3-
lmph; (b) CF3-lmpa. (c) Backbone superposition of CF3-lmph (green)
and CF3-lmpa (gray) molecular models after 10 ns of restrained
molecular dynamics.
Figure 7. Pro-apoptotic and toxic effect of ebelactone on HeLa cells.
The modulation of a commercially available APEH inhibitor on cell
viability was preliminarily evaluated on HeLa cells. Caspase 3 activity
and LDH release was evaluated upon 24 h exposure with increasing
concentrations of ebelactone (a). Caspase 3 activity was expressed as
fold increase as compared to untreated culture. Culture media from
untreated culture were used as control, and those from cells exposed to
1% TritonX-100 were used as positive control (100% release). The
dose-dependent effect CF3-lmph (open titled squares) or with the
control peptide CF3-lmpd (black circles) on cell viability was
compared with that produced by ebelactone treatment (white
triangles) (b). The data from triplicate analysis from three different
experiments are expressed as means ± SD. ***, ** Significantly
different P < 0.005 or 0.01, from respective controls.
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290 targeting this pathway has been indicated as a suitable approach
291 for anticancer therapies.19,20 Also a role in protein structure and
292 function regulation has been persistently evoked due to its
293 capability to remove acetyl-amino acids from the N-terminus of
294 a large set of cytoplasmic proteins,2 which, depending on the
295 presence/absence of this small post-translational modification,
296 could not properly fold and thus be tagged for degradation.4,6 A
297 more extensive understanding of APEH functions is thus
298 needed, also in view of the recently reported involvement in the
299 regulation of proteasome activity, and this necessarily involves
300 the development of specific modulators of enzymatic activity
301 and a more detailed view of its interaction network and of
302 related modulators. In this instance, enzyme inhibitors and
303 interactors, with different mechanisms of action and structure,
304 can play a major role, as they enable elucidation of downstream
305 effects mediated by processed substrates or by interrupted or
306 promoted interactions.
307 With the aim of developing new APEH inhibitors, we have
308 prepared and screened a complex library of synthetic peptides
309 modified on the N-terminus by a set of diverse chemical groups
310 in order to investigate the space around the enzyme site of
311 action and also to prevent undesired substrate-like behaviors of
312 the peptides exposed to the enzyme. After five iterative rounds
313 of screening and resynthesis needed to elucidate the whole
314 peptide structure, we have identified the peptide CF3-lmph as
315 the one best inhibiting APEH in vitro. At variance with
316 inhibitors previously described, the one we report in this study
317 shows an uncommon uncompetitive mechanism of inhibition
318 which is generally characterized by the binding of inhibitors to
319enzyme: substrate (ES) complexes and their inactivation
320induced by a delay in the release of processed substrates.
321CF3-lmph shows selectivity toward APEH, because, among
322the different serine proteases we have tested, it only blocks to a
323limited extent (30%) carboxypeptidase Y, with an IC50 which is
324more than twice that exhibited toward APEH (about 210 μM
325for carboxypeptidase Y and about 98 μM for APEH). The
326inhibition specificity is also demonstrated by the lack of activity
327of the acetylated and NH2-free variants, indicating a direct
328involvement of fluorine atoms in the recognition and blocking
329of the ES complex. This is consistent with the observation that
330several organophosphorus compounds such as chlorpyrifos,
331dichlorvos, and naled, which share with the peptide the
332multihalogenated structure, also inhibit APEH.21 We can thus
333reasonably hypothesize that halogens (bromine, fluorine, and
334chlorine), or more generally, highly electronegative centers, are
335likely an important discriminant for enzyme recognition.
336Also the presence of D-histidine on position 4 of the
337tetrapeptide is very important for activity, and indeed mutants
338bearing D-Ala or D-Asp on the same position are not active. It is
339important to point out that the conformations of the inactive
340CF3-lmpa and NH2-lmph peptides are essentially identical to
341that of the active CF3-lmph, with a bent conformation around
342the D-proline residue on position 3. This suggests that, beyond
343fluorines, the imidazole ring on the histidine side chain plays a
344crucial role in binding and inhibiting APEH. Again, given the
345strong structural similarity between imidazole and triazole rings,
346which are the core structures of many potent serine hydrolase
347inhibitors, we can reasonably speculate that the peptide shares
348with these at least one recognition site. Note that the peptide
349we have isolated in our screening does not apparently mimic
350any of the substrates recently identified for APEH,2 still in
351agreement with the observation that CF3-lmph does not bind
352into the catalytic pocket. Nevertheless, because potent triazole
353inhibitors have been isolated with competition assays, we can
354presume that the peptide inhibitor recognizes APEH on a
355region nearby the catalytic site.
356While a role for APEH has been more clearly delineated in
357neurodegenerative diseases,11 the occurrence of different
358phenotypic outcomes on cells treated with APEH inhibitors
359renders much more elusive the involvement of this enzyme in
360cancer.9 The opposed effects observed certainly depend on the
361different experimental settings and cell lines utilized in the
362various studies; however, we cannot exclude that they could be
363associated to the mechanism of action of the diverse APEH
364inhibitors used, thus introducing a further level of complexity
365toward the understanding of the overall role played by this
366enzyme in cell homeostasis. We have recently reported that
367competitive APEH inhibition in Caco-2 cancer cells by SsCEI
368peptides reproducing the RSL of a proteic APEH inhibitor is
369paralleled by a downregulation of proteasome functions and an
370increase of caspase 3 activity that, in turn, induce a sustained
371and strong reduction of cell proliferation.6 A similar effect is
372observed when the same cells are treated with the non-
373competitive inhibitor trans10-cis12 CLA that binds the enzyme
374on a site adjacent to the catalytic pocket. Further, the effects are
375synergistic when the two compounds are used in combination.6
376On the contrary, the use of other competitive APEH inhibitors
377on mouse T cells strongly stimulates cell proliferation.2
378To try to further address this very important aspect, we have
379used CF3-lmph, along with an inactive control, to stimulate two
380different cell lines, A375 and HeLa, which are melanoma and
381cervical cancer cell lines, respectively. Though the peptide very
Figure 8. Down-regulation of APEH activity by CF3-lmph in HeLa
and A375 cells. APEH activity was measured in HeLa (a) or A375 (b)
cells incubated with 50 μM, 100 μM and 150 μM CF3-lmph (white
bars) or with the control peptide CF3-lmpd (black bars) for 24 h.
Caspase-3 activities and LDH release were measured in HeLa (c) or
A375 cells (d). The cytotoxic effect of the different treatments was
evaluated by measuring the LDH release in the culture media. Media
from untreated culture were used as control (gray bars). Media from
cells exposed to 1% Triton X-100 were used as positive control (c, d
insert). The data are expressed as means ± SD. ***, ** Significantly
different P < 0.005 or 0.01, from respective controls.
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382 efficiently crosses cell membranes, reduces enzyme activity in
383 the cytoplasm, and is not toxic compared to other known
384 inhibitors, for example ebelactone (see Figure 7a), it only
385 slightly affects cell proliferation, inducing a reduction in cell
386 vitality which is negligible compared to that of controls and to
387 that previously observed in Caco-2 cells treated with
388 competitive and noncompetitive inhibitors.6 As also shown
389 on mouse T cells, which even tend to proliferate when treated
390 with APEH competitive inhibitors, this effect is certainly
391 explained by the different cell lines used, which could display a
392 different set of substrates, or by their metabolic status, but we
393 cannot exclude that also the different mechanism of inhibition
394 could influence cell proliferation by affecting or altering the
395 network of interactions that regulates the functions of APEH.
396 This hypothesis opens a new intriguing question regarding the
397 role played by APEH nonsubstrate interactors, which are so far
398 completely unknown.
399 We have identified the first uncompetitive APEH inhibitor,
400 which is selective, has a conformationally defined structure, and
401 contains molecular determinants common to other known
402 inhibitors. In contrast to competitive inhibitors, which lose
403 potency as substrate concentration rises, uncompetitive
404 inhibitors become more potent as the substrate concentration
405 increases in an inhibited open system.22 This can be a
406 significant advantage in vivo when the physiological context
407 exposes the enzyme to high levels of substrate concentrations.
408 Despite the low potency in the micromolar range, the
409 structural properties, the ease of synthesis, and unusual
410 mechanism of action make this tetrapeptide an appealing and
411 innovative tool for the systematic design of a new class of more
412 potent and less toxic protease inhibitors, which may comple-
413 ment the active site-targeted molecules in future therapeutic
414 applications.
415 ■ EXPERIMENTAL SECTION
416 Materials. Protected amino acids for the synthesis of peptides were
417 from GL-Biochem (Shanghai, PRC) and Novabiochem (Laufelfingen,
418 Switzerland). Coupling agents were from GL-Biochem (Shanghai,
419 PRC); solvents, such as acetonitrile (CH3CN), dimethylformamide
420 (DMF), and methanol (CH3OH), were from Sigma-Aldrich (Milan,
421 Italy). Chemicals for the preparation of libraries and enzymes for
422 biochemical assays, including caspase-3 fluorimetric Assay Kits, and
423 other chemicals of the highest purity were also from Sigma-Aldrich
424 (Milan, Italy). Dulbecco’s Modified Eagle Medium (DMEM), L-
425 glutamine, penicillin−streptomycin, and fetal bovine serum (FBS) for
426 cell culture were from Gibco-BRL. Porcine liver APEH was obtained
427 by Takara. Acetyl-Ala-pNA was from Bachem.
428 Peptide Library Design, Synthesis, and Characterization.
429 Peptide libraries were designed in a simplified format as reported in
430 Marasco et al.12 By this approach, a small set of amino acids is chosen
431 to represent the chemical space occupied by very short peptides which
432 can be seen as precursors or templates of small molecular scaffolds.
433 Preferentially, only non natural or D-amino acids are included in these
434 sets in order to potentially select enzyme-resistant new peptides. The
t1 435 set used here, reported in Table 1, includes aspartic acid as
436 representative of amino acids with acidic side chains, arginine and
437 histidine representing basic amino acids, glutamine and S-
438 acetamidomethyl(Acm)-cysteine representing residues with amides
439 on the side chain, phenylalanine and tyrosine as being representative of
440 aromatic residues, serine representing residues with hydroxyl groups,
441 leucine and methionine representing bulky hydrophobic amino acids,
442 and alanine representing amino acids with small hydrophobic side
443 chains. Proline was used to eventually select peptides with bent
444 conformations. Note that histidine was used as an additional basic
445 residue also by virtue of its aromaticity. The choice of this set of
446 residues was also determined by their difference in MW in order to
447facilitate eventual identification of active components by tandem mass
448spectrometry methods.
12 As APEH is capable of removing acetyl-
449amino acids from the N-terminus of peptides and proteins, we set out
450 t2to not acetylate the peptides but instead to introduce, on the N-
451 t2t3terminal position, seven groups (see Table 2) with very different
452physicochemical properties in order to (i) prevent substrate-like effects
453and (ii) explore the chemical space around the N-terminal residue.
454These groups were chosen to introduce charges (succinic acid),
455aromatic groups (phenyl, Z, and 6-Cl-Z), bulky polyaromatic rings
456(Dabcyl), and small hydrophilic groups (trifluoroacetic acid (TFA)
457and pyroglutamate). The library was synthesized by the solid-phase
458method on a global 140 μmol scale following the Fmoc/tBu
459methodology.23 Fmoc deprotection was achieved by treatment with
Table 1. Set of Amino Acids Used To Assemble the
Tetrapeptide Library of General Formula Yi-X1-X2-X3-X4-
NH2 on the X Position
N
building block, three-
letter code protected derivative used for the X positions
1 D-Ala Nα-Fmoc-alanine
2 D-Arg Nα-Fmoc-arginine (NΓ-
pentamethyldihydrobenzofuran)
3 D-Asp Nα-Fmoc-aspartic acid (tert-butyl ester)
4 D-Cys(Acm) Nα-Fmoc-cysteine(S-acetamydomethyl)
5 D-Gln Nα-Fmoc-glutamine (Nδ-trityl)
6 D-His Nα-Fmoc-histidine(Nε-trityl)
7 D-Leu Nα-Fmoc-leucine
8 D-Met Nα-Fmoc-methionine
9 D-Phe Nα-Fmoc-phenylalanine
10 D-Pro Nα-Fmoc-proline
11 D-Ser Nα-Fmoc- serine(O-tert-butyl-ether)
12 D-Tyr Nα-Fmoc-tyrosine(O-tert-butyl-ether)
Table 2. Set of Carboxylic Acids Used To Modify the
Tetrapeptide Library of General Formula Yi-X1-X2-X3-X4-
NH2 on the Yi Position
Yi
N building block derivative used for modifying the N-terminus
1 Succ succinic anhydride
2 Z benzyloxycarbonyl-OSu
3 pGlu pyroglutamic acid
4 2Cl-Z 2Cl-benzyloxycarbonyl-OSu
5 TFA trifluoroacetic acid
6 Dabcyl Dabcyl-OSu
7 benzoyl benzoic acid
Table 3. Inhibition Profile of CF3-lmph
a
enzyme pH
IC50
[μM]
maximal
concentration
tested [μM]
maximal
inhibition
[%]
APEH 7.5 98.0 1000 72
chymotrypsin 8.0* >1000 1000 <1
elastase 8.0* >1000 1000 <1
trypsin 8.0* >1000 1000 <1
carboxypeptidase Y 7.0 210 1000 30
subtilisin 7.5 >1000 1000 <1
proteinase K 7.5 >1000 1000 <1
aThe IC50 values of the tetrapeptide inhibitor were determined in 50
mM Tris-HCl (supplemented with 20 mM CaCl2*) saline buffer at the
optimal pH for the enzyme−substrate pair and at increasing
concentrations, of CF3-lmph, up to 1.0 mM.
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460 30% piperidine in DMF. Couplings with amino acids or nonactivated
461 carboxylic acids (3, 5, and 7 in Table 2) were performed by activating,
462 with 1 equiv of HATU, 2 equiv of DIEA, and 10 equiv of Fmoc-
463 protected amino acids or carboxylic acids. Random positions were
464 obtained by coupling equimolar mixtures of the chosen set of amino
465 acids used in very large excess to suppress preferential acylations
466 deriving from differences in reactivity.
467 The first library was prepared by four sequential incorporations of
468 mixtures of the 12 amino acids; the resin batch was then split into 7
469 identical aliquots to which the 7 different carboxylic acids were
470 coupled. Subsequent libraries, identified by the iterative screening,
471 were prepared in the same way and on the same synthesis scale. In the
472 last step, 12 single peptides were prepared and purified before
473 screening. Complex peptide mixtures were characterized by pool
474 amino acid analysis comparing experimental amino acid distribution
475 with those calculated assuming an equimolar distribution of all
476 components in the pools. Single peptides and mixtures up to 12
477 components were easily characterized by LC-MS as reported
478 elsewhere, identifying peptides by MW determination and in some
479 cases by sequence assignment by tandem mass spectrometry. Cleavage
480 of peptide mixtures from the resin was afforded by treatment with
481 TFA−triisopropylsilane (TIS)−H2O mixtures (90:5:5, v/v/v) and
482 subsequent precipitation in cold diethyl ether. Single peptides were
483 purified by semipreparative RP-HPLC on an ONYX 10 × 1 cm i.d.
484 C18 monolithic column, operating at 15 mL/min, using H2O and
485 CH3CN as eluents, both supplemented with 0.05% TFA. Gradients
486 were chosen on the basis of peptide sequences. Libraries and single
487 peptides were prepared as amidated derivatives. Canonical Fmoc-
488 protected D-amino acids were used in all syntheses. D-Cys(Acm) was
489 also introduced as the corresponding Fmoc derivative. A RINK amide
490 resin with a 0.57 mmol/g substitution level was used in all syntheses.
491 Most couplings and deprotection reactions were performed at room
492 temperature for 5 min. In some specific cases, microwaves were used
493 to improve reaction yields. A common kitchen microwave oven used at
494 the minimum power was utilized for this purpose. Microwave-assisted
495 couplings and deprotection reactions were carried out for 1.5 min with
496 repeated 5 s on−off cycles. Cleavages were carried out in the same way
497 for 1 min. After lyophilization, peptide material was dissolved in
498 dimethyl sulfoxide (DMSO) at 10 mg/mL and stored frozen until use.
499 Single peptides were characterized by RP-HPLC and LC-MS using an
500 ONYX 50 × 2 mm i.d. C18 monolithic column, operating at 0.6 mL/
501 min, using H2O (eluent A) and CH3CN (eluent B) as eluents, both
502 supplemented with 0.05% TFA. Gradients were from 2% to 45% of
503 eluent B in 9 min. Detection was achieved with a photodiode array set
504 between 200 and 320 nm and with an ion trap mass spectrometer
505 (Deca XP, ThermoFisher). Purity was checked on chromatograms
506 extracted at 214 nm and on TIC (total ion current) traces obtained by
507 full scans between 200 and 2000 m/z. Identity of peptides was
508 confirmed by MW determination and tandem mass analyses. Peptides
509 were all >95% pure, as determined by RP-HPLC and LC-MS analyses.
510 Enzyme Inhibition Assay and Screening of the Peptide
511 Library. Porcine liver APEH activity was measured spectrophoto-
512 metrically using the chromogenic substrate acetyl-Ala-pNA. The
513 reaction mixture (0.2 mL) containing pure APEH (0.5 nM) in 50
514 mM Tris-HCl buffer, pH 7.5 (Tris buffer), was preincubated at 37 °C
515 for 2 min. Then, 25 μM acetyl-Ala-pNA was added and the release of
516 p-nitroanilide (ε410 nm = 8800 M
−1 cm−1) was measured by recording
517 the absorbance increase at 410 nm on a BIOTEK multiwavelength
518 plate reader, equipped with a thermostatted compartment. APEH
519 activity was expressed in IU. Assays were performed in 96-well
520 polyethylene plates in duplicates or triplicates.
521 Inhibition by library components was carried out by using a fixed
522 concentration of APEH (0.5 nM) and fixed concentrations of libraries
523 as described below. Depending on the screening steps, peptide
524 mixtures or single peptides were preincubated with the enzyme for 30
525 min at 37 °C before addition of the substrate, and the enzymatic
526 activity was then followed as described above. Each inhibition
527 experiment was carried out in duplicate wells. The first library
528 (seven sublibraries) was screened in duplicate at a global concentration
529 of 200 μM, assuming an average peptide molecular weight of 600 amu.
530Data were processed, averaging values from duplicate wells, and the
531slope was calculated by linear regression analysis. The percentage of
532inhibition was determined by comparing slopes from inhibition assays
533with that from the control experiment. To confirm and strengthen
534results after each screening step, dose−response assays with the
535positive mixtures were performed at concentrations ranging between
53610 and 200 μM. In the second screening step, the 12 libraries bearing
537the trifluoroacetyl (TFA) group on the N-terminus were screened at a
538nominal concentration of 40 μM, assuming again an average MW of
539600 amu. The same average molecular weight was assumed for the
540subsequent third (library concentration 100 μM) and fourth screening
541round (50 μM). Single peptides in the final fifth step were purified and
542characterized by LC-MS, assessing purity and identity. They were
543assayed at a concentration of 50 μM.
544Enzyme Assays with APEH and Other Enzymes. Porcine liver
545APEH activity was measured spectrophotometrically using the
546chromogenic substrate acetyl-Ala-pNA. The reaction mixture (1 mL)
547containing pure APEH (38 ng) or an appropriate amount of cell
548extract in Tris buffer was preincubated at 37 °C for 2 min. Then, 25
549μM acetyl-Ala-pNA was added and the release of p-nitroanilide (ε410 =
5508800 M−1 cm−1) was measured by recording the absorbance increase
551at 410 nm on a Cary 100 Scan (Varian) UV/vis spectrophotometer,
552equipped with a thermostatted cuvette compartment. APEH activity
553was expressed in IU. The carboxypeptidase Y, elastase, chymotrypsin-
554like activity of proteasome, trypsin, and subtilisin activities were
555evaluated according to previously published methods.24 Proteinase K
556activity was measured according to the manufacturer’s instructions.
557Protease inhibiting activities of the selected peptides were carried
558out using a fixed amount of enzymes (5 nM) and increasing peptide
559concentrations, up to 1 mM. Mixtures were preincubated for 30 min at
56037 °C before the addition of the substrate, and the enzymatic activities
561were followed as described above. To determine the mechanism of
562APEH inhibition, Lineweaver−Burk double reciprocal plots of data at
563increasing inhibitor and substrate concentrations were constructed.
564For this experiment, APEH (5 nM) was incubated, with or without
565inhibitor at 50 μM and 100 μM concentrations, and assayed at
566increasing substrate concentrations. The reciprocals of the rate of the
567substrate hydrolysis for each inhibitor concentration were plotted
568against the reciprocals of the substrate concentrations. The inhibition
569constant Ki was determined by the Lineweaver−Burk equation for the
570uncompetitive type of inhibition [1/V = 1/Vmax × (1 + i/Ki) + (Km/
571Vmax) × 1/S].
572Circular Dichroism Analysis. CD spectra were obtained on a
573Jasco J-715 spectropolarimeter for peptide solutions at 2.0 × 10−4 M
574concentration in 5 mM Tris−HCl, pH 7.0, or in acetate buffer, pH 5.0,
57525 °C. Hellma quartz cells of 1-cm path length were used in the far UV
576(190−250 nm). The temperature of the sample cell was regulated by a
577PTC-348 WI thermostat. Spectra were signal-averaged over three
578scans and baseline-corrected by subtracting a buffer spectrum. Due to
579the presence of only D residues, the entire spectrum was multiplied by
580−1.
581NMR Analysis. NMR characterization of peptides was performed
582in water at 25 °C. Samples were prepared by dissolving weighted
583amounts of each peptide in water (spectroscopic purity), adding D2O
584(ARMAR, isotopic purity 99,8%) for a final ratio 90/10 v/v. Final
585concentrations were ca. 2.0−2.5 mM. Details concerning NMR
586analyses are reported in the Supporting Information.
587Molecular Dynamics (MD) Simulations. MD simulations were
588performed as reported in the Supporting Information.
589Cell Cultures. Human melanoma (A375) and cervical cancer cells
590(HeLa), kindly donated by Dr. Rosanna Palumbo (IBB, CNR), were
591cultivated in DMEM supplemented with 10% FBS, 1 mM glutamine,
592and 100 units/mL penicillin−streptomycin at 37 °C in a humidified
5935% CO2 atmosphere. The cells were split using trypsin−ethyl-
594endiaminetetraacetic acid (EDTA) solution and plated in six-well
595plates at a density of 8 × 104 cells/mL, and the medium was replaced
596every 2−3 days. Cells at 60−70% confluence were incubated with the
597selected peptides at different concentrations.
598Apoptosis Assays. The pro-apoptotic ability of the tetrapeptides
599were assayed by measuring the caspase-3 activity using fluorometric
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600 kits, according to the manufacturer instructions. These assays were
601 based on hydrolysis of the substrate acetyl-Asp-Glu-Val-Asp-7-amido-
602 4-methylcoumarin (Ac-DEVD-AMC) by caspase-3. The release of the
603 7-AMC moiety in protein extracts prepared from the differently
604 treated cells was evaluated by fluorimetry (excitation 360 nm, emission
605 460 nm). Their amounts were calculated by means of a standard curve
606 prepared with pure AMC, and following normalization for protein
607 content, the activities were calculated as nmoles AMC/mg protein and
608 expressed as fold increase as compared to control culture.
609 Cytotoxicity Assays. The release of LDH was used as the marker
610 for cell toxicity.25 The culture supernatants were sampled at the end of
611 the incubations and centrifuged (4000g, 5 min, and 4 °C). Aliquots of
612 the clear supernatant (10 μL) were incubated with 190 μL of reaction
613 buffer (200 mM Tris/HCl, pH 8.0, 0.7 mM p-iodonitrotetrazolium
614 violet, 50 mM L-lactic acid, 0.3 mM phenazine methoxysulfate, 0.4 mM
615 NAD) for 30 min at 37 °C. Absorbance was measured at 490 nm, and
616 the results were expressed as percentages of total LDH release from
617 control cultures treated with 1% (w/v) Triton X-100 and calculated as:
− −
−
[(experimental value blank value)/(total lysis blank value)
100]
618 Statistical Analysis. Data were obtained from triplicate analyses of
619 three different preparations, and the results were expressed as means ±
620 SD. Statistical analysis and IC50 values were calculated with the
621 SigmaPlot 10.0 software through a nonlinear curve-fitting method and
622 using a simple binding isotherm equation. Groups were compared by
623 Student’s t test, and P < 0.05 was considered as significant.
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Scope: The involvement of oxidative stress in gluten-induced toxicity has been evidenced in
vitro and in clinical studies but has never been examined in vivo. We recently demonstrated
the protective activity of conjugated linoleic acid (CLA), which functions by the activation of
nuclear factor erythroid 2-related factor2 (Nrf2), a key transcription factor for the synthesis of
antioxidant and detoxifying enzymes (phase 2). Here, we evaluate the involvement of nuclear
factor erythroid 2-related factor2 in gliadin-mediated toxicity in human Caco-2 intestinal cells
and in gliadin-sensitive human leukocyte antigen-DQ8 transgenic mice (DQ8) and the
protective activity of CLA.
Methods and results: Gliadin effects in differentiated Caco-2 cells and in DQ8 mice, fed with
a gliadin-containing diet with or without CLA supplementation, were evaluated by combining
enzymatic, immunochemical, immunohistochemical, and quantitative real-time PCR (qRT-
PCR) assays. Gliadin toxicity was accompanied by downregulation of phase 2 and elevates
proteasome-acylpeptide hydrolase activities in vitro and in vivo. Notably, gliadin was unable to
generate severe oxidative stress extent or pathological consequences in DQ8 mice intestine
comparable to those found in celiac patients and the alterations produced were hampered by
CLA.
Conclusion: The beneficial effects of CLA against the depletion of crucial intestinal cyto-
protective defenses indicates a novel nutritional approach for the treatment of intestinal
disease associated with altered redox homeostasis.
Keywords:
Conjugated linoleic acid / Gluten toxicity / Nrf2-mediated defenses /
Proteasome-acylpeptide hydrolase activity
1 Introduction
Celiac disease (CD) is a chronic inflammatory pathology of
the small intestine, resulting from a complex interplay
between environmental and genetic factors [1]. Indeed, the
main wheat gluten protein (gliadin) and related proteins
from rye and barley represent the environmental factors
responsible for the immunotoxic response in CD patients
[2]. During the past few years, significant progress has been
made in clarifying the different factors that contribute to the
pathogenesis of CD. In addition, the presence of human
Abbreviations: APEH, acylpeptide hydrolase; CD, celiac disease;
CLA, conjugated linoleic acid; GCL, g-glutamylcysteine ligase;
GFD, gluten-free diet; GSHtot, total thiols; GSSG, glutathione
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leukocyte antigen (HLA) class II DQ2 and/or DQ8 [3] has
been linked to the events leading to gluten toxicity and
intestinal damage; however, their presence is necessary but
not sufficient for the development of such disease [4].
Transgenic mice expressing human leukocyte antigen-DQ8
in the absence of endogenous mouse class II genes,
nontransgenic for human CD4 [5] (DQ8 mice) are widely
used for investigating gluten sensitivity [6–8], but in the
absence of immunization, gluten is generally well tolerated
by the intestine of both DQ8 or DQ2 mice as oral tolerance
is still operative [8, 9]. However, despite the large amount of
data on immunological factors, the biochemical mechan-
isms underlying gluten toxicity are not completely under-
stood.
Among the different mechanisms, oxidative stress has
been implicated in the pathophysiology of CD by clinical
evidence [10] and by in vitro studies [11] but the underlying
mechanisms are still unclear. Indeed, oxidants and/or a
defective antioxidant defense play a crucial role in the
generation of the oxidative stress implicated in the patho-
genesis of inflammatory diseases. The epithelium of the
small intestine is a dynamic system that is continuously
renewed by a differentiation process, and redox status has
an important role in these stages. Moreover, owing to the
constant exposure to potentially noxious substances, intest-
inal mucosa is endowed with efficient defenses to preserve
cellular integrity and tissue homeostasis. Among these
defenses, the nuclear factor erythroid 2-related factor2
(Nrf2) transcription factor has been recognized as the key
regulator [12], and its activation, via the modification of
cysteine residues of Kelch-like ECH-associated protein 1
(Keap1) in the cytoplasm, triggers Nrf2 release from the
Keap1/Nrf2 complex. The ensuing translocation of Nrf2 into
the nucleus activates the transcription of a battery of genes
coding for antioxidant and detoxifying proteins (phase 2
enzymes: g-glutamylcysteine ligase, GCL; glutathione
S-transferase, GST; glutathione peroxidase, GSHPx;
NAD(P)H:quinone oxidoreductase, NQO1; and heme
oxygenase-1, HO-1) [13].
Besides the Nrf2 pathway, several proteases have been
reported to play a detoxifying role by degrading oxidatively
damaged cytosolic proteins. The ubiquitin–proteasome
pathway plays a key role in a broad array of cellular
processes (cell cycle, apoptosis, and differentiation) [14],
and the proteolytic activity of the proteasome, a major
multicomponent enzymatic system, controls and regulates
the accumulation of potentially cytotoxic protein aggregates
in an ATP- and ubiquitin-independent manner [15]. Addi-
tionally, acylpeptide hydrolase (APEH), a novel serine-
peptidase enzyme belonging to the prolyl-oligopeptidase
family, was recently demonstrated to contribute to the
proteasome-mediated elimination of potentially cytotoxic
proteins [16].
The potential protective effect displayed by n-3 PUFA on
inflammatory bowel disease has been recently reviewed [17]
and similarly to n-3 PUFA, conjugated linoleic acid (CLA)
has been recognized to promote beneficial effects in animal
models of several pathologies, including inflammatory,
autoimmune diseases [18], and experimentally induced
colitis [19]. In these studies, the modulatory activity of n-3
PUFA and CLA on the peroxisome proliferator-activated
receptor g-NF-kB pathway was demonstrated to contribute
to the anti-inflammatory activities of these compounds. In
addition, our recent data showing the ability of CLA to
enhance Nrf2-mediated defenses in vitro and in vivo raises
the possibility that CLA can also exert its protective effects
through this mechanism of action [20].
The major objective of this study was to evaluate the
detrimental effects of gluten on intestinal antioxidant and
detoxifying defenses in vitro and in vivo and to investigate
the protective effects of CLA against gluten-induced toxicity
in the small intestine of DQ8 mice.
2 Materials and methods
2.1 Reagents
An isomeric mixture of CLA (38.5% t10, c12, 37.4% c9, t11),
known as TonalinTM, was from Natural. N-Suc-LLVY-AMC,
BSA, a-lactalbumin, and other chemicals of the highest
purity were from Sigma-Aldrich (St. Louis, MO, USA) or
Calbiochem (La Jolla, CA, USA).
2.2 Cell culture and in vitro experiments
The Caco-2 cell line was obtained from the American Type
Culture Collection (ATCC, Gaithersburg, MD, USA) and
was studied between passages 16 and 35. This is a well-
described cell line that spontaneously differentiates and
becoming morphologically and functionally similar to
enterocytes, and therefore differentiated cells. Unless
otherwise specified, in the present study, cells after 21 days
postseeding (differentiated) were incubated for 48 h at 371C
with 1mg/mL of a peptic–tryptic digest of gliadin (pt-glia) or
with the same amount of a-lactalbumin (control) prepared
according to a published protocol [21].
2.3 In vivo experiments
Transgenic DQ8 mice were bred and maintained in patho-
gen-free conditions at our animal facility and used at the age
of 6–12wk. All procedures for the use of laboratory animals
met the guidelines of the Italian Ministry of Health
(permission accreditation no. 164/99-A). Animals were from
a colony reared for several generations on a gluten-free diet
(GFD) (Altromin-MT-mod, Rieper S.p.A. Italy).
Gluten toxicity in vivo was initially studied in animal
groups (n5 9 each) fed for 3wk with a standard diet (StD) or
with a GFD. As the StD and GFD differed in both soy and
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wheat proteins, we subsequently used a modified GFD
(MGFD), adding only wheat proteins to the GFD to speci-
fically analyze the in vivo toxicity of gluten (Supporting
Information Table 1). Four groups of female DQ8 mice
(n5 9 each) were used, and two of these groups were swit-
ched to MGFD for 3wk. Starting from 2 days before the
change of diet and during the trial, two groups of animals
(one fed with GFD and the other with MGFD) were
intraorally administered 20mg of CLA/day (five times/wk).
At the end of this time, the mice were sacrificed. The
amount of CLA administered, upon normalization to the
body surface area [22], corresponded to a dose (4.9 g/day)
comparable to that used in the clinical trials [23]. All mice
were maintained under strict pathogen-free conditions and
had free access to drinking water.
2.4 Protein extract and brush border membrane
vesicle preparation
Cytosolic and nuclear extracts from Caco-2 cells and intest-
inal tissue were prepared by using the previously published
protocols [20] and, if not used immediately, the prepared
extracts were frozen on dry ice and stored in aliquots at
ÿ801C. Before their use, protein concentration was
determined by protein assay (Bio-Rad). Brush border
membrane vesicles were prepared from small intestine
samples (approx., 10mg) accordingly to a published method
[24].
2.5 Proteasome and APEH assays
APEH activity was measured using the substrate, acetyl-
A-pNA (Bachem). The reaction mixture (1mL) containing
the appropriate amount of cell extract in 50mM Tris-HCl
buffer, pH 7.5, was preincubated at 371C for 2min. Then,
1mM acetyl-A-pNA was added, and the release of
p-nitroanilide e4105 8800Mÿ1 cmÿ1) was measured
following the absorbance increase at 410 nm on a Cary 100
SCAN (VARIAN) spectrophotometer equipped with a ther-
mostated cuvette. APEH activity is expressed in IU.
The synthetic fluorescent substrate, N-Suc-LLVT-AMC,
was used for the measurement of the chymotrypsin-like
activity of the 20S proteasome at a final concentration of
80 mM. The reaction mixture (0.9mL) containing partially
purified proteasome was preincubated (as above) in buffer.
N-Suc-LLVT-AMC was added, and the release of fluorescent
product (7AMC: 7-amino 4-methylcoumarin) was monitored
for 5min by a fluorimeter (Perkin–Elmer LS 50B) (lEx5
380 nm and lEm5 460 nm).
Partial purification of the proteasome from Caco-2 and/or
individual mouse small intestinal protein extracts (0.7mg)
was carried out by gel filtration chromatography on a
Superdex 200 column connected to a SMART system and
eluted at 0.1mL/min in 50mM Tris-HCl, 0.1M NaCl, pH
7.5. Active fractions, for both APEH and proteasome,
were separately collected and used for further analysis. A
typical chromatogram is shown in Supporting Information
Fig. 1.
2.6 RNA isolation and quantitative real-time PCR
analysis
Total RNA was isolated from the small intestine of DQ8
mice that were fed with GFD or MGFD and with or without
the CLA supplement by using the MELTTM Total Nucleic
Acid Isolation System (Ambion). Total RNA was then
reverse transcribed using the Transcriptor First Strand
cDNA Synthesis Kit (Roche). A total of 50 ng of reverse-
transcribed complementary DNA was amplified by quanti-
tative real-time PCR (qRT-PCR) on an iCycler iQTM
(Bio-Rad) using 300 nM gene-specific primers, iQTM SYBR
Green Supermix (Bio-Rad) and the following PCR condi-
tions: 1 cycle at 951C for 10min (denaturation), 951C for 15 s
(amplification) and 40 cycles of 601C for 30 s, and 721C for
30 s. The MgCl2 concentration used was 3mM for GAPDH
and GCL and 6mM for NQO1. The expression level of
GAPDH was used as an internal control. Raw cycle threshold
values (Ct values) obtained for GCL and NQO1 were subtracted
from the Ct value obtained for GAPDH transcript levels.
The final graphical data were derived from the 2ÿDDCt
formula, where DDCt5 (Ct, targetÿCt, GAPDH)sampleÿ(Ct, targetÿCt,
GAPDH)control, where ‘‘sample’’ mice are those fed with MGFD
with or without CLA or with GFD and CLA, and ‘‘control’’ mice
are those fed with GFD. The primers utilized were as follows:
GCL, 50-CAAAGGCAGTCAAATCTGGTG-30 and 50-TGGA
GCAGCTGTATCAGTGG-30; NQO1, 50-TTCTCTGGCCGA
TTCAGAGT-30 and 50-TCTGGTTGTCAGCTGGAATG-30;
and GAPDH, 50-TAGACTCCACGACATACTCAGCA-30 and
50-GTCGGTGTGAACGGATTTG-30.
2.7 Immunohistochemistry and microscopic
evaluation
The preparation of proximal jejunum fragments and the
subsequent analysis (morphometrical, immunohistochem-
ical and cell apoptosis determination) were carried out
according to the published protocols [7].
2.8 Statistical analysis
Values are presented as the mean7SD. Statistical analysis
was performed with GraphPad Instat 3 software (San Diego,
CA, USA). Groups were compared by the Student’s
t-test, and po0.05 was considered as significant. Correla-
tion analysis was performed using the Statistical Package
for Social Sciences (SPSS version 8.0; SPSS, Chicago, IL,
USA).
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3 Results
3.1 Redox status and detoxifying enzyme activities
are influenced by the differentiation status of
Caco-2 cells
The majority of in vitro investigations aimed at the estimation
of the pro-oxidant activity of gliadin have been carried out
using undifferentiated cultures [11]. To investigate the varia-
tion of several antioxidant and detoxifying molecules at
different stages of cell differentiation, total thiols (GSHtot),
glutathione disulfide (GSSG) concentration, phase 2 enzymes
(g-GCL, GST, and NQO1), proteasome, and APEH activities
were assayed in Caco-2 cells at different stages of differ-
entiation, as evaluated by following the intestinal alkaline
phosphatase (IAP) activity. As expected, significantly higher
GST activity (po0.005) was found in differentiated Caco-2
cells as compared with undifferentiated cultures (Supporting
Information Fig. 2A). By contrast, intracellular GSHtot, but
not GSSG content, progressively declined during differentia-
tion (Supporting Information Fig. 2B). Similarly, a reduction
in both NQO1 and GCL activities occurred during this
process (po0.01) (Supporting Information Fig. 2C). Protea-
some activity exhibited a strong increase during the prolif-
erative phase, with a maximum reached in confluent cultures
followed by a progressive reduction thereafter. A similar trend
was observed for APEH specific activity, but the maximum
was reached 7 days after confluence. Higher specific activity
of APEH was found in differentiated cells as compared with
undifferentiated ones (Supporting Information Fig. 2D).
3.2 The pro-oxidant activity of gliadin reduces cell
viability and detoxifying enzyme activities but
not tissue transglutaminase expression
The influence of cell differentiation status on susceptibility
to gliadin-induced oxidative stress was investigated. Intra-
cellular GSHtot content was measured in preconfluent
(6 days after plating), differentiating and in differentiated
cells (14 and 21 days after plating, respectively) that were
incubated for 48 h with increasing concentrations of pt-glia.
The results showed a dose-dependent decline in intracellular
GSHtot in comparison to untreated cells (control) that was
independent of the differentiation stage (Fig. 1A).
To determine the effects of pt-glia exposure on differ-
entiated Caco-2 cell viability, caspase-3 activity and the
amount of lactate dehydrogenase (LDH) released in the
media were measured upon 48 h of incubation with 0.5 or
1mg/mL of pt-glia. Treatment with the highest concentra-
tion produced a significant pro-apoptotic effect when
compared with cells exposed to an equal amount of a
peptic–tryptic digest of a-lactalbumin (control) (po0.01)
(Fig. 1B). Similarly, increased levels of protein-bound
carbonyls (PC) and a marked reduction of IAP activity
(po0.05) resulted from pt-glia treatment (Fig. 1C). In
contrast, no difference in tissue transglutaminase (tTG)
expression was noted between cells incubated for 48 h with
pt-glia and controls although treatment with known tTG
activators produced a noticeable increase in tTG levels
(Fig. 1D). Figure 1E shows the effect of pt-glia on proteasome
and APEH activities. In agreement with the accumulation of
PC proteins, a significant enhancement of both specific activ-
ities was observed (from 18.470.2 to 27.071.9U/mg 103;
p5 0.002 and from 32.072.8 to 41.073.2mU/mg;
p5 0.012 for proteasome and APEH activity, respectively).
3.3 Gliadin downregulates Nrf2-activated defenses
in Caco-2 cells
GSH synthesis and its export from the cell are the main
strategies to control GSH intracellular content [25]. To
Figure 1. Gliadin exposure enhances apoptosis, PC accumula-
tion, proteasome–APEH activities, and reduces IAP activity in
Caco-2 cells (A). Caspase-3 activity and lactate dehydrogenase
release were measured in Caco2 cells following 48h of incuba-
tion with gliadin (B). PC levels and IAP activity were measured in
differentiated cells exposed to 0.5 or 1mg/mL of pt-glia (C).
Representative Western immunoblot of tTG expression in
protein extracts from differentiated Caco-2 cells incubated with
1mg/mL of gliadin or treated with tTG activators (100 mM trans-
retinoic acid: TRA or 50 mM actinomycin D: ActD) for 24h. Actin
was used as loading control (D). The chymotrypsin-like activity
of the proteasome and APEH-specific activities were measured
in differentiated cultures incubated with 1mg/mL of pt-glia (E).
Results are expressed as the mean7SD. , Significantly
different (po0.005 oro0.01) from controls.
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examine the mechanism by which gliadin perturbs the
redox status GSHtot and GSSG concentrations were
measured in the cytoplasm and in the culture media of cells
exposed to pt-glia for 48 h. Incubation with pt-glia decreased
intracellular GSHtot (po0.001) without affecting GSSG
content (Fig. 2A). Moreover, a significant decline in GSHtot
and GSSG concentrations was also found in the culture
media when compared with the control (from 2.8570.53 to
1.8270.14 nmol/mg/min; p5 0.0021 and from 1.4770.22
to 0.7270.42nmol/mg/min; p5 0.014, respectively) (Fig. 2B).
To further investigate the mechanism underlying the
ability of gliadin to reduce intracellular GSHtot levels, we
measured the effect of pt-glia treatment on the activity of
GCL, the rate-limiting enzyme in GSH synthesis. As shown
in Fig. 2C, a significant reduction in enzyme activity (from
8.1571.45 to 4.671.74 nmol NAD/mg/min; po0.005) was
associated with the decrease of Nrf2 levels (57 kDa) in the
nuclear extracts and the accumulation of the GCL caspase-
cleaved form (60 kDa) in the cytoplasm of pt-glia-treated
cells as compared with controls (Fig. 2C, inset). To further
confirm the involvement of the Nrf2-ARE pathway, the
effects of pt-glia exposure (1mg/mL for 48 h) on NQO1 and
GST activities was also investigated. The observed reduction
in the enzymatic activities of both (p5 0.0008 and 0.0052 for
GST and NQO1, respectively) (Fig. 2D) confirms the gliadin
ability to downregulate Nrf2-mediated defenses in vitro. The
probable role of gliadin-mediated oxidative stress in the
reduced activity of IAP was next examined. GSHtot
concentration and IAP activity were measured in cells
exposed to pt-glia and supplemented with or without
buthionine sulfoximine (BSO), a specific inhibitor of GCL or
with the antioxidant butylated hydroxyanisole (BHA).
Besides the expected decrease in GSHtot and IAP activity
produced by gliadin exposure, the two-fold reduction of
IAP activity (following buthionine sulfoximine treatment)
together with its significant increase in cells incubated with
BHA (po0.05) (Supporting Information Fig. 3) indicated
the role of intracellular redox status in the regulation of IAP
activity.
3.4 Gluten intake reduces Nrf2-activated defenses
without pathological consequences in DQ8
transgenic mice
To identify possible deleterious effects of gluten intake on
animal and intestinal redox status, detoxifying defenses and
morphological alterations were examined in DQ8 mice
following 3wk of treatment with StD. The gluten intake did
not influenced intestinal tTG expression (Fig. 3A) or
caspase-3 activity in the small intestine (Fig. 3B). Similarly,
gluten intake only produces minimal alteration of animal
redox status as shown by the negligible variation in GSHtot
levels (Fig. 3B, lower panel) or PC levels in blood serum sera
(data not shown). In contrast, StD intake produced a
significant alteration in GST activity and PC content in the
intestines of these mice (po0.001) (Fig. 3A). Interestingly,
when the GSHtot content of individual mice was plotted
against IAP values, a significant positive correlation between
these levels was apparent (r5 0.66; p5 0.036) (Fig. 3B,
upper panel). Notably, the lower intestinal GSHtot content,
decreased GSHPx, and IAP activities measured in StD-
treated animals compared with mice fed with GFD
(p5 0.0004, 0.025, and 0.0007, respectively) were not asso-
ciated with some typical pathological alterations of CD
(morphological change or increased number of CD31
lymphocytes) (Table 1).
3.5 Biopsies from CD patients exhibit high oxidative
stress conditions
Next, to compare the alterations produced by gluten intake
in the small intestine of DQ8 mice to those occurring in CD,
tTG expression, PC amount, GST, IAP, and proteasome-
APEH specific activities were examined in human biopsies
from CD patients. Intestinal biopsies of healthy volunteers
were used as controls. Significantly lower GST (po0.001)
and proteasome–APEH activities (p5 0.035 and5 0.023,
respectively) were detected in CD samples as compared with
Figure 2. Gliadin exposure reduces intracellular phase 2 enzyme
activity in vitro. GSHtot and GSSG concentrations were
measured in differentiated Caco-2 cells (A) or in the culture
medium following 48h of incubation with 1mg/mL of pt-glia, (B)
GCL activity and (C) representative Western immunoblot show-
ing GCL expression in differentiated cells following 48h of
exposure to 1mg/mL of pt-glia. Actin was used as loading
control (C, inset). GST and NQO1 activities were evaluated in
Caco-2 cells exposed to 1mg/mL of gliadin for 48h. (D). Results
are expressed as the mean7SD. , , Significantly different
(po0.005, o0.01 or o0.05) from controls.
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those from healthy volunteers (Fig. 3C and D). As expected,
a marked increase in tTG expression and PC content was
found in CD patients when compared with healthy indivi-
duals (Fig. 3C) and a conspicuous reduction of IAP activity
was also observed in CD patients (data not shown).
3.6 CLA treatment impairs the gluten-mediated
decrease in intestinal defenses
To specifically analyze the effect gluten intake in DQ8 mice,
the animals were fed with a diet which differed from GFD
only for the addition of wheat proteins (MGFD). Animals
receiving GFD were used as controls. Feeding with MGFD
reduced intestinal GSHtot content (p5 0.0012) (Fig. 4A)
and GST and NQO1 activities (p5 0.0031 and 0.001,
respectively) (Fig. 4B), as well as HO-1 and GCL (full-length
form, 70 kDa) expression (Fig. 4C). Remarkably, CLA
administration in MGFD mice resulted in a significant
enhancement of GSHtot content (Fig. 4A) (p5 0.0002)
elevated the expression of the HO-1 and GCL proteins (full-
length form, 70 kDa) (Fig. 4C) and resulted in increased
mRNA levels of GCL and NQO1 (Fig. 4D). As expected,
MGFD treatment was associated with significant increases
in PC levels (p5 0.0003) (Fig. 5A), a two-fold decrease in
IAP activity (0.0007) (Fig. 5B) and enhanced proteasome–
APEH specific activities when compared with controls
(p5 0.003 and o0.001, respectively) (Fig. 5C, 5D). To eval-
uate the Nrf2 involvement in gluten-mediated toxicity, CLA
was used as Nrf2 inducer. Noticeably, CLA administration
in MGFD-treated animals restored PC and GSHtot levels
(Figs. 4A and 5A) and reinstated intestinal protective
enzymes activity that had been perturbed by gluten (Figs. 4B
and 5B–D). Finally, when individual average values of
proteasome activity were plotted against APEH or PC levels,
Figure 3. Elevated oxidative stress is observed in CD patient
biopsies in comparison to the small intestine of gluten-fed DQ8
transgenic mice. PC accumulation, GST activity (A), and caspase-
3 activity were measured in the small intestine of DQ8 mice fed
for 3wk with GFD or StD. (B). Representative Western immu-
noblot of tTG expression in the intestine of mice receiving
different treatments. Actin was used as loading control (A, inset).
PC accumulation, GST activity, and (C) proteasome–APEH-
specific activities were measured in human biopsies from heal-
thy or CD patients (D). Representative Western immunoblot
showing tTG expression in human intestinal proteins. Actin was
used as loading control (C, inset). Results are expressed as the
mean7SD from triplicate analyses. , Significantly different
(po0.005 or o0.01) from GFD-fed mice.
Figure 4. CLA impairs the gluten-mediated decrease in anti-
oxidant/detoxifying defenses in vivo. Small intestine samples
from DQ8 mice fed with GFD or MGFD and with or without the
CLA supplement were examined for their GSHtot content (A) and
GST and NQO1 activities (B). Results are expressed as the
mean7SD from triplicate analyses. , Significantly different
(po0.005 oro0.01) from GFD-fed mice (C). Representative
Western immunoblot of the intestinal expression of GCL and
HO-1 from differently treated DQ8 mice. Actin was used
as loading control (C). mRNA levels of GCL and NQO1 from
the intestines of DQ8 mice receiving different treatments.
The housekeeping gene, glyceraldehyde 3-phosphate dehy-
drogenase (G6PD) was used as control, and results were
normalized by taking the mRNA levels of GFD in mice to be 1 (D).
Table 1. The effects of GFD or gluten-containing diet (StD) intake
on DQ8 mice intestine
GFD StD
GSHtot (nmol/mg/min) 19.272.1 9.671.1
GPx (nmol/mg/min) 121.5731.2 90.4728.5
IAP (nmol pNPP/mg/min) 12.571.6 8.571.3
Sucrase isomaltase (U/mg/h) 2.071.5 2.271.0
Height of intestinal villi (mm) 670723 640746
CD31 (cells/mm) 20.570.7 20.873.5
Results are given as mean7SD from triplicate analysis.
,Significantly different (po0.005 or o0.05) from controls.
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a significant positive correlation was found (r5 0.935,
p5 0.0016 and r5 0.926; p5 0.0001, respectively).
4 Discussion
The present study confirms the in vitro pro-oxidant activity
of gliadin on differentiated Caco-2 cells and demonstrates,
for the first time, its in vivo ability to downregulate crucial
intestinal defenses. Furthermore, the reported results verify
CLA-induced enhancement of the Nrf2 pathway and the
central role of this mechanism in the mediation of intestinal
protection.
The lower GSHtot content, together with the variation in
proteasome–APEH activities during the active metabolic
phase, is consistent with a reduced GSH requirement
during differentiation and with cellular needs for increased
degradation activities during cell proliferation [25]. The
decrease of NQO1 activity, which plays a protective effect
toward the formation of highly reactive toxic compounds
[26], is consistent with the association of cell differentiation
with the decline of detoxifying ability [27]. GST enhance-
ment during Caco-2 differentiation is not unexpected and
indicates the development of chemoresistance [28].
Gliadin toxicity on redox homeostasis in differentiated
Caco-2 cells is consistent with that reported on undiffer-
entiated culture [11] but, in our hands, gliadin treatment
only produces a small proapoptotic activity and it is unable
to alter tTG expression. This is an ubiquitous intracellular
enzyme and its enhanced activity/expression represents an
active cellular response to oxidative stress [29]. In particular,
the lack of in vitro effect of gliadin on tTG expression is
apparently in contrast with the literature data [30, 31]
although expression found in biopsies of CD patients is in
good accordance with the literature [32]. Bearing in mind
that enhanced activity/expression of tTG represents an
active cellular response to oxidative stress [29], it is thus
likely that chemoresistance development, in differentiated
culture might be responsible for the reduced susceptibility
to gliadin toxicity. Moreover, the lack of influence of dietary
gluten on tTG expression and on the levels of typical
pathological markers in mice intestine is consistent with
data, indicating that gluten is well tolerated by DQ8 mouse
[8]. PC accumulation is a characteristic feature of aging and
of a number of pathologies, including inflammatory bowel
disease [33] and little is known about the influence of gluten
on PC yield. Here, we provide evidence that gliadin raises
PC levels in both in vitro and in vivo models and our in vivo
data showing that noxious consequences produced by gluten
intake are unable to affect the animal redox status are in
agreement with the hypothesis that dietary gluten is insuf-
ficient to trigger oxidative stress conditions comparable to
those found in CD patients [34].
The relevance of Nrf2-mediated defenses in intestinal
protection was recently reviewed [14], and among the phase
2 enzymes, GCL has been recognized as the rate-limiting
enzyme in GSH synthesis. The alteration of GSH levels may
have deleterious effects on both organ homeostasis and
disease progression [25]. We confirm the ability of gliadin to
decrease intracellular GSHtot content and to block the
activity of Nrf2-activated enzymes in vitro [11] and we
demonstrate for the first time the ability of gluten to
downregulate phase 2 enzyme activity/expression.
The antidifferentiation effect of pt-glia ability was
deduced by its ability to affect IAP [35], which was recently
demonstrated to play an important role in detoxifying
bacterial lipopolysaccharide [36]. The negative correlation
between intracellular GSHtot and IAP activity, consistently
with data on the inhibitory effect of oxidative stress [37, 38]
indicates the modulatory role of Nrf2/ARE pathway on IAP
functioning rather than the result of histological injury [39].
Our study demonstrates, for the first time, the in vitro
and in vivo ability of gluten to increase the enzymatic
activity of the proteasome–APEH system. The marked
reduction in proteasome–APEH function detected in
intestinal biopsies from untreated CD patients, together
with decreased IAP levels, could mirror the severe oxidative
stress conditions associated with mucosal lesions in CD;
however, further correlation studies on a larger population
of CD patients are required.
The ability of CLA to attenuate the oxidative stress
cascade has been shown previously [18, 20, 40, 41]. Conse-
quently, to examine the mechanism whereby gluten down-
regulates intestinal defenses, it was used as an in vivo
inducer of Nrf2 pathway. Notably, the association between
the increase of cytoprotective defenses with the inhibition of
gluten-mediated toxicity in the mouse intestine substanti-
ates the beneficial effects of CLA on the Nrf2 pathway
Figure 5. CLA protects against gluten-mediated oxidative stress
in vivo. Duodenum samples from DQ8 mice fed with GFD or
MGFD and with or without the CLA supplement were examined
for (A) their PC concentration and (B) IAP, (C) proteasome and
(D) APEH activities, which were measured in the mice receiving
different treatments. Results are presented as the mean7SD
from triplicate analyses. , Significantly different (po0.005
or o0.01) from controls.
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[20, 40] and supports the relevance of Nrf2 activation against
toxic insults in experimental colitis [42]. Taken together,
these data indicate the possible use of CLA for the
management of intestinal pathologies associated with the
depletion of antioxidant/detoxifying defenses. Our results
are in good accordance with the previous studies demon-
strating the chemo-protective effects of supplementation
with mixed CLA isomers on animal [19, 43, 44]. However,
since the biological effects of the CLA mixture are likely due
to the separate action of its components, further studies are
necessary to determine the role of individual isomer in the
protective effects against gluten toxicity.
Possible mechanisms by which gluten downregulates
intestinal antioxidant/detoxifying may include either indir-
ect modulation of the Nrf2-pathway via the proteasome–
APEH system or direct inhibition of Nrf2. However, based
on the negligible effects of dietary gluten on intestinal
mRNA levels of phase 2 enzymes, the latter hypothesis can
be excluded. In addition, bearing in mind that Nrf2 is a
known proteasome substrate [45], the hypothesized role
played by an increased activity of proteasome–APEH func-
tion on the decreased Nrf2-mediated protection upon gluten
exposure is supported by data from CLA-supplemented
animals. In addition, the ability of CLA to enhance the
activity/expression of phase 2 enzymes and to restore
proteasome–APEH activity levels is consistent with the
reported effects of Nrf2 activation [46, 47]. In fact, it is likely
that the release of Nrf2 from Keap1 inhibitor, triggered by
CLA, promotes the escape of the Nrf2 protein from protea-
somal degradation, thus protecting intestinal cells from
gluten-mediated toxicity.
In conclusion, the ability of dietary gluten to produce
deleterious effects on several crucial intestinal defense
mechanisms, but not the pathological signs associated with
CD, is consistent with the hypothesis that gluten exposure
may represent only a predisposing factor for further unde-
termined insults. Moreover, we have identified a novel
mechanism by which gluten perturbs several pivotal
intestinal defenses and we have discovered the potential
therapeutic efficacy of CLA against gluten-mediated toxicity
(Supporting Information Fig. 4).
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